UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934

Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:

o Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:
Preliminary Proxy Statement
oCONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2))
xDefinitive Proxy Statement
oDefinitive Additional Materials
oSoliciting Material Pursuant to Section 240.14a-12

AKORN, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Akorn, Inc.Payment of Filing Fee (Check the appropriate box):
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (check the appropriate box):
xNo fee required.
oFee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)(1) Title of each class of securities to which transaction applies:___________________________________________________
(2)(2) Aggregate number of securities to which transaction applies:___________________________________________________
(3)
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set
(set forth the amount on
which the filing fee is calculated and state how it was determined):_______________________________________________
(4)(4) Proposed maximum aggregate value of transaction:___________________________________________________________
(5)(5) Total fee paid:_______________________________________________________________________________________
oFee paid previously with preliminary materials.
oCheck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)(1) Amount Previously Paid:_______________________________________________________________________________
(2)(2) Form. Schedule or Registration Statement No.:_______________________________________________________________
(3)(3) Filing Party:_________________________________________________________________________________________
(4)(4) Date Filed:__________________________________________________________________________________________




PROXY MATERIALS

Logo

1925 West Field Court, Suite 300

Lake Forest, Illinois 60045


NOTICE OF 2014 ANNUAL MEETING OF SHAREHOLDERS
To Be Held May 2, 2014


TO THE SHAREHOLDERS OF AKORN, INC.:

Dear Shareholder:

You are cordially invited to attend the 20142016 annual meeting of shareholders of Akorn, Inc. (the “Company,” “we,” “our,” “us” or “Akorn”) to be held at 10:00 a.m., local time (Central Daylight Time) on May 2, 2014,July 1st, 2016, at the Company’s corporate headquarters at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045 for the following purposes, as more fully described in the accompanying proxy statement:

1.To elect eight directors,
2.To ratify the appointment of BDO USA, LLP as the Company’s independent registered public accountant,
3.To approve through an advisory vote the Company’s executive compensation program, and
4.To transact such other matters as may properly come before the meeting.

You may attend the meeting in person or by proxy. Only shareholders or their legal proxy holders will be allowed to attend the 2016 annual meeting. To be admitted to the 2016 annual meeting, you must present a form of government-issued photo identification and valid proof of ownership of the Company’s common stock as of May 11, 2016 or a valid legal proxy.

Your vote is important. We strongly urge you to cast your vote as soon as possible, even if you currently plan to attend the meeting in person. You may vote your shares by Internet or telephone, or if you request a paper copy of the proxy materials, by following the instructions on the proxy card or the voting instruction form you receive with those materials.

We appreciate your investment in the Company.

By Order of the Board of Directors

/S/ Raj Rai

Raj Rai

Chief Executive Officer

May 20, 2016

 
1. 

Notice
of the2016 Annual Meeting

The 2016 annual meeting of shareholders of Akorn, Inc., a Louisiana corporation, will be held at the time and place and for the purposes indicated below.

July 1, 2016

10:00 a.m., Local Time

1925 West Field Court, Suite 300, Lake Forest, Illinois 60045

Items of Business:To elect seveneight directors from the nominees named in the proxy statement to serve until the Board of Directors.2017 annual meeting or until their successors are elected and qualified (Proposal 1);
To ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2016 (Proposal 2);
To approve, through a non-binding advisory vote, the Company’s executive compensation program (Proposal 3); and
To transact such other matters as may properly come before the meeting and any adjournment or postponement thereof.
   
 2.Recommendations of the Board:To ratify the selection by our Audit CommitteeThe Board of KPMG LLPDirectors unanimously recommends that you vote as our independent registered public accounting firm for the fiscal year ending December 31, 2014.follows: “FOR ALL” nominees in Proposal 1 and “FOR” Proposals 2 and 3.
   
 3.Record Date:To approve the adoptionShareholders of record as of the Akorn, Inc. 2014 Stock Option Plan.close of business May 11, 2016, are entitled notice of and to vote at the 2016 annual meeting.
   
 4.Voting:Your vote is very important.To approveensure your representation at the meeting, please vote your shares as soon as possible, by non-binding advisory voteInternet or telephone, or if you request a paper copy of the Company’s executive compensation program.proxy materials, by the proxy card or voter instruction form included therein.

By Order of the Board of Directors

/S/ Raj Rai

Raj Rai

Chief Executive Officer

Important Notice Regarding the Availability of Proxy Materials for the

Annual Meeting of Shareholders to Be Held on July 1, 2016.

The proxy statement, the form of proxy card, and the annual report to shareholders for the

fiscal year ending December 31, 2015 are available at http://www.proxyvote.com.

Table of Contents

PROXY STATEMENT5
  
I. CORPORATE GOVERNANCE AND RELATED MATTERS6
Corporate Governance6
Report of the Audit Committee10
Certain Relationships and Related Transactions11
Section 16(a) Beneficial Ownership Reporting Compliance13
Code of Ethics13
 5.
II. PROPOSALSTo transact such other14
Proposal 1 Election of Directors14
Proposal 2 Ratification of the Appointment of BDO USA, LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 201619
Proposal 3 Approval by Non-Binding Advisory Vote of the Company’s Current Executive Compensation Program21
III. EXECUTIVE COMPENSATION AND OTHER INFORMATION22
Executive Summary22
Compensation Discussion and further business, if any, as lawfully may be brought before the meeting.Analysis23
Compensation Committee Report32
Executive Compensation Tables33
Director Compensation41
Compensation Committee Interlocks and Insider Participation43
Equity Compensation Plans43
IV. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT44
V. QUESTIONS AND ANSWERS46

AKORN, INC. - 2016 Proxy Statement4

AKORN, INC.

1925 West Field Court, Suite 300

Lake Forest, Illinois 60045

May 20, 2016

Proxy Statement

For the Annual Meeting of Shareholders to be held July 1, 2016

The record date for the determinationBoard of the shareholders entitledDirectors of Akorn is furnishing you this proxy statement to votesolicit proxies on its behalf to be voted at the 2016 annual meeting or at any adjournment thereof is the close of business on March 7, 2014.  A list of shareholders entitled to vote at theof Akorn, Inc. The meeting will be open to the examination of any shareholder, for any purpose germane to the meeting,held at the location of the meeting on and during ordinary business hours for 10 days prior to the meeting at our principal offices locatedCompany’s headquarters, at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

As outlined in the proxy statement, the Board of Directors recommends that you vote “FOR” each of the nominees under Proposal60045, on July 1, and “FOR” Proposals 2, 3 and 4.  Please refer to the proxy statement for detailed information on each of the proposals.
By Order of the Board of Directors
/s/ Raj Rai
Raj Rai
Chief Executive Officer


Lake Forest, Illinois
April 4, 2014

It is important that your shares be represented2016, at the meeting regardless of the number of shares you hold.  Whether or not you expect to attend the meeting in person, please complete, date, sign and return the accompanying proxy in the enclosed envelope to ensure the presence of a quorum at the meeting.  Even if you have voted by proxy, and you attend the meeting, you may, if you prefer, revoke your proxy and vote your shares in person.  Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you will not be permitted to vote in person at the meeting unless you first obtain a legal proxy issued in your name from the record holder.
This Proxy Statement is dated April 4, 2014 and was first mailed to shareholders of Akorn, Inc. on or about April 9, 2014. 10:00 a.m., local time.

This proxy statement contains information on matters to be voted upon at the annual meeting or any adjournments of that meeting.

As of the date of this proxy statement, management is unaware of any other matter for action by shareholders at the meeting other than those described in the accompanying Notice of the 2016 Annual Meeting. All properly executed written proxies and all properly completed proxies submitted by telephone or Internet that are delivered pursuant to this solicitation will be voted at the meeting in accordance with the directions given in the proxy, unless the proxy is revoked prior to completion of voting at the meeting.

A one-page notice was mailed to you regarding the Internet availability of our proxy materials. The Notice of Internet Availability of Proxy Materials (the “Notice”) was sent in place of a paper copy of the proxy materials in order to help reduce the environmental impact of our annual meeting, and reduce the cost to Akorn associated with the printing and mailing of the proxy material.

The Notice provides you with instructions on how to access the proxy materials over the Internet or request a printed copy of the materials, and instructions for voting over the Internet. You may follow the instructions in the Notice to elect to receive future proxy materials in print by mail or electronically by email.

The proxy materials for our 2016 annual meeting include: (1) The Notice of 2016 Annual Meeting of Shareholders; (2) This Proxy Statement for the Annual Meeting; and (3) Akorn’s Annual Report for the year ended December 31, 2015. If you request paper versions, then the proxy materials will also include the proxy card or voting instruction form for the 2016 annual meeting.

Please see the section “Questions and Answers” at the back of this proxy statement for more information regarding the proxy materials, the 2016 annual meeting, voting, submitting proposals for next year’s annual meeting and other related matters.

This proxy statement is dated May 20, 2016 and we are first furnishing the proxy materials to shareholders on May 20, 2016.

Important Notice Regarding the Availability of Proxy Materials for the

Annual Meeting of

Shareholders to Be Held on May 2, 2014.

July 1, 2016:

The Notice of Annual Meeting, proxy statement, including the Akorn, Inc. 2014 Stock Option Plan and form of proxy card, and the 20132015 annual report to

shareholders are available at http://www.proxyvote.com.



www.proxyvote.com.

AKORN, INC.

1925 West Field Court, Suite 300
Lake Forest, Illinois  60045
PROXY STATEMENT
For the Annual Meeting of Shareholders
To Be Held May 2, 2014
QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING
Why have I received these materials?
This proxy statement and the enclosed proxy card were sent to you because our Board of Directors (“Board”) is soliciting your proxy to vote at the annual meeting of shareholders to be held on May 2, 2014.  You are cordially invited to attend the annual meeting and are requested to vote on the proposals described in this proxy statement.  We intend to mail this proxy statement and accompanying proxy card and the 2013 annual report on or about April 9, 2014 to all shareholders entitled to vote at the annual meeting.
Who is entitled to vote at the Annual Meeting?
Shareholders of record as of the close of business on March 7, 2014 will be entitled to vote at the annual meeting.  On March 7, 2014, there were 96,653,483 shares of common stock outstanding and entitled to vote.  On each matter, the holders of the common stock will be entitled to one vote for each share of common stock held as of the record date. There is no cumulative voting with respect to the election of directors.
Shareholder of Record: Shares Registered in Your Name.  If on March 7, 2014 you were a “record” shareholder of common stock (that is, if you held common stock in your own name in the stock records maintained by our transfer agent, Computershare Investor Services, LLC (“Computershare”), you may vote in person at the annual meeting or by proxy.  Whether or not you intend to attend the annual meeting, we encourage you to complete and sign the accompanying proxy card and return it in accordance with the instructions provided to ensure that your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker or Bank.  If on March 7, 2014, you were the beneficial owner of shares of common stock held in “street name” (that is, a shareholder who held common stock through a broker or other nominee) then these materials are being forwarded to you by the broker or other nominee.  You may direct your broker or other nominee how to vote your shares of common stock.  However, you will have to obtain a proxy form from the institution that holds your shares and follow the voting instructions on the form.  If you wish to attend the annual meeting and vote in person, you may attend the meeting but may not be able to vote in person unless you first obtain a legal proxy issued in your name from your broker or other nominee.
What am I voting on?
There are three matters scheduled for a vote:
 - 2016 Proxy Statement5

 Election of seven directors;
Ratification of the selection by our Audit Committee of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
Approval of the Akorn, Inc. 2014 Stock Option Plan; and
Approval by non-binding advisory vote of the Company’s executive compensation program.
How do I vote?
You may either vote “FOR” or “WITHHOLD” for any or all of the Company’s nominees for Director.  You may vote “FOR” or “AGAINST” or “ABSTAIN” from voting to ratify the Company’s selection of KPMG LLP as its independent registered public accounting firm, voting to approve the Akorn, Inc. 2014 Stock Option Plan, and on the voting to approve by non-binding advisory vote the Company’s executive compensation program.

Shareholder of Record: Shares Registered in Your Name.  If you are a shareholder of record, you may vote in person at the annual meeting, or you may vote by proxy using the enclosed proxy card. You may also vote over the Internet at www.proxyvote.com or vote by telephone at 1 (800) 690-6903. Please see the proxy card for voting instructions.

Whether or not you plan to attend the annual meeting, we urge you to vote by proxy to ensure your vote is counted.  You may still attend the annual meeting and vote in person if you have already voted by proxy.
To vote in person, come to the annual meeting and we will give you a ballot when you arrive.

To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided.  If you return your signed proxy card to us before the annual meeting, we will vote your shares as you direct.
Certain shareholders may also vote online at www.proxyvote.com or over the phone by calling       1 (800) 690-6903.

Beneficial Owner: Shares Registered in the Name of Broker or Bank.  If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a proxy card and voting instructions with these proxy materials from that organization rather than from Akorn.  In order to vote, complete and mail the proxy card received from your broker or bank to ensure that your vote is counted.  Alternatively, you may vote by telephone or over the Internet as instructed by your broker, bank or such other applicable agent.  To vote in person at the annual meeting, you must obtain a valid proxy from your broker, bank, or other agent.  Follow the instructions from your broker, bank, or other agent included with these proxy materials, or contact your broker, bank, or such other agent to request a proxy form.
How many votes do I have?
Each share of common stock is entitled to one vote with respect to each matter to be voted on at the annual meeting.
What constitutes a quorum for purposes of the annual meeting?
A quorum of shareholders is necessary to hold a valid meeting.  The presence at the annual meeting in person or by proxy of the holders of a majority of the voting power of all outstanding shares of common stock entitled to vote, or 48,326,742 votes, shall constitute a quorum for the transaction of business at the meeting.  Proxies marked as abstaining (including proxies containing broker non-votes) on any matter to be acted upon by shareholders will be treated as present at the meeting for purposes of determining a quorum but will not be counted as votes cast on such matters.  If there is no quorum, a majority of the votes present at the meeting may adjourn the meeting to another date.
How does the Board recommend that I vote my shares?
The Board’s recommendation is set forth together with the description of each item in this proxy statement.  In summary, the Board recommends a vote:
FOR the election of the seven nominees for director;
FOR the ratification of the selection by our Audit Committee of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
FOR approval of the Akorn, Inc. 2014 Stock Option Plan; and
FOR the approval, by non-binding resolution, of the Company’s executive compensation program.
With respect to any other matter that properly comes before the annual meeting, the proxies will vote as recommended by the Board or, if no recommendation is given, in their own discretion.  As of the date of this proxy statement, the Board had no knowledge of any business other than that described herein that would be presented for consideration at the annual meeting.
2

What if I return a proxy card but do not make specific choices?
Shareholders of Record:  Shares Registered in your Name.  If you are the shareholder of record and return a signed and dated proxy card without marking any voting selections, your shares will be voted “FOR” the election of all seven nominees for director, “FOR” the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014, “FOR” approval of the Akorn, Inc. 2014 Stock Option Plan, and “FOR” the approval of our executive compensation program. If any other matter is properly presented at the annual meeting, your proxy (the individual named on your proxy card) will vote your shares using his best judgment.
Beneficial Owner:  Shares Registered in the Name of a Broker or Bank.  If you are the beneficial owner, but not the shareholder of record, and do not provide your nominee instruction with respect to any voting selections, your shares may not be voted by your nominee for the election of any of the seven nominees for director, approval of the Akorn, Inc. 2014 Stock Option Plan, or the approval by non-binding advisory vote of our executive compensation program, as these proposals are considered “non-routine”.  In such case, your vote will be considered a “broker non-vote.”  However, your shares may be voted by your nominee for the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.
How many votes are needed to approve each proposal?
Proposal 1.  The election of directors will be determined by a plurality of the votes cast at the annual meeting by shares represented in person or by proxy and entitled to vote for the election of directors.  A plurality means the highest number of “FOR” votes.  Therefore, the seven nominees receiving the most proper “FOR” votes will be elected.  Abstentions and broker non-votes will have no effect on the outcome.
Proposal 2.  The ratification of the selection by our Audit Committee of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014 requires a “FOR” vote from a majority of the votes cast.  Abstention and broker non-votes will have no effect on the outcome.
Proposal 3.  The approval of the Akorn, Inc. 2014 Stock Option Plan requires a “FOR” vote from a majority of the votes cast.  Abstention and broker non-votes will have no effect on the outcome.

Proposal 4.  The approval by advisory vote of the Company’s executive compensation program is non-binding to the Company.   Passage of this advisory vote requires affirmative vote of the majority of votes cast.  Abstentions and broker non-votes will have no effect on the outcome.   Since this vote is non-binding, the Company maintains the right to adopt or maintain an executive compensation plan that has not been ratified by affirmative vote of its shareholders.

Can I revoke or change my vote after I return my proxy card?
Yes.  For shareholders of record, any time after you have submitted a proxy card and before the proxy card is exercised, you may revoke or change your vote in one of three ways:
You may submit a written notice of revocation to Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois  60045.
You may submit a proxy bearing a later date.
You may attend the annual meeting and vote in person.  Attendance at the meeting will not, by itself, revoke a proxy.

For beneficial owners, you will need to revoke or resubmit your proxy through your nominee and in accordance with its procedures.  In order to attend the annual meeting and vote in person, you will need to obtain a proxy from your nominee, the shareholder of record.
3

Who will bear the expense of soliciting proxies in connection with this proxy statement?
Akorn will bear the cost of soliciting proxies in the form enclosed.  In addition to the solicitation by mail, proxies may be solicited personally or by telephone, facsimile, online posting or electronic transmission by our employees.  Our employees will not receive any additional compensation for participating in proxy solicitation.  We may reimburse brokers holding common stock in their names or in the names of their nominees for their expenses in sending proxy materials to the beneficial owners of such common stock.
Is there any information that I should know about future annual meetings?
Any shareholder who intends to present a proposal at the 2015 annual meeting of shareholders must deliver the proposal to Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045 not later than December 1, 2014, or if such year's annual meeting has been changed by more than 30 days from the date of the previous year's meeting, then the deadline is a reasonable time before Akorn begins to print and send its proxy materials, if the proposal is to be submitted for inclusion in our proxy materials for that meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Any notice of a shareholder proposal submitted after December 1, 2014, or if such year's annual meeting has been changed by more than 30 days from the date of the previous year's meeting, a reasonable time before Akorn begins to print and send its proxy materials, will be considered untimely and outside the processes of Rule 14a-8 of the Exchange Act.

What does it mean if I receive more than one proxy?
If you receive more than one proxy, it means you have multiple accounts with brokers and/or our transfer agent.  Please vote all of these shares.  We recommend that you contact your broker and/or our transfer agent to consolidate as many accounts as possible under the same name and address.  Our transfer agent is Computershare – Essential Registry Team, located at 350 Indiana Street, Suite 750, Golden, Colorado 80401 and may be reached at (303) 262-0678.

4


I.  PROPOSALS
PROPOSAL 1.  ELECTION OF DIRECTORS
The Board has nominated seven candidates for election at the annual meeting and recommends that shareholders vote “FOR” the election of all seven nominees.  All of the nominees listed below are currently directors.  If elected at the annual meeting, each of these nominees would serve until the 2015 annual meeting and until his or her successor is elected and has qualified, or until the director’s death, resignation or removal.  Directors are elected by a plurality of the votes properly cast in person or by proxy.  The seven nominees receiving the highest number of affirmative votes will be elected.  In the unanticipated event that one or more of such nominees becomes unavailable as a candidate for director, the persons named in the accompanying proxy will vote for another candidate nominated by the Board.  Each person nominated for election has agreed to serve if elected.  We have no reason to believe that any nominee will be unable to serve.
The following table and narrative description sets forth, as of March 7, 2014, the age, principal occupation and employment, position with us, directorships in other public corporations, and year first elected as one of our directors, of each of the seven individuals nominated for election as director.  Unless otherwise indicated, each nominee has been engaged in the principal occupation or occupations described below for more than the past five years.
 NameAgeDirector SincePresent Position with Akorn
    
 John N.  Kapoor, Ph.D.701990Chairman of the Board
 
Kenneth S. Abramowitz 1
632010Director
 Adrienne L. Graves 2,3602012Director
 
Ronald M.  Johnson 1,2
682003Director
 
Steven J. Meyer 1,3
572009Director
 Brian Tambi682009Director
 
Alan Weinstein 2,3
712009Director
     
1  Member of the Audit Committee.  Mr. Meyer is Chair of this committee.
2  Member of the Compensation Committee. Mr. Johnson is Chair of this committee.
Member of the Nominating and Corporate Governance Committee. Mr. Weinstein is Chair of this committee.

John N.  Kapoor, Ph.D.  Dr.  Kapoor has served as the Chairman of our Board since October 1990.  Dr.  Kapoor served as our interim Chief Executive Officer from March 2001 to May 2002 and as our Chief Executive Officer from May 2002 to December 2002.  Dr. Kapoor is the President of EJ Financial Enterprises, Inc.  (a health care consulting and investment company).  Dr. Kapoor is the chairman of the board of directors of Insys Therapeutics, Inc. (NASDAQ: INSY) a publicly held drug development company focused on pain and oncology, into which NeoPharm, Inc.  (previously a publicly held biopharmaceutical company) merged in October 2010.   Prior to NeoPharm’s merger, Dr. Kapoor was the chairman of its board of directors. Under agreements between us and the John N. Kapoor Trust dated 9/20/89 (the “Kapoor Trust”), the beneficiary and sole trustee of which is Dr. John N. Kapoor, our Chairman of the Board, the Kapoor Trust is entitled to designate one individual to be nominated and recommended by our Board for election as a director.   Dr. Kapoor was designated by the Kapoor Trust for this purpose.
Kenneth S. Abramowitz.  Mr. Abramowitz was elected to the Board of Directors in May 2010.  Mr. Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Prior to that, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Company where he covered the medical supply, hospital management and Health Maintenance Organization (HMO) industries for 23 years. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an M.B.A. from Harvard Business School in 1976. Mr. Abramowitz currently sits on the Board of Directors of EKOS Corporation, OptiScan Biomedical Corporation, Cerapedics, Inc., Valtech Cardio and Small Bone Innovations, Inc. He previously served as a director at Option Care, Inc., Sightline Technologies Ltd and Power Medical Interventions, as well as MedPointe and ConnectiCare Holdings, Inc.
5

Adrienne L. Graves, Ph.D.  Dr. Graves was appointed a director by the Board in March 2012.  Dr. Graves is a visual scientist by training and a global industry leader in ophthalmology. From 2002 to 2010, Dr. Graves was President and Chief Executive Officer of Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. She joined Santen Inc. in 1995 as Vice President of Clinical Affairs to initiate the company's clinical development efforts in the U.S. Prior to joining Santen Inc., Dr. Graves spent nine years with Alcon Laboratories, Inc. in various roles. She currently serves on the Boards of TearLab Corporation, Encore Vision, the American Academy of Ophthalmology Foundation, the Pan-American Ophthalmology Foundation, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation, KeepYourSight Foundation, the Corporation Committee for the Brown University Medical School, Aerpio Therapeutics, Himalayan Cataract Project and the Advisory Board for Amach Capital Partners. Dr. Graves also co-founded Ophthalmic Women Leaders and Glaucoma 360. She received her B.A. in Psychology with honors from Brown University, her PhD in Psychobiology from the University of Michigan and completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Ronald M.  Johnson.  Mr. Johnson was appointed a director by the Board in May 2003.   Mr. Johnson served as president of Becker & Associates Consulting, a firm which provides consulting services to the pharmaceutical, biologics and medical device industries on United States Food and Drug Administration (“FDA”) regulatory requirements, until retiring from that firm April 2013.  Mr. Johnson currently serves as an independent consultant.  Previously, Mr. Johnson was Executive Vice President of The Lewin Group, a subsidiary of Quintiles Transnational, Inc., which provides various healthcare consulting services to state and federal governments, healthcare insurers and healthcare institutions.  Prior to joining The Lewin Group, Mr. Johnson served as Executive Vice President of Quintiles Consulting, a business unit of Quintiles Transnational, Inc. from 1997 to 2006.  Quintiles Consulting provides consulting services to the pharmaceutical, medical device, biologic and biotechnology industries in their efforts to meet FDA regulatory requirements. Mr. Johnson also spent 30 years with the FDA, holding various senior level positions primarily in the compliance and enforcement areas.  

Steven J. Meyer.  Mr. Meyer was appointed a director by the Board in June 2009.  Since 2005, Mr. Meyer has served as the Chief Financial Officer of JVM Realty, a private firm specializing in the acquisition, re-positioning and management of multi-family housing for qualified investors.  Mr. Meyer sits on the Board of Directors for INSYS Therapeutics.  Mr. Meyer also served as the Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at Baxter International, Inc.
Brian Tambi.  Mr. Tambi was appointed a director by the Board in June 2009.  Since August 2006, Mr. Tambi has served as the Chairman of the Board, President & CEO of BrianT Laboratories and has been a member of the Board of Directors of Insys Therapeutics since July 2007.  From November 1995 to July 2006, Mr. Tambi was the Chairman of the Board, President & CEO of Morton Grove Pharmaceuticals, Inc., a leading manufacturer and marketer of oral liquid and topical pharmaceuticals.  Mr. Tambi has over 30 years of executive management experience with companies such as IVAX Corporation, Fujisawa Pharmaceutical Company USA, LyphoMed Inc., and Bristol-Myers International Group.  EJ Funds nominated Mr. Tambi to serve on the Board of Directors pursuant to its rights under the April 13, 2009 Modification, Warrant and Investor Rights Agreement with EJ Funds that, among other things, granted EJ Funds the right to require us to nominate two directors to serve on our Board of Directors.
Alan Weinstein.  Mr. Weinstein was appointed a director by the Board in July 2009.  Since 2000, Mr. Weinstein has provided consulting services to supplier clients in the areas of hospital organization, hospital operations, and working with group purchasing  organizations.  Previously, Mr. Weinstein was the Founder and President of Premier, Inc., an organization which provides various shared services to member hospitals.  Mr. Weinstein serves as a director on the boards of Vascular Pathways, Inc., Precyse, SutureExpress and OpenMarkets, and serves on the board of trustees of the Rosalind Franklin University of Medicine and Science.
There is no family relationship among any of the directors or executive officers of the Company.

During the past ten years none of the persons currently serving as executive officers and/or directors of the Company has been the subject matter of any of the following legal proceedings that are required to be disclosed pursuant to Item 401(f) of Regulation S-K, including: (a) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (b) any criminal convictions; (c) any order, judgment, or decree permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; (d) any finding by a court, the Securities and Exchange Commission or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud; or (e) any sanction or order of any self-regulatory organization or registered entity or equivalent exchange, association or entity. Further, no such legal proceedings are believed to be contemplated by governmental authorities against any director or executive officer.
6

The Board of Directors recommends a vote “FOR” each of the named nominees in Proposal 1.
The Company’s Board of Directors consists of nine seats, two of which are currently vacant and are expected to remain vacant beyond the date of the Company’s 2014 annual meeting.  Proxies cannot be voted for a greater number of persons than the number of nominees.

7

PROPOSAL 2.  RATIFICATION OF THE SELECTION OF KPMG LLP AS OUR INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2014
The Board is seeking shareholder ratification of the Audit Committee’s selection of KPMG LLP (“KPMG”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2014.  KPMG was engaged by the Company to serve as its independent registered public accounting firm for the year ended December 31, 2013 and began the engagement in the second quarter of 2013.  Although the Company is not required to submit the selection of independent registered public accountants for shareholder approval, if the shareholders do not ratify this selection, the Board may reconsider the selection of KPMG. The Board considers KPMG to be well qualified to serve as the independent auditors for the Company, and fully intends to retain KPMG’s services throughout 2014.  However, even if the selection is ratified, our Board reserves the right to direct the appointment of a different independent registered public accounting firm at any time during the year if the Audit Committee and Board determine that the change would be in our best interests.

Representatives of KPMG will be in attendance at the 2014 annual meeting, will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions from shareholders regarding their engagement.

Change in Independent Auditor

The Audit Committee conducted a competitive process to determine the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013. The Audit Committee invited several national accounting firms to participate in this process, including Ernst & Young LLP (“E&Y”), the Company’s independent registered public accounting firm for the five fiscal years ended December 31. 2012. As a result of this process and following careful deliberation, on March 22, 2013, the Audit Committee approved the engagement of KPMG as the Company’s independent registered public accounting firm for 2013 and the dismissal of E&Y.  This change became effective upon E&Y’s completion of audit services for the Company’s first fiscal quarter ending March 31, 2013 and the filing of the Company’s Quarterly Report on Form 10-Q for the same quarter with the Securities and Exchange Commission.

During the Company’s fiscal year ended December 31, 2012 and through the date of E&Y’s dismissal, neither the Company, nor anyone on its behalf, consulted KPMG regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, in any case where a written report or oral advice was provided by KPMG to the Company that KPMG concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a “disagreement” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

Information Pertaining to E&Y

The report of E&Y on the Company’s consolidated financial statements for the fiscal year ended December 31, 2012 did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principle, and included explanatory paragraphs.

During the Company’s fiscal years ended December 31, 2012 and through the date of E&Y’s dismissal, there were no “disagreements” between the Company and E&Y on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of E&Y would have caused E&Y to make reference to the subject matter of the disagreement in connection with its reports on the Company’s consolidated financial statements for such years.

During the year ended December 31, 2012, there were “reportable events”.  As further disclosed in the Company’s Form 10-Q for the quarterly period ended June 30, 2012, the Company concluded there was a material weakness in the design and operating effectiveness of the Company’s internal control over financial reporting, which primarily related to accounting for business combinations during the financial statement close process. As further disclosed in the Company’s Form 10-K for the fiscal year ended December 31, 2012, E&Y’s report on the effectiveness of internal control over financial reporting as of December 31, 2012 included an adverse opinion on the Company’s internal control over financial reporting due to the effect of a material weakness related to the financial statement close process.
8

The Company provided E&Y and KPMG with a copy of the above disclosures. E&Y and KPMG were provided with an opportunity to furnish to the Company a letter presenting its views, to the extent the above disclosures were believed to be incorrect or incomplete, to be included in this proxy statement. Neither has provided such a letter to the Company prior to the filing of this proxy statement. The Company also provided E&Y with a copy of its Form 8-K filed with the SEC on March 28, 2013 announcing the change in independent registered public accounting firm containing substantially the same disclosure as above and requested that E&Y provide the Company with a letter addressed to the Securities and Exchange Commission stating whether or not E&Y agrees with the disclosures contained therein. A copy of E&Y’s letter was attached as Exhibit 16.1 to that Form 8-K filed with the SEC on March 28, 2013.

Independent Registered Public Accounting Firm Fees

The following table presents fees for professional audit services by KPMG and E&Y for the audit of Akorn’s annual financial statements for the years ended December 31, 2013 and December 31, 2012, respectively, and fees billed for other services rendered by KPMG and E&Y during these periods (amounts in thousands):
  2013  2013  2013  2012 
  E&Y  KPMG  Total  Total (E&Y) 
Audit Fees (1) $100  $1,112  $1,212  $1,194 
Audit-Related Fees (2)    235   235   
Tax Fees    44   44   
All Other Fees        
Total $100  $1,391  $1,491  $1,194 

(1)  Audit Fees billed by E&Y and KPMG were for various professional services provided to the Company, including:
a.  the audit of our consolidated financial statements as of and for the years then ended, as included in our Annual Reports on form 10-K filed with the SEC;Back to Contents
b.  I.the audit of our  internal controls over financial reporting as required by Section 404 of the Sarbanes-Oxley Act of 2002;Corporate Governance and Related Matters

CORPORATE GOVERNANCE

c.  the reviewsBoard of our condensed consolidated interim financial statements, as filed on Forms 10-Q with the SEC;Directors
d.  the audit of historical financial statements of acquired businesses by E&Y for inclusion in the Company’s Form 8-K filings.

The E&Y 2012 audit fees include $310K that was related to additional year-end audit work.  These additional fees were not included in the Audit Fees disclosed in the Company’s prior year proxy statement because the amount was unknown at that time.

(2)  Audit-Related Fees in 2013 consisted of due diligence services provided by KPMG in relation to the planned acquisition of Hi-Tech Pharmacal Co., Inc.

Audit Committee Pre-Approval Policies and Procedures
The Audit Committee has considered whether the provision of services covered in the preceding paragraphs is compatible with maintaining independence of our registered public accounting firm.  At their regularly scheduled and special meetings, the Audit Committee considers and pre-approves any audit and non-audit services to be performed for us by our independent registered public accounting firm.  For 2013, the Audit Committee pre-approved all of the audit services, audit-related services and tax services that were performed by KPMG.

The Board of Directors unanimously recommends that you vote “FOR” the ratification of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.

9

PROPOSAL 3.   APPROVAL OF THE AKORN, INC. 2014 STOCK OPTION PLAN.
Background
On December 30, 2013, the Board of Directors adopted the Akorn. Inc. 2014 Stock Option Plan (the “2014 Option Plan”), reserving 7,500,000 shares of Company common stock for issuance under the 2014 Option Plan.  The Board’s adoption of the 2014 Option Plan is contingent upon the receipt of shareholder approval of the 2014 Option Plan.

Shareholder approval of the 2014 Option Plan is sought:  (i) because our existing Amended and Restated Akorn, Inc. 2003 Stock Option Plan (the “2003 Option Plan”) expired on November 6, 2013 in accordance with its terms and is no longer available for future grants (although outstanding awards under the 2003 Option Plan will continue in accordance with their terms); (ii) to give the Company the flexibility to grant Awards (as defined below) that are comparable to awards that our peer group companies have the ability to grant; (iii) to permit the issuance of options which will qualify as incentive options pursuant to the Internal Revenue Code of 1986, as amended (the “Code”); and (iv) to comply with Rule 5635(c) of the NASDAQ Rules, which requires shareholder approval of equity compensation plans in which officers, directors, employees, or consultants may participate.

The 2014 Option Plan is intended to provide incentives to officers, employees, consultants and advisers (including members of the Board) who contribute to the success of the Company by offering them the opportunity to acquire an ownership interest in us.  The Board believes that this also will help to align the interests of its management, directors, employees and other personnel with the interests of shareholders.

Until its expiration on November 6, 2013, the Company had one equity compensation plan in place that permitted the Company to grant various equity based awards, that being the 2003 Option Plan.  Initially, we had in place the Akorn, Inc. 2003 Stock Option Plan that was approved by our Board on November 6, 2003 and approved by our shareholders on July 8, 2004.  On March 29, 2005, our Board approved the Amended and Restated Akorn, Inc. 2003 Stock Option Plan effective as of April 1, 2005, and this plan was subsequently approved by our shareholders on May 27, 2005. Since its approval, the Board adopted various amendments to the 2003 Option Plan, each of which was approved by our shareholders, and which served to increase the number of shares of common stock reserved for issuance pursuant to the 2003 Option Plan.  At the time of the 2003 Option Plan’s expiration on November 6, 2013, a total of 19,000,000 shares of common stock were reserved for issuance under the 2003 Option Plan, of which 6,816,500 shares remained available for future awards.  However, pursuant to the terms of the 2003 Option Plan, no awards could be granted beyond November 6, 2013, so these 6,816,500 remaining shares are no longer available for issuance under the 2003 Option Plan.

If the 2014 Option Plan is approved, the aggregate number of shares of common stock that will be reserved and available for issuance pursuant to Awards under the 2014 Option Plan will be 7,500,000, which includes the 6,816,500 shares that remained available for future awards under the 2003 Option Plan when it expired on November 6, 2013. Therefore, the total number of shares available for Awards under the 2014 Option Plan, assuming approval by shareholders of the 2014 Option Plan, is an increase of 683,500 shares from the number of shares that remained available for future awards under the 2003 Option Plan. In setting the number of proposed shares issuable under the 2014 Option Plan, the Compensation Committee and the Board considered a number of factors. These factors, which are discussed further below, included:
The total outstanding equity awards under the 2003 Option Plan, and how long the shares available under the 2014 Option Plan (if such plan is approved by shareholders) are expected to last;
Historical equity award granting practices, including the Company’s three-year average share usage rate (commonly referred to as “burn rate”); and
Expected dilution.

10

Set forth below is the number of shares available for issuance pursuant to outstanding equity awards under the 2003 Option Plan as of March 31, 2014:
  Number of Shares  
As a Percentage of
Stock Outstanding (1)
 
Shares reserved for issuance pursuant to outstanding stock options (2)  9,167,195   9.5%
Shares reserved for issuance pursuant to unvested restricted stock awards  15,946   0.0%
Shares available for issuance pursuant to future equity awards (3)   ─% 
Total shares reserved for issuance pursuant to outstanding equity awards under the 2003 Option Plan (3)  9,183,141   9.5%
         
(1)The percentages are based on outstanding shares of common stock on March 31, 2014.
(2)As of March 31, 2014, the 9,167,195 options outstanding under the 2003 Option Plan had a weighted average exercise price of $4.45 per share and a weighted average term remaining term of 1.36 years.
(3)The 2003 Option Plan expired on November 6, 2013 and no further awards may be granted under that plan.

As mentioned above, in setting and recommending to shareholders the number of shares authorized under the 2014 Option Plan, the Compensation Committee and the Board considered the historical number of equity awards granted under the 2003 Option Plan in the past three full years.  The Company used 353,000, 1,256,000 and 2,030,000, of the shares authorized under the 2003 Option Plan to make equity awards in the years 2013, 2012 and 2011, respectively.
The Compensation Committee and the Board also considered the Company’s three-year average burn rate (2011-2013) of approximately 1.3%, which is lower than the industry thresholds established by certain major proxy advisory firms.

The administrator (defined below) will have full discretion to determine the number and amount of Awards to be granted to employees and directors under the 2014 Option Plan, subject to the terms of the plan. Therefore, the future benefits or amounts that would be received by the executive officers and directors under the 2014 Option Plan are not determinable at this time.

If the adoption of the 2014 Option Plan is approved by the shareholders, any options previously granted under the 2003 Option Plan shall continue in full force and effect under the terms of the 2003 Option Plan and shall not be changed nor modified as a result of approval of the 2014 Option Plan.  However, the Company expects that it would utilize the 2014 Option Plan for future Awards.  If the shareholders do not approve the adoption of the 2014 Option Plan, the Company may be unable to provide adequate stock-based incentives to new or existing officers, directors or employees of the Company.

Summary Plan Description

The following is a summary of the 2014 Option Plan. This summary is qualified in its entirety by reference to the complete text of the 2014 Option Plan, which is attached as Appendix A to this Proxy Statement. You are urged to read the actual text of the 2014 Option Plan in its entirety.

Eligible Participants

Any director, employee, consultant or advisor (including any prospective director, employee, consultant or advisor) of Akorn or any affiliate of Akorn shall be eligible to be designated a participant in the 2014 Option Plan for purposes of receiving Awards. However, incentive stock options (“ISOs”) may be granted only to employees.  As of December 31, 2013, Akorn and its subsidiaries employed 1,103 permanent and 359 temporary employees.

Plan Administration

Our Board, or one or more committees appointed by our Board, will administer the 2014 Option Plan (in either case, the “administrator”).  In the case of Awards intended to qualify as “performance based compensation” within the meaning of Section 162(m) of the Code, the administrator will consist of two or more “outside directors” within the meaning of Section 162(m).  The administrator will have the power to determine the terms of the Awards, including the exercise price (which may be changed by the administrator after the date of grant), the number of shares subject to each Award, the exercisability of the Awards and the form of consideration payable upon exercise.  Subject to shareholder approval, the administrator also will have the power to implement an Award exchange program (whereby Awards may be exchanged or cancelled for Awards with lower exercise prices or different terms), or a program through which participants may reduce cash compensation payable in exchange for Awards.  The administrator may also create other stock based awards that are valued in whole or in part by reference to (or are otherwise based on) shares of our common stock.
11

Shares Available For Awards

Subject to adjustment as provided below, the aggregate number of shares of our common stock that may be issued pursuant to Awards granted under the 2014 Option Plan is 7,500,000, of which 1,500,000 may be granted as ISOs.  As of April 1, 2014, no awards have been made pursuant to the 2014 Option Plan.

If an Award expires or is terminated or canceled without having been exercised or settled in full, it is forfeited back to us and the terminated portion of the award (or forfeited or repurchased shares subject to the award) will become available for future grant or sale under the 2014 Option Plan (unless it has terminated).  Shares are not deemed to be issued under the 2014 Option Plan with respect to any portion of an Award that is settled in cash.  If the exercise or purchase price of an award is paid for through the tender of shares, or tax withholding obligations are met through the tender or withholding of shares, those shares tendered or withheld will again be available for issuance under the 2014 Option Plan.

In the event a change, such as a stock split, is made in our capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested awards in the number of shares subject to each outstanding option or other awards in order to prevent dilution or enlargement of the benefits or potential benefits intended to be provided under the 2014 Option Plan.  The administrator also may make provisions for adjusting the number of Awards in the event we effect one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of our outstanding common stock.  Awards may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the award on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the administrator may provide that each award granted under the 2014 Option Plan shall terminate as of a date fixed by the administrator.

Awards

The 2014 Option Plan provides for the grant of options intended to qualify as ISOs under Section 422 of the Code to our and our affiliates’ employees and non-statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, performance unit awards, performance share awards and other stock based awards (each, an “Award”) to our and our affiliates’ directors, employees, consultants and advisors.

Stock Options.  An option is the right to purchase shares of our common stock at a fixed exercise price for a fixed period of time. The administrator may grant both ISOs and NSOs under the 2014 Option Plan.  Except as otherwise determined by the administrator in an Award agreement, the exercise price for options cannot be less than the fair market value (as defined in the 2014 Option Plan) of our common stock on the date of grant.  The term of each option will be determined by the administrator; provided that no ISO will be exercisable after the tenth anniversary of the date the option is granted.  In the case of ISOs granted to an employee who, at the time of the grant of an option, owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any of our affiliates, the exercise price cannot be less than 110% of the fair market value of a share of our common stock on the date of grant and its term will be five years or less from the date of grant.  As of March 31, 2014, the fair market value of our common stock was $22.00 per share, which represents the closing market price of our stock that day as reported on the NASDAQ Global Select Market.  All options granted under the 2014 Option Plan will be NSOs unless the applicable Award agreement expressly states that the option is intended to be an ISO.

Options shall vest and become exercisable as determined by the administrator.  The exercise price will be payable with cash (or its equivalent) or by other methods as permitted by the administrator to the extent permitted by applicable law.
12

If a participant’s employment or relationship with the Company is terminated, the participant (or his or her designated beneficiary or estate representative in the case of death) may exercise his or her option within such period of time as is specified in the Award agreement to the extent that the option is vested on the date of termination.  In the absence of a specified time in the Award agreement, the option will remain exercisable for three months following the date of termination, except in the case where termination is as a result of disability or death, in which case the option will remain exercisable for 12 months following the date of termination.

The administrator may at any time offer to buy out an option previously granted for a payment in cash or shares of our common stock based on such terms and conditions as the administrator shall establish in compliance with Section 409A of the Code and communicate to the participant at the time that such offer is made.

Restricted Stock.  Restricted stock Awards are Awards of shares of our common stock that vest in accordance with terms and conditions established by the administrator.  The administrator may impose whatever conditions to vesting it determines to be appropriate.  The administrator will determine the number of shares of restricted stock granted to any employee.  The administrator determines the purchase price of any grants of restricted stock and, unless the administrator determines otherwise, shares that do not vest typically will be subject to forfeiture or to our right of repurchase, which we may exercise upon the voluntary or involuntary termination of the purchaser’s service with us for any reason including death or disability.  Holders of restricted stock may exercise voting rights with respect to such stock, unless the administrator determines otherwise. During the period of restriction, holders of restricted stock will be entitled to receive all dividends and other distributions paid with respect to such stock unless otherwise provided in the Award agreement. If any such dividends or distributions are paid in shares of our common stock, such shares will be subject to the same restrictions on transferability and forfeitability as the restricted stock with respect to which they were paid.

Unrestricted Stock.  Subject to the terms of an Award agreement, a participant may be Awarded (or sold at a discount) shares of our common stock that are not subject to restrictions on transfer, in consideration for past services rendered to us, our affiliates or for other valid consideration.

Stock Appreciation Rights.  A stock appreciation right is the right to receive an amount equal to the appreciation in the fair market value of our common stock between the exercise date and the date of grant, for that number of shares of our common stock with respect to which the stock appreciation right is exercised. We may either pay the appreciation in cash, in shares of our common stock with equivalent value, or in some combination, as determined by the administrator and in conformance with Section 409A of the Code. The administrator determines the exercise price of stock appreciation rights, the vesting schedule and other terms and conditions of stock appreciation rights; however, stock appreciation rights expire under the same rules that apply to stock options. The administrator may at any time offer to buy out for a payment in cash or shares of our common stock a stock appreciation right previously granted based on such terms and conditions as the administrator shall establish and communicate to the participant at the time that such offer is made.

Performance Units and Performance Shares.  Performance units and performance shares are Awards that will result in a payment to a participant only if performance goals established by the administrator are achieved or the Awards otherwise vest. The administrator will establish performance goals in its discretion, which, depending on the extent to which they are met, will determine the number and/or value of performance units and performance shares to be paid to the participant. The performance goals may be based upon the achievement of company-wide, divisional or individual goals or objectives, or any other basis determined by the administrator. Payment for performance units and performance shares may be made in cash or in shares of our common stock with equivalent value, or in some combination, as determined by the administrator. Performance units will have an initial dollar value established by the administrator prior to the grant date. Performance shares will have an initial value equal to the fair market value of our common stock on the grant date.

Restricted Stock Units.  Restricted stock units are Awards of restricted stock, performance shares and/or performance units that are paid out in installments or on a deferred basis as determined by the administrator in its sole discretion in accordance with rules and procedures established by the administrator and in conformance with Section 409A of the Code.

Other Stock Based Awards.  The administrator has the authority to create Awards under the 2014 Option Plan in addition to those specifically described in the 2014 Option Plan. These Awards must be valued in whole or in part by reference to, or must otherwise be based on, the shares of our common stock.
13

Performance Goals

The administrator may designate any Award as a qualified performance-based award for the purpose of making the Award fully deductible without regard to the $1,000,000 deduction limit imposed by Section 162(m) of the Code. If an Award is so designated, the administrator must establish objectively determinable performance goals for the Award. Performance periods for such Awards must be at least twelve months and may be any longer period. Performance goals for such Awards shall be based on one or more of the following criteria, which may be expressed in terms of Company-wide objectives or in terms of objectives that relate to the performance of a subsidiary or a division, region, department or function within the Company or a subsidiary: earnings (e.g., earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization; or earnings per share); financial return ratios (e.g., return on investment; return on invested capital; return on equity; or return on assets); increase in revenue, operating or net cash flows; cash flow return on investment; total shareholder return; market share; net operating income, operating income or net income; debt load reduction; expense management; economic value added; stock price; and strategic business objectives, consisting of one or more objectives based on meeting specific cost targets, business expansion goals and goals relating to acquisitions or divestitures.

Transferability of Awards

Generally, unless the administrator determines otherwise, the 2014 Option Plan does not allow for the transfer of Awards other than by will or by the laws of descent and distribution, and only the participant may exercise an Award during his or her lifetime.

Amendment and Termination of the 2014 Option Plan

The Board may at any time amend, alter, suspend or terminate the 2014 Option Plan, subject to applicable shareholder approval requirements under federal or state law or NASDAQ rules. Unless sooner terminated, the 2014 Option Plan shall terminate on December 30, 2023, the date that is 10 years from the date the 2014 Option Plan was adopted by the Board.

Effectiveness

The 2014 Option Plan was adopted by the Board on December 30, 2013.  The Board’s adoption of the 2014 Option Plan is contingent upon the plan’s approval by the shareholders, and therefore the 2014 Option Plan will only become effective upon approval of our shareholders.

Liquidation or Dissolution of Akorn

In the event of the proposed dissolution or liquidation of Akorn, the administrator will notify each participant as soon as practicable prior to the effective date of such proposed transaction.  The administrator in its discretion may provide for a participant to have the right to exercise his or her Award, to the extent applicable, until 10 days prior to such transaction as to all of the stock covered thereby, including shares of our common stock as to which such Award would not otherwise be exercisable.  In addition, the administrator may provide that any Akorn repurchase option or forfeiture rights applicable to any Award shall lapse 100%, and that any Award vesting shall accelerate 100%, provided the proposed dissolution or liquidation takes place at the time and in the manner contemplated.  To the extent it has not been previously exercised or vested, an Award will terminate immediately prior to the consummation of such proposed action.

Change in Control

Generally, in the event Akorn experiences a “change in control,” as that term is defined in the 2014 Option Plan, it is anticipated that Awards will be assumed by the successor corporation or that the successor corporation will substitute an equivalent Award in its place.  However, if the successor corporation cannot or will not assume or substitute the outstanding Award, then the administrator may provide that the vesting of any Award shall accelerate 100%.  If accelerated, the administrator shall give the recipient 15 days’ notice from which to exercise the vested Awards. At the end of such 15-day period, the Awards shall terminate if they are not exercised.

14


Federal Income Tax Consequences

To the Optionees or Recipients.

NSOs.  An optionee generally will not recognize any income for federal income tax purposes on the grant of an NSO. Upon the exercise of an NSO, an optionee generally will recognize compensation taxable as ordinary income, equal to the difference between the fair market value of our common stock on the date of exercise and the exercise price. If the optionee is an employee of the Company, this compensation is subject to withholding taxes.  An optionee will recognize gain or loss on the sale or exchange of stock acquired pursuant to an exercise of an NSO.  Such gain or loss will be equal to the difference between the optionee’s adjusted basis in the stock, which will include the exercise price and any ordinary income recognized on exercise of the option, and the fair market value of the stock on the date of sale or exchange.  The gain may be subject to preferential tax treatment if the stock has been held for more than one year.

ISOs.  An optionee will not recognize any income for federal income tax purposes on the grant of an ISO. Upon the exercise of an ISO, tax is deferred until the underlying stock is sold (though the spread at exercise may be a tax preference for purposes of the Alternative Minimum Tax).  When sold, the ISO is taxed at the capital gains rate on the full amount of appreciation for the sales proceeds over the option cost, provided the employee has satisfied the holding period prescribed for ISOs — the longer of two (2) years from the date of grant or one (1) year from the date of exercise.  If the ISO stock is sold within the holding period, the option is taxed as an NSO.

Restricted Stock.  Generally, a recipient recognizes no income from the grant of a restricted stock award until the grant is no longer subject to a substantial risk of forfeiture.  Upon the lapse of a substantial risk of forfeiture (i.e., the restricted stock becomes vested), the recipient has taxable income equal to the excess of the fair market value of the restricted stock over the amount paid, if any.  Upon a later disposition, the computation of taxable gain will take into account any previous taxes paid, and the gain may be subject to preferential tax treatment if the restricted stock has been held for more than one year.

Unrestricted Stock.  Unrestricted stock generally has the same tax consequences as restricted stock.

Stock Appreciation Rights.  A recipient of a stock appreciation right will generally recognize ordinary income for federal income tax purposes, the timing of which depends on the terms of the underlying Award agreement and Section 409A of the Code.

Performance Units and Performance Shares.  A recipient of a performance unit/share generally recognizes no income until the performance objectives are satisfied. If the payout is in stock, the recipient has taxable income equal to the excess of the fair market value of the stock over the amount paid, if any.  Upon a later disposition, the computation of taxable gain will take into account any previous taxes paid, and the gain may be subject to preferential tax treatment if the stock has been held for more than one year. If the payout is in cash, the recipient has ordinary income equal to the amount of cash received.

Restricted Stock Units. Restricted stock units must comply with Section 409A of the Code, and will be taxed in accordance with the terms of its underlying Award agreement.

Other Stock Based Awards. The taxation of other stock based Awards depends on the nature of the Award.

To Akorn.

With the exception of ISO Awards, we generally are entitled to a tax deduction at the time and in the amount that the optionee/recipient recognizes ordinary income in connection with the grant or exercise of the Award. As to grants of ISOs, we generally receive no tax deduction associated with such grant except when the recipient has a disqualifying disposition. Upon a disqualifying disposition, the option loses its ISO status, converts to a NSO, and is taxed accordingly.


The Board believes that the adoption of the 2014 Option Plan is in the best interest of Akorn and its shareholders
and, therefore, unanimously recommends that the shareholders vote “FOR” approval of the adoption of
the 2014 Option Plan.

15


PROPOSAL 4.   APPROVAL BY NON-BINDING ADVISORY VOTE OF THE COMPANY’S CURRENT
EXECUTIVE COMPENSATION PROGRAM.
You are being asked to vote on a proposal commonly known as a “say-on-pay” proposal, which gives you the opportunity to express your approval or disapproval, on a non-binding advisory basis, of our executive officer compensation program, policies and practices through the following resolution:
“RESOLVED, that the shareholders of Akorn, Inc. approve, on an advisory basis, the Company’s executive compensation program, as described in the Compensation Discussion and Analysis, the compensation tables and the accompanying narrative disclosure set forth, pursuant to Item 402 of Regulation S-K, in the Company’s proxy statement for the 2014 annual meeting of shareholders.”
We urge you to consider the various factors regarding our executive compensation program, policies and practices as detailed in the Compensation Discussion and Analysis.  As discussed in the Compensation Discussion and Analysis, we believe that our executive compensation program is competitive and governed by pay-for-performance principles which emphasize compensation opportunities that reward results.  Our use of stock-based incentives reinforces the alignment of the interests of our executives with those of our long-term shareholders, thereby supporting the Company’s strategic objectives and mission.
This advisory vote is in accordance with requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), adopted in mid-2010. The Dodd-Frank Act required that public companies give their shareholders the opportunity to cast advisory votes relating to executive compensation at the first annual meeting of shareholders held after January 21, 2011.  Further, companies were required to hold an initial advisory vote on the frequency with which future advisory votes should be held – whether every one, two or three years – and must hold subsequent votes on the frequency of such advisory votes at least every six years.  The SEC adopted rules to implement the provisions of the Dodd-Frank Act relating to this requirement.
In advance of the Company’s 2011 annual meeting of shareholders, the Board of Directors had recommended that future advisory votes on the Company’s executive officer compensation program should occur every year.  At the 2011 annual meeting of shareholders, the majority of the Company’s shareholders voted in favor of holding future advisory votes every year, and the Company’s Board of Directors subsequently adopted this as its official position.  Accordingly, this Proposal 4 is being submitted to you to obtain the advisory vote of the shareholders in accordance with the Dodd-Frank Act, Section 14A of the Exchange Act and the rules of the Securities and Exchange Commission. We expect that the next shareholder advisory vote on the Company’s executive compensation program will take place at the 2015 annual meeting of shareholders.
Because your vote is advisory, it will not be binding upon the Board of Directors. However, our Board of Directors (including our Compensation Committee) will take into account the outcome of the vote when considering future decisions affecting executive compensation as it deems appropriate.


The Board of Directors unanimously recommends that you vote “FOR” approval of the Company’s
executive compensation program.

16


II. CORPORATE GOVERNANCE AND RELATED MATTERS
Board of Directors

The age, principal occupation and employment, position with us, directorships in other public corporations, qualifications for directorship and year first elected or appointed as one of our directors, of each of our nominees and current directors, as applicable, as of March 7, 2014May 1, 2016 are included in this proxy statement under the heading “PROPOSAL 1. ELECTION OF DIRECTORS” above and are incorporated herein by reference.

Independence of the Board of Directors
can be found starting on page 14.

Independence of the Board of Directors

Our common stock is traded on The NASDAQ Global Select Market (“NASDAQ”). The Board has determined that a majority of the members of, and nominees to, the Board qualify as “independent,” as defined by the listing standards of NASDAQ. Consistent with these considerations, after review of all relevant transactions and relationships between each director and nominee, or any of his family members, and the Company, its senior management and its independent auditors, the Board has further determined that all of our directors and nominees to serve as directors are “independent” under the listing standards of NASDAQ, except for Dr. Kapoor and Mr. Tambi. In making this determination, the Board considered that there were no new transactions or relationships between its current directors and the Company, its senior management and its independent auditors since last making this determination.

Leadership Roles

Leadership Roles

Our bylaws do not require that the positions of Chairman of the Board of Directors and Chief Executive Officer (“CEO”) be separate. Our bylaws allow for the flexibility to decide how the two positions should be filled based on the circumstances existing at any given time. Further, the Board does not have a formal policy relating to the separation of the offices of Chairman of the Board and CEO. Our offices of Chairman of the Board and CEO have been separate since 2002, when our Chairman, John Kapoor last served as both Chairman of the Board and CEO. Currently, with the separation of the positions, the Chairman of the Board oversees strategic planning for the Company, and the CEO oversees the day-to-day planning, execution and operational matters. The Board believes that the separation of the two roles provides a balance of these important responsibilities and best suits the skills of Dr. Kapoor and Mr. Rai. However, the Board believes that retaining the flexibility to unify the two roles is beneficial to the Company, and as such, the Board intends to continue to exercise its discretion in combining or separating these positions depending on the particular circumstances and needs of the Company at any time.


Risk Management

Risk Management

We accept the premise that with innovation and progress we must also confront various risks. We also recognize that risk can be predicted, evaluated, avoided and/or managed. Further, the Board acknowledges that inappropriate risk avoidance and management could damage Company assets as well as shareholder value. Given these principles, senior management is responsible for assessing and managing the Company’s various exposures to risk on a day-to-day basis, including the creation of appropriate risk management and compliance programs and policies. We have developed a consistent, systemic and integrated approach to risk management to help determine how best to identify, manage and mitigate significant risks throughout the Company. The Board is responsible for overseeing management in the execution of its responsibilities and for assessing the Company’s approach to risk management. The Board’s role in risk oversight of the Company is consistent with the Company’s leadership structure, with the CEO and other members of senior management having responsibility for assessing and managing the Company’s risk exposure, and the Board providing guidance in these areas.

AKORN, INC. - 2016 Proxy Statement     6

 Executive Sessions of Independent Directors
Executive Sessions of Independent Directors and Shareholder Communications

Our independent directors meet periodically in executive sessions when only independent directors are present. Persons interested in communicating with the independent directors may address correspondence to a particular director or to the independent directors generally, in care of Corporate Secretary, Akorn, Inc., 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

17


Board Meetings and Annual Meeting Attendance

Our Board Meetings

Duringheld 14 meetings in 2014 and 14 meetings in 2015. Each of our directors attended 75% or more of the year ended December 31, 2013,aggregate number of meetings of our Board held thirteen (13)during the period in which he or she was a director and the number of meetings held by all Board committees on which he or she served during each of which four (4) were regular quarterly meetings2014 and nine (9) were special meetings.  Various committees of our Board met fifteen (15) times during 2013.2015. Directors are strongly encouraged to attend the annual meeting of shareholders unless extenuating circumstances prevent them from attending, although we do not have a formal, written policy requiring such attendance. AllDue to our extended non-filing period, our last annual meeting of the Company’s directors attended at least 75% of the aggregate number of meetings of the Board held during 2013.  All but one of the directors attended at least 75% of the meetings of the Board committees on which they serve, the once exception being Mr. Johnson, who attended four of six audit committee meetings held during the year.shareholders was in May 2014. All members of the Board at the time of the 2013 annual meeting attended the 20132014 annual meeting.

Committees of the Board

Committees of the Board

The Board has three standing committees: an audit committee (the “Audit Committee”), a compensation committee (the “Compensation Committee”), and a nominating and corporate governance committee (the “Nominating and Corporate Governance Committee”), with. From time to time, the Board may create special committees. For example, in July 2015, the Board created a special litigation committee (the “Special Litigation Committee”) to advise upon certain litigation matters. The below chart shows the current members and chairpersons of each committee indicated below.

our three standing committees and the Special Litigation Committee, though the Board has created other special committees from time to time which committees may not necessarily be described herein.

 The Audit Committee consists of Mr. Meyer (Chair), Mr. Johnson,CompensationNominating and Mr. Abramowitz.CorporateSpecial Litigation
 The CompensationAudit Committee consists of Mr. Johnson (Chair), Mr. Weinstein and Dr. Graves.CommitteeGovernance CommitteeCommittee
John N. Kapoor, Ph.D.
The Nominating and Corporate Governance Committee consists of Mr.
Kenneth S. AbramowitzMember
Adrienne L. GravesChairMemberMember
Ronald M. JohnsonMemberMember
Steven J. MeyerChairMember
Terry Allison RappuhnMemberChair
Brian Tambi
Alan Weinstein (Chair),
       Mr. Meyer, and Dr. Graves.
MemberChairMember

The composition of Board committees is reviewed and determined each year at the initial meeting of the Board after the annual meeting of shareholders.

Audit Committee

Audit Committee

The Audit Committee of the Board oversees our corporate accounting and financial reporting process and audits of our financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the Company’s independent auditors;registered public accounting firm (the “independent auditors”); determines and approves the engagement of the independent auditors; determines whether to retain or terminate the existing independent auditors or to appoint and engage new independent auditors; reviews and approves the retention of the independent auditors to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on our audit engagement team as required by law; confers with management and the independent auditors regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; reviews and approves all related person transactions; reviews the financial statements to be included in our Annual Report on Form 10-K and quarterly reports on Form 10-Q; and discusses with management and the independent auditors the results of the annual audit and the results of the reviews of our quarterly financial statements. The Audit Committee met six (6)fifty-two (52) times during the 20132015 fiscal year. A current copy of the Audit Committee Charter, which has been adopted and approved by the Board, is available on our website at http://www.akorn.com (the contents of such website are not incorporated into this proxy statement).

AKORN, INC. - 2016 Proxy Statement     7

The Board has reviewed NASDAQ’s definition of independence for Audit Committee members and has determined that all members of our Audit Committee are “independent” under the listing standards of NASDAQ. Further, the Board determined that each of the members of the Audit Committee is “independent” in accordance with Rule 10A-3 of the Exchange Act. The Board has determined that Mr. Meyer qualifiesand Ms. Rappuhn each qualify as an “audit committee financial expert,” as defined in applicable SEC rules. The Board made a qualitative assessment of Mr. Meyer’s level of knowledge and experience based on a number of factors, including his formal education, and his experience as the Chief Financial Officer of JVM Realty, a private firm specializing in the acquisition, re-positioning and management of multi-family housing for qualified investors, as well as his experience as Corporate Treasurer and International Controller and VPVice President of Global Operations at Baxter International, Inc. The Board also made a qualitative assessment of Ms. Rappuhn’s level of knowledge and experience based on a number of factors, including her formal education and her experience as a Chief Financial Officer of Quorum Health Group, Inc., a previously public company that owned and operated acute care hospitals, as well as her experience as VP, Controller and Assistant Treasurer and VP, Internal Audit at Quorum, her 15 years of experience with Ernst & Young, LLP and her prior service as audit committee chairperson for other public companies. Shareholders should understand that this designation is a disclosure requirement of the SEC related to Mr. Meyer’s and Ms. Rappuhn’s experience and understanding with respect to certain accounting and auditing matters. The designation does not impose upon Mr. Meyer or Ms. Rappuhn any duties, obligations or liabilities that are greater than are generally imposed on himthem as a membermembers of the Audit Committee and the Board, and histheir designation as an audit committee financial expert pursuant to this SEC requirement does not affect the duties, obligations or liabilities of any other member of our Audit Committee or the Board.

18

Compensation Committee

Compensation Committee

The Compensation Committee, which met five (5)ten (10) times during 2013,2015, reviews and approves the overall compensation strategy and policies for the Company. The Compensation Committee reviews and approves corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; reviews and approves the compensation and other terms of employment of our executive officers; and administers equity awards and stock purchase plans. Each member of the Compensation Committee has been determined by the Board to be “independent” under the listing standards of NASDAQ. A current copy of the Compensation Committee Charter, which has been adopted and approved by the Board, is available on our website at http://www.akorn.com (the contents of such website are not incorporated into this proxy statement). The Compensation Committee has authority to obtain advice and seek assistance from internal and external accounting and other advisors and to determine the extent of funding necessary for the payment of any consultant retained to advise it.


 Nominating and Corporate Governance Committee

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is responsible for developing and implementing policies and processes regarding corporate governance matters, assessing Board membership needs and making recommendations regarding potential director candidates to the Board. A current copy of the Nominating and Corporate Governance Committee Charter, which has been adopted and approved by the Board, is available on our website at http://www.akorn.com (the contents of such website are not incorporated into this proxy statement). Each member of the Nominating and Corporate Governance Committee has been determined by the Board to be “independent” under the listing standards of NASDAQ. The Nominating and Corporate Governance Committee met four (4)two (2) times during 2013.

2015.

The Board believes that candidates for director should have certain minimum qualifications, including being able to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Board also considers such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of our shareholders. However, the Board retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of shareholders. In conducting this assessment, the Board considers skills, diversity, age, and such other factors as it deems appropriate given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. The Board strives to achieve diversity in the broadest sense, including persons diverse in geography, age, gender, ethnicity, knowledge and experiences. Although the Board does not have a stand-alone diversity policy, the Board’s overall diversity is a significant consideration in the director selection and nomination process. The Board and Nominating and Corporate Governance Committee assess the effectiveness of board diversity efforts in connection with the annual nomination process as well as in new director searches. Currently, almost half of the Directors are women or minorities. In the case of incumbent directors whose terms of office are set to expire, the Board and the Nominating and Corporate Governance Committee review such directors’ overall service to the Company during their term, including the number of meetings attended, level of participation, quality of performance, and any other relationships and transactions that might impair such director’s independence. In the case of new director candidates, the Board also determines whether the nominee must be independent, which determination is based upon applicable SEC and NASDAQ rules.

AKORN, INC. - 2016 Proxy Statement     8

Board members should possess such attributes and experience as are necessary to provide a broad range of personal characteristics, including diversity, management skills, and pharmaceutical industry, financial, technological, business and international experience. Directors selected should be able to commit the requisite time for preparation and attendance at regularly scheduled Board and committee meetings, as well as be able to participate in other matters necessary for good corporate governance.

In order to identify a potential Board candidate, the Board uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Board conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Board meets to discuss and consider such candidates’ qualifications and then selects a nominee for recommendation to the Board by majority vote. To date, the Board has not paid a fee to any third party to assist in the process of identifying or evaluating director candidates, nor has the Board rejected a director nominee from a shareholder or shareholders. Upon the election of nominees at our annual meeting of shareholders on May 2, 2014,July 1, 2016 the Board will have two vacancies, one ofvacancy, which is reserved for a nominee to be named by our Chairman, Dr. John Kapoor, in accordance with terms of a Modification, Warrant and Investor Rights Agreement entered into on April 13, 2009 between the Company and EJ Funds, LP, a company controlled by our Chairman.

19

Although there is no formal procedure for shareholders to recommend nominees for the Board, the Nominating and Corporate Governance Committee will consider such recommendations for the 2017 annual meeting if received by November 24, 2016, and if subsequent to the 2017 annual meeting, recommendations will be considered if received 120 days in advance of the annual meeting,date on which the Company released its definitive proxy statement in the previous year, addressed to the Nominating and Corporate Governance Committee, in care of Corporate Secretary, Akorn, Inc., 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045. Such recommendations should be addressed to the Nominating and Corporate Governance Committee at our address and provide all information relating to such person that the shareholder desires to nominate that is required to be disclosed in solicitation of proxies pursuant to Regulation 14A under the Exchange Act. The Board does not believe that a formal procedure for shareholders to recommend nominees for the Board is necessary because every effort has been made to ensure that nominees recommended by shareholders are given appropriate consideration by the Nominating and Corporate Governance Committee.


 Board Member Qualifications
John N.  Kapoor, Ph.D.

Special Litigation Committee

The Nominating and Corporate GovernanceSpecial Litigation Committee has nominated Dr. Kapoor to serve on the Board because of his business leadership and industry experience as Chief Executive Officer of health care and pharmaceutical companies and the President of EJ Financial Enterprises, Inc.


In addition, Dr. Kapoor’s outside board experience with Introgen Therapeutics, Inc. and as former chairman of the board of directors of NeoPharm, Inc. and Option Care, Inc. provides him with valuable perspective for guiding us.

Kenneth S. Abramowitz.
The Nominating and Corporate Governance Committee has nominated Mr. Abramowitz to serve on the Board because of his business leadership and industry experience currently as a co-founder and Managing General Partner of NGN Capital and previously as Managing Director at The Carlyle Group in New York, and as an Analyst at Sanford C. Bernstein & Company.
In addition, Mr. Abramowitz’s outside board experience as a member of the Board of Directors of EKOS Corporation, OptiScan Biomedical Corporation, Cerapedics, Inc., Valtech Cardiowas formed in 2015 to consider action to be taken by the Company with respect to certain shareholder demand letters and Small Bone Innovations, Inc.litigation claims made. The Special Litigation Committee met 8 times during the 2015 fiscal year.

Shareholder Outreach Program

We have a robust shareholder outreach program, facilitated by our Investor Relations department and previous service on the boards of Option Care, Inc., Sightline Technologies Ltd and Power Medical Interventions, as well as MedPointe, MultiPlan Acquisition Holdings and ConnectiCare Holdings, Inc. provides him with valuable perspective for guiding us.

Adrienne L. Graves, Ph.D.

The Nominating and Corporate Governance Committee has nominated Dr. Graves to serve on the Board because of her extensive business leadership experience and scientific background in ophthalmic pharmaceutical development and marketing, principally her experience as President,supported by senior leaders from our organization, including our CEO and Global Corporate Officer of Santen Inc.,CFO. Through our outreach program, we speak with our shareholders on a U.S. subsidiary of Japan’s market leader in ophthalmic pharmaceuticals.  Also considered valuable is her past experienceregular basis throughout the year. Our Investor Relations team and senior managers also speak with Alcon Laboratories, Inc., for which at various times she served as Senior VP, World Wide Clinical Developmentanalysts and as VP Clinical Affairs.

Ronald M.  Johnson.
The Nominating and Corporate Governance Committee has nominated Mr. Johnsonothers who advise our shareholders on their ownership positions about general matters related to serve on the Board because of his business leadership, FDA consultation and industry experience as president of Becker & Associates Consulting, Executive Vice President of The Lewin Group, Executive Vice President of Quintiles Consulting and thirty years employment experience with the FDA, primarily in the compliance and enforcement areas, as well as his ongoing experience providing consulting services to the pharmaceutical, medical device, biologic and biotechnology industries in their efforts to meet FDA regulatory requirements.

20


Steven J. Meyer.
The Nominating and Corporate Governance Committee has nominated Mr. Meyer to serve on the Board because of his business leadership and industry experience as the Chief Financial Officer of JVM Realty, experience as the Corporate Treasurer and International Controller and VP of Global Operations at Baxter International, Inc., and membership on the Board of Directors of Insys Therapeutics.
 Brian Tambi.
The Nominating and Corporate Governance Committee has nominated Mr. Tambi to serve on the Board because of his business leadership, FDA and industry experience as the Chairman of the Board, President & CEO of BrianT Laboratories, former Chairman of the Board, President & CEO of Morton Grove Pharmaceuticals, Inc., member of the Board of Directors of Insys Therapeutics, and his executive management experience with companies such as IVAX Corporation, Fujisawa Pharmaceutical Company USA, LyphoMed Inc., and Bristol-Myers International Group.
Alan Weinstein.
The Nominating and Corporate Governance Committee has nominated Mr. Weinstein to serve on the Board because of his business leadership and industry experience as a consultant to supplier clients in the areas of hospital organization, hospital operations, and working with group purchasing  organizations; and his experience as the Founder and President of Premier, Inc.  Additionally, Mr. Weinstein’s past and present experience as a member of the Board of Directors of American DG Energy, SterilMed, Precyse, SutureExpress, Vascular Pathways and OpenMarkets is important to us.

Communications with the Board
Akorn.

Communications with the Board

Shareholders and other interested parties who wish to communicate with the Board of Directors, or a particular director or group of directors, may do so by sending a letter to Akorn, Inc., Attention: Corporate Secretary, 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045. The mailing envelope should contain a clear notation indicating that the enclosed letter is a “Board Communication” or “Director Communication”, and the letter should indicate whether the intended recipients are the entire Board, a specific group or committee of the Board, or an individual director. All such communications received by the Company will be promptly copied and distributed to the appropriate director or directors.

AKORN, INC. - 2016 Proxy Statement     9

REPORT OF THE AUDIT COMMITTEE

The Audit Committee oversees Akorn’s financial reporting process on behalf of the Board. As part of this oversight function, the Audit Committee oversees Akorn’s compliance with legal and regulatory compliance and monitors Akorn’s compliance with Section 404 of the Sarbanes-Oxley Act of 2002, which includes receiving regular reports and representations by management of Akorn and its independent auditors, each of whom is given full and unlimited access to the Audit Committee to discuss any matters which they believe should be brought to our attention.

In carrying out its responsibilities, the Audit Committee acts in an oversight capacity. Management has the primary responsibility for the financial statements and the reporting process, including the system of internal controls.

In this context, the Audit Committee has met and discussed the audited financial statements with management. Management represented to the Audit Committee that Akorn’s consolidated financial statements were prepared in accordance with generally accepted accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with management and the independent auditors.

The Audit Committee discussed with the independent auditors matters required to be discussed by Public Company Oversight Board Auditing Standard No.16. In addition, the Audit Committee has discussed with the independent auditors the auditors’ independence from Akorn and its management, including the matters in the written disclosures and the applicable letter received by the Audit Committee from the independent auditors as required by PCAOB Ethics and Independence Rule 3526,Communication with Audit Committees Concerning Independence.Independence. The Audit Committee has also reviewed the certifications of the executive officers of Akorn attached as exhibits to Akorn’s Annual Report on Form 10-K for the 20132015 fiscal year as well as all reports issued by Akorn’s independent auditor related to its audit of Akorn’s financial statements for the 20132014 and 2015 fiscal yearyears and the effectiveness of Akorn’s internal control over financial reporting.

21

The Audit Committee has also considered whether the independent auditors’ provision of non-audit services to Akorn is compatible with the auditors’ independence.

In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board, and the Board approved, the inclusion of the audited comprehensive consolidated financial statements in Akorn’s Annual Report on Form 10-K for the year ended December 31, 2013,2015, for filing with the SEC.

This report is submitted by the Audit Committee, consisting of:


Steven J. Meyer (chair)

Kenneth S. Abramowitz

Ronald M. Johnson

Terry Allison Rappuhn

AKORN, INC. - 2016 Proxy Statement     10

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Review and Approval of Transactions with Related Persons

Under the Company’s Code of Ethics, all employees and Approvaldirectors must report any activity that would cause or appear to cause a conflict of Transactions with Related Persons

Pursuant to its charter, the Audit Committee reviews and approves allinterest on his or her part, including any potential related party transactions. Akorn’s Board recognizes that certain transactions althoughpresent a heightened risk of conflicts of interest or the Board asperception of a whole may also review and approve such transactions.  The procedure forconflict of interest. As a result, in 2016, the Company adopted a written Policy on Related-Party Transactions (“Related-Party Transactions Policy”) to help ensure that all related-party transactions will be subject to review, approval or ratification in accordance with certain procedures.

The Related-Party Transactions Policy applies to any transaction where the Company is a participant and a related person has or will have a direct or indirect material interest. A “related person” is defined as our directors, director nominees, executive officers, beneficial owners more than 5% of the outstanding shares of our common stock and the respective immediate family members of all such persons. Under the policy, a “related-party transaction” is defined as any transaction or relationship in which the Company is or will be a participant and any related party has or will have a direct or indirect material interest.

Pursuant to our Related-Party Transactions Policy, prior to entering into a related-party transaction, a related party is required to notify the General Counsel of any material interest that such person (or his or her immediate family member) has or may have in the proposed transaction. The notice should include a description of the material terms of the transaction, including the related person and his or her relationship to the Company, the related person’s interest and role in the proposed transaction, and the aggregate cost to or benefit to be derived by the related person and the Company if known. From time to time, the Company may also take measures to identify potential related party transactions that might not have been self-reported. For example, in 2016, the internal audit department required all employees at the director level and above to answer a survey regarding their knowledge of any potential related-party transactions involving themselves, their direct reports or any other employees of the Company since January 1, 2015. In 2016, the internal audit department also cross-checked names of related parties of the Company’s officers and directors against the names in the Company’s accounts payable and accounts receivable databases to identify any potential related party transactions that may have occurred since January 2015. Any transactions that were identified during such processes (self-reporting, survey, cross-checking names in databases) were presented to the General Counsel and the Audit Committee for review.

Under our Related-Party Transactions Policy, the General Counsel notifies the Audit Committee of any pending or proposed related-party transaction (or existing transaction that was not previously reported). Pursuant to the policy, our General Counsel is responsible for the review and, if appropriate, approval of related-party transactions in which the aggregate amount involved is expected to be $50,000 or less in any fiscal year. Pursuant to the policy, the General Counsel will consult with one or more officers when making such determination. The Audit Committee is responsible for the review and, if appropriate, approval of related-party transactions in which the aggregate amount involved may be expected to exceed $50,000 in any fiscal year. No related party is allowed to participate in any deliberation or approval of a related party transaction may involve discussingfor which he or she or any member of his or her immediate family is a related party.

Pursuant to the terms and purposespolicy, in the event the Company, a director, any member of senior management or other employee becomes aware of a related-party transaction with a related person at any time since the beginning of the transaction with management, discussingprevious fiscal year which has not been approved under the policy, he or she is required to report the transaction withto the external auditors, and reviewing financial statements and related disclosures.  In addition,General Counsel, who will refer the Board and the Audit Committee review the details of major deals and transactions to ensure that they do not involve related-party transactions.  Members of management have been informed and understand that they are to bring related party transactionsmatter to the Audit Committee as appropriate.

In determining whether to approve or ratify a transaction, the Audit Committee or General Counsel, as the case may be, considers all of the relevant facts and circumstances they deem appropriate, including, but not limited to, the Board for approval.  These policiesterms and procedures are evidencedcircumstances of the transaction, the extent of the related party’s interest in the transaction, the nature of the Company’s participation in the transaction, the availability to the Company of alternative means or transactions to obtain like benefits, the results of an appraisal, whether the transaction was entered into on terms no less favorable to the Company than the terms generally available to an unaffiliated third-party under the same or similar circumstances, and whether the transaction is fair to the Company and in the interest of the Company and its stockholders. In addition, pursuant to the Audit Committee Charter, the Audit Committee discusses with the independent auditor the Company’s identification, accounting for and disclosures of related-party transactions and any concerns members of the Audit Committee have regarding any related-party transactions.

The Related-Party Transaction Policy classifies certain transactions as pre-approved, including: (a) employment of executive officers and director compensation, if the compensation is required to be reported under Item 402 of Regulation S-K and the officer is not an immediate family member of another officer or director; (b) transactions with another company or charitable contributions if the related person’s only relationship is as an employee (other than executive officer), director or beneficial owner of less than 10% of that company’s outstanding equity if the aggregate amount involved does not exceed the greater of (or in the case of a charity, the lesser of) $200,000 or 2% of that company’s total annual revenues or charitable organization’s total annual receipts; (c) transactions where the related person’s interest arises solely from the ownership of the Company’s Codestock and all stockholders benefit on a pro rata basis; (d) regulated transactions involving services as a common or contract carrier or public utility at rates fixed in conformity with law or governmental authority; and (e) transactions where the rates or charges involved are determined by competitive bids.

AKORN, INC. - 2016 Proxy Statement    �� 11

Certain Transactions and Relationships

In accordance with Item 404(a) of Ethics.

Certain Transactions
Regulation S-K, below are descriptions of related-party transactions that existed or that we have entered into since the beginning of 2015 and the amount involved was more than $120,000 and certain other relationships.

John N. Kapoor, Ph.D., our Chairman of the Board and aan over 5% shareholder, is the President of EJ Financial Enterprises, Inc., a health carehealthcare consulting investment company (“EJ Financial”). EJ Financial is involved in the management of health carehealthcare companies in various fields and Dr. Kapoor is involved in various capacities with the management and operation of these companies. The John N. Kapoor Trust dated September 20, 1989 (the “Kapoor Trust”), the beneficiary and sole trustee of which is Dr. Kapoor, is a principal shareholder of each of these companies. Although these companies do not currently compete directly with us, certain companies with which EJ Financial is involved are in the pharmaceutical business. Discoveries made by, or other activities of, one or more of these companies could render our products less competitive or obsolete.

As of December 31, 2015, Dr. Kapoor beneficially controls more than 25% of our common stock. As a result, Dr. Kapoor can strongly influence, and potentially control, the outcome of our corporate actions, including the election of our directors and transactions involving a change of control. This concentrated control limits other shareholders’ ability to influence corporate matters and, as a result, the Company may take actions that other shareholders do not view as beneficial. Further, decisions made by Dr. Kapoor with respect to his and his related parties’ ownership or trading of our common stock could have an adverse effect on the market value of our common stock and an adverse effect on our business.

The Kapoor Trust is entitled to nominate one person to serve on our Board of Directors pursuant to the Stock Purchase Agreement dated November 15, 1990. Dr. Kapoor was designated by the Kapoor Trust for this purpose. See “Directors” and “Director Compensation” for more information.

EJ Funds, LP, a company controlled by Dr. Kapoor, is entitled to nominate two persons to serve on our Board of Directors pursuant to the Modification, Warrant and Investor Rights Agreement dated April 13, 2009. Mr. Tambi was nominated by EJ Funds, LP to serve on our Board of Directors for this purpose. The other seat for nomination remains vacant. See “Directors” and “Director Compensation” for more information.

The Company paid $1,081,000 forobtained legal services obtained during 2013totaling $1.7 million for the year ended December 31, 2015 from Polsinelli PC, (formerly Polsinelli Shughart PC), a firm for which the spouse of the Company’s Senior Vice President, General Counsel and Secretary is a shareholder.


Certain of the Company’s named executive officers have

The Company has entered into employment or consulting agreements and offer letters with the Company.its Named Executive Officers. The terms of such agreements are described under“Compensation Discussion and Analysis” and“Potential Payments Upon Termination.”

Our former CFO entered into a letter agreement with the Company in Section IV below.connection with his resignation. The material terms of the letter agreement are described under “Potential Payments Upon Termination.”

Our executive officers and directors have equity ownership in our Company. See“Outstanding Equity Awards at 2015 Fiscal Year End Table”and Item 12 –“Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.”

Board Independence

Our Board has determined that all of our directors, other than Dr. Kapoor and Mr. Tambi, are “independent” as defined in the federal securities laws and applicable NASDAQ rules for service on our Board. In recommending to the Board that each of the independent directors be classified as independent, the Nominating and Governance Committee also considered whether there were any facts or circumstances that might impair the independence of each of those directors. In making this determination, the Board considered all transactions and relationships discussed above under “Certain Transactions and Relationships.

AKORN, INC.- 2016 Proxy Statement12


SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act requires our officers, directors and anyexecutive officers and persons who beneficially own more than 10% of our common stock to file reports of security ownership of, and transactionschanges in our common stocksuch ownership with the SEC and furnish copies of such reports to us.SEC. Based solely on our review of the copiesreports that have been filed by or on behalf of such forms and amendments thereto furnished to uspersons in this regard and written representations that no other such statements were required,from them, we believe that during fiscal year 2013 our officers, directors and any person whom we understand beneficially owns more than 10% of our common stock complied with all such requirements.


persons have timely filed all reports required by Section 16(a) of the Exchange Act during 2015.

CODE OF ETHICS

Our Board has adopted a Code of Ethics that is applicable to all employees, including our principal executive officer, principal financial officer, principal accounting officer, controller and persons performing similar functions.functions, as well as members of the Board. We willintend to satisfy any disclosure requirements under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, any provision of the Code of Ethics with respect to our principal executive officer, principal financial officer, principal accounting officer, controller and persons performing similar functions by disclosing the nature of such amendment or waiver on our website or in a report on Form 8-K. A copy of the Code of Ethics can be obtained at our website.

Our website address is http://www.akorn.com (the contents of such website are not incorporated into this proxy statement).  In addition, our Board has adopted a general code of ethics that is applicable to all of our employees and directors.

Our Audit Committee has adopted a whistleblower policy in compliance with Section 806 of the Sarbanes-Oxley Act and Section 21F of the Exchange Act. The whistleblower policy allows employees to confidentially submit a good faith complaint regarding accounting or audit matters to the Audit Committee and management without fear of dismissal or retaliation. This policy, as well as a copy of our codeCode of ethics, wasEthics, is distributed to all our employees for signature and signed copies are on file in our Human Resources Department.


AKORN, INC.- 2016 Proxy Statement      13


III.  SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
As
II.PROPOSALS

PROPOSAL 1ELECTION OF DIRECTORS

The Company’s Board of Directors (“Board”) consists of nine seats. At the beginning of 2015, two of the seats were vacant. Upon recommendation from one of our independent Board members, Terry Allison Rappuhn was considered for directorship. After review, vetting and recommendation by our Nominating and Corporate Governance Committee, on April 20, 2015, the Board approved the appointment of Ms. Rappuhn to fill one of two vacant seats on the Board at that time and to join the Company’s Audit Committee. In March 7, 2014,2015, Ronald M. Johnson informed the following persons were directors,Company of his decision not to stand for reelection to the Board at the 2015 annual meeting for personal health reasons, but agreed to be retained to provide regulatory and compliance consulting services with respect to FDA related matters. Due to the ongoing restatement process, the Company did not hold an annual meeting in 2015, and Mr. Johnson has continued to serve on the Board. Mr. Johnson has since recovered from his health matters, withdrawn his resignation and agreed to stand for re-election at the 2016 annual meeting. Currently, there is one remaining vacant seat, which is reserved for a nominee to be named by EJ Funds, LP, a company controlled by our Chairman. Under the Modification, Warrant and Investor Rights Agreement entered into on April 13, 2009, EJ Funds, LP, has the right to name nominees “Named Executive Officers” (as definedfor two seats on our Board. Mr. Tambi was nominated to one of those seats and the second remains vacant.

The Board has nominated eight candidates for election at the 2016 annual meeting and recommends that shareholders vote “FOR ALL” eight nominees. All of the nominees listed below are currently directors. If elected at the 2016 annual meeting, each of these nominees would serve until the 2017 annual meeting and until his or her successor is elected and has qualified, or, if earlier, until the director’s death, resignation or removal. Directors are elected by a plurality of the votes properly cast in Section IV below),person or others with beneficial ownershipby proxy. The eight nominees receiving the highest number of 5%affirmative votes will be elected. In the unanticipated event that one or more of our common stock.  The information set forth below has been determinedsuch nominees becomes unavailable as a candidate for director, the persons named in accordance with Rule 13d-3 under the Exchange Act based upon information furnished to us or to the SECaccompanying proxy will vote for another candidate nominated by the persons listed.  Unless otherwise noted,Board. Each person nominated for election has agreed to serve if elected. We have no reason to believe that any nominee will be unable to serve.

The following table and narrative description sets forth, as of May 1, 2016, the addressage, principal occupation and employment, position with us, directorships in other public corporations, and year first elected or appointed as one of our directors, of each of the following persons is 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

Beneficial Ownership of Holders of 5%eight individuals nominated for election as director. Unless otherwise indicated, each nominee has been engaged in the principal occupation or occupations described below for more of our Common Stock, Directors, and Named Executive Officers:
 
Beneficial Owner
 
Shares
Beneficially Owned (1)
 Percent of Class 
Holders of 5% or more of our common stock (excluding Directors and Named Executive Officers):        
BlackRock, Inc.  7,505,906    (2)  7.77% 
Columbia Wanger Asset Management, LLC  7,263,695    (3)  7.52% 
Oak Ridge Investments LLC  5,575,735    (4)  5.77% 
         
Directors:        
John N.  Kapoor, Ph.D.  31,582,967    (5)  30.41% 
Kenneth S. Abramowitz  72,872    (6)  
       *
 
Adrienne L. Graves, Ph.D.  29,557    (7)  
       *
 
Ronald M.  Johnson  201,557    (8)  
       *
 
Steven J. Meyer  101,456    (9)  
       *
 
Brian Tambi  89,557  (10)  
       *
 
Alan Weinstein  134,057  (10)  
       *
 
Named Executive Officers:        
Raj Rai  3,966,300  (11)  3.94% 
Timothy A. Dick  802,099  (12)  
       *
 
Joseph Bonaccorsi  596,085  (13)  
       *
 
Bruce Kutinsky, Pharm. D.  413,537  (14)  
       *
 
John R.  Sabat  183,522  (15)  
       *
 
Mark M. Silverberg          500,351  (16)  
       *
 
Directors and Named Executive Officers as a
group (13 persons)
  
         
38,673,917
   
 
35.00%
 

(*) indicates Beneficial Ownership of less than 1%.

the past five years.

Name Age Director Since Present Position with Akorn
John N. Kapoor, Ph.D. 72 1990 Chairman of the Board
Kenneth S. Abramowitz 65 2010 Director
Adrienne L. Graves 62 2012 Director
Ronald M. Johnson 70 2003 Director
Steven J. Meyer 59 2009 Director
Terry Allison Rappuhn 59 2015 Director
Brian Tambi 71 2009 Director
Alan Weinstein 73 2009 Director

AKORN, INC. - 2016 Proxy Statement     14

(1)Includes all shares beneficially owned, whether directly and indirectly, individually or together with associates, jointly or as community property with a spouse, as well as any shares as to which beneficial ownership may be acquired within 60 days of March 7, 2014 by the exercise of options, warrants or other convertible securities.  Unless otherwise specified in the footnotes that follow, the indicated person or entity has sole voting power and sole investment power with respect to the shares.
(2)
The stock ownership of BlackRock, Inc. is as of December 31, 2013 as reflected in the Schedule 13G/A filed with the SEC on February 10, 2014.  The address of BlackRock, Inc. is 40 East 52nd Street, New York, New York 10022.
(3)
The stock ownership of Columbia Wanger Asset Management, LLC is as of December 31, 2013 as reflected in the Schedule 13G/A filed with the SEC on February 6, 2014.  The address of Columbia Wanger Asset Management, LLC is 227 West Monroe Street, Suite 3000, Chicago, Illinois 60606.
24

(4)    
The stock ownership of Oak Ridge Investments LLC is as of December 31, 2013 as reflected in the Schedule 13G filed with the SEC on February 3, 2014.  The address of Oak Ridge Investments LLC is 10 South LaSalle Street, Suite 1900, Chicago, Illinois 60603.
(5)              Includes (i) 16,561,656 shares of common stock owned by the Kapoor Trust, of which Dr. Kapoor is the sole trustee and beneficiary, (ii) 4,224,185 shares owned by various grantor retained annuity trusts (“GRATs”) of which Dr. Kapoor is the sole trustee and various family members are the beneficiaries, (iii) 498,452 shares of common stock owned directly by Dr. Kapoor, (iv) 2,278 unvested restricted stock awards to Dr. Kapoor scheduled to vest on May 3, 2014, (v) 2,970,644 shares owned by EJ Financial / Akorn Management L.P., of which Dr. Kapoor is the managing general partner, (vi) 133,439 shares of common stock owned by several trusts, the trustee of which is an employee of EJ Financial Enterprises Inc., a company for which Dr. Kapoor serves as President, and the beneficiaries of which are Dr. Kapoor’s children, (vii) 3,590,445 shares of common stock issuable upon exercise of warrants issued to the EJ Funds LP, and (viii) 3,601,868 shares of common stock issuable upon the exercise of warrants held by the Kapoor Trust.  Dr. Kapoor holds sole voting and dispositive power over 25,021,878 beneficially-owned shares and holds shared voting and dispositive power over 6,561,089 beneficially owned shares, which includes the 2,970,644 shares owned by EJ Financial / Akorn Management L.P and the 3,590,445 shares of common stock issuable upon exercise of warrants issued to the EJ Funds LP.
(6)Beneficial ownership for Mr. Abramowitz includes (i) 51,585 shares of common stock issuable upon exercise of options and (ii) 2,278 shares of restricted common stock scheduled to vest on May 3, 2014.
(7)Beneficial ownership for Dr. Graves includes (i) 20,000 shares of common stock issuable upon exercise of options and (ii) 2,278 shares of restricted common stock scheduled to vest on May 3, 2014.
(8)Beneficial ownership for Mr. Johnson includes (i) 120,000 shares of common stock issuable upon exercise of options and (ii) 2,278 shares of restricted common stock scheduled to vest on May 3, 2014.
(9)Beneficial ownership for Mr. Meyer includes (i) 40,000 shares of common stock issuable upon exercise of options and (ii) 2,278 shares of restricted common stock scheduled to vest on May 3, 2014.
(10)
(11)
Beneficial ownership for each of Messrs. Tambi and Weinstein includes (i) 70,000 shares of common stock issuable upon exercise of options and (ii) 2,278 shares of restricted common stock scheduled to vest on May 3, 2014.
Beneficial ownership for Mr. Rai consists of 3,966,300 shares of common stock issuable upon the exercise of options.
(12)Beneficial ownership for Mr. Dick includes 779,900 shares of common stock issuable upon the exercise of options.  
(13)
Beneficial ownership for Mr. Bonaccorsi includes 528,025 shares of common stock issuable upon the exercise of options.
(14)
Beneficial ownership for Dr. Kutinsky includes 405,300 shares of common stock issuable upon the exercise of stock options.
(15)
Beneficial ownership for Mr. Sabat includes 146,148 shares of common stock issuable upon the exercise of stock options.
(16)Beneficial ownership for Mr. Silverberg includes 452,975 shares of common stock issuable upon the exercise of stock options.Back to Contents

25

EQUITY COMPENSATION PLANS
Equity Compensation Plans
Under

JOHN KAPOOR, PH.D

Director Since: 1990

Age: 72

Dr. Kapoor has served as the 2003 Option Plan, options have been granted to employees and directors.  As of March 31, 2014, 9,167,195 shares remain outstanding under the 2003 Option Plan.  However, on November 6, 2013 the 2003 Option Plan expired in accordance with its terms and is no longer available for future grants.  Options granted under the 2003 Plan have exercise prices equivalent to the market valueChairman of our common stock on the date of grant and expire five years from that date.  Options historically granted toBoard since October 1990. Dr. Kapoor served as our Directors vested immediately upon grant.  All options granted from May 4, 2012 through November 6, 2013 vest annually over a four-year period.  Most of the options granted under the 2003 Plan prior to May 4, 2012 vest annually over a three-year vesting period.  All existing option and restricted stock awards as of November 6, 2013, the date of expiration of the 2003 Option Plan, will remain intact through their various expiration dates, but no further awards can be granted pursuant to the 2003 Option Plan.  The Company is seeking shareholder approval of the 2014 Option Plan, which was adopted by the Board of Directors on December 30, 2013.  Under this plan, which would replace the expired 2003 Option Plan, 7,500,000 shares of common stock may be issued pursuant to options and other stock-based awards. (See Proposal 3 and Appendix A for further details.)  The 7,500,000 shares set aside for issuance under the 2014 Option Plan is inclusive of the 6,816,500 shares authorized but unissued from the terminated 2003 Option Plan.

The Akorn, Inc. Employee Stock Purchase Plan (the “ESPP”) permits eligible employees to acquire shares of our common stock through payroll deductions in whole percentages from 1% to 15% of eligible wages, at a 15% discount from the market price of our common stock, subject to an annual maximum purchase of $25,000 in market value of common stock.  A maximum of 2,000,000 shares of our common stock may be issued under the ESPP.  

We do not have any equity compensation plans that have not been approved by our shareholders, with exception of the 2014 Option Plan which is being presented for shareholder approval in this Proxy Statement.
Summary Table.  The following table sets forth certain information as of December 31, 2013, with respect to compensation plans under which shares of Akorn common stock were issuable as of that date. 
Plan Category 
Number of securities
to be issued upon
exercise of
outstanding options,
warrants and rights
  
Weighted-average
exercise price of
outstanding options,
warrants and rights
  
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in the
first column)
 
Equity Compensation plans
approved by security holders:
  9,227,898(2)  $4.45   646,593(1)(2) 
Equity Compensation plans
not approved by security holders:
 
 
-
  
 
-
  
 
-
 
             
Total  9,227,898(2)  $4.45   646,593(1)(2) 

(1) Includes 646,593 shares of common stock available for future issuance under the ESPP.  When the 2003 Option Plan expired on November 6, 2013, there were 6,816,500 previously available shares that expired.
(2) 
There were 72,948 shares of Akorn Inc. common stock issued pursuant to employee participation in the ESPP during 2013.  These shares have been reflected in the table above as if they were issued at December 31, 2013, though they were actually issued in January 2014.

26


IV.  EXECUTIVE COMPENSATION AND OTHER INFORMATION
Executive Officers
The following table identifies our current executive officers, the positions they hold, and the year in which they became an officer, as of March 7, 2014.  Our officers are appointed by the Board to hold office until their successors are elected and qualified. 
NamePositionAge
Year Became
Officer
    
Raj RaiChief Executive Officer (“CEO”)472009
Timothy A. DickChief Financial Officer (“CFO”)442009
Joseph BonaccorsiSenior Vice President, General Counsel, and Secretary (“General Counsel”)492009
Bruce KutinskyChief Operating Officer (“COO”)482010
John R. SabatSenior Vice President, National Accounts and Trade Relations642004
Mark M. SilverbergExecutive Vice President, Global Quality Assurance and Alliance Management602006

Raj Rai.  Mr. Rai was appointed Interiminterim Chief Executive Officer in June 2009,from March 2001 to May 2002 and appointedas our Chief Executive Officer infrom May 2010.  He had been appointed Strategic Consultant2002 to December 2002. Dr. Kapoor is the Special CommitteePresident of EJ Financial Enterprises, Inc., a healthcare consulting and investment company. Dr. Kapoor is the chairman of the Board in February 2009, following the departureboard of our formerdirectors, President and Chief Executive Officer.Officer of Insys Therapeutics, Inc. (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology, into which NeoPharm, Inc. (previously a publicly held biopharmaceutical company) merged in October 2010. Prior to joining Akorn, Mr. RaiNeoPharm’s merger, Dr. Kapoor was the President and CEOchairman of its board of directors. Previously, Dr. Kapoor was the chairman of the board of directors of Option Care, Inc., a leading provider of home infusion pharmacy and specialty pharmacy services, which was acquired by Walgreen Co. in August 2007. Dr. Kapoor received his Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and a B.S. in Pharmacy from Bombay University in India. Under agreements between us and the John N. Kapoor Trust dated 9/20/89 (the “Kapoor Trust”), the beneficiary and sole trustee of which is Dr. John N. Kapoor, the Kapoor Trust is entitled to designate one individual to be nominated and recommended by our Board for election as a director. Dr. Kapoor was designated by the Kapoor Trust for this purpose.

Among other qualifications, Dr. Kapoor brings to Akorn’s Board a breadth and depth of pharmaceutical industry and operational knowledge, entrepreneurial vision, business leadership and valuable perspective that he has gained as a founder of generic pharmaceutical companies as well as from his current and prior service as chief executive officer, chairman and director of a number of publicly and privately held healthcare, pharmaceutical and health services companies.

KENNETH ABRAMOWITZ

Director Since: 2010

Age: 65

Committees: Audit

Mr. RaiAbramowitz was elected to the Board in May 2010. Mr. Abramowitz is Managing General Partner of NGN Capital, a venture capital firm that he co-founded in 2003 which focuses on investments in the healthcare and biotechnology sectors. Mr. Abramowitz joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003 and focused on U.S. buyout opportunities in the healthcare industry. Prior to that, Mr. Abramowitz worked as an analyst at Sanford C. Bernstein & Company, where he covered the medical supply, hospital management and health maintenance organization (HMO) industries for 23 years. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an M.B.A. from Harvard Business School in 1976. Mr. Abramowitz currently sits on the boards of the following privately held companies: OptiScan Biomedical Corporation (a company that develops continuous monitoring systems for use in hospital ICUs), Cerapedics, Inc. (an orthobiologics company), Entera Bio Ltd. (a biotechnology company) and Valtech Cardio Ltd. (a company that develops and manufactures cardiovascular devices for mitral and tricuspid valve repair and replacement). Mr. Abramowitz previously served as a director at EKOS Corp., Small Bone Innovations, Inc., Option Care, Inc., Sightline Technologies Ltd. (acquired by Stryker) and Power Medical Interventions (acquired by Covidien), as well as MedPointe and ConnectiCare Holdings, Inc.

Among other qualifications, Mr. Abramowitz brings to Akorn’s Board analytical expertise, in-depth research and valuable perspective of healthcare and biotechnology companies gained from his experience as a co-founder, managing general partner and his other leadership and analyst roles at international investment firms with specialization in healthcare, as well as his current and prior service on the boards of privately held healthcare, biotechnology and medical device companies.

AKORN, INC. - 2016 Proxy Statement15

ADRIENNE GRAVES, PH.D

Director Since: 2012

Age: 62

Committees: Compensation (chair), Nominating and Corporate Governance, Special Litigation

Dr. Graves was appointed a director by the Board in March 2012. Dr. Graves is a visual scientist by training and a global industry leader in ophthalmology. From 2002 to 2010, Dr. Graves was President and Chief Executive Officer of Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., Japan’s market leader in ophthalmic pharmaceuticals. Dr. Graves joined Santen Inc. in 1995 as Vice President of Clinical Affairs to initiate the company’s clinical development efforts in the U.S. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc. in various roles, including Senior Vice President, World Wide Clinical Development and Vice President Clinical Affairs. She currently serves on the boards of directors of the public companies TearLab Corporation (NASDAQ: TEAR) and Nicox SA (Euronext Paris; COX) and the privately held companies Aerpio Therapeutics, Envisia Therapeutics and Encore Vision. Dr. Graves is also a board member for several non-profit organizations, including the American Academy of Ophthalmology Foundation, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation, KeepYourSight Foundation, the Corporation Committee for the Brown University Medical School and Himalayan Cataract Project. Dr. Graves co-founded Ophthalmic Women Leaders and Glaucoma 360. She received her B.A. in Psychology with honors from Brown University, her Ph. D. in Psychobiology from the University of Michigan and completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Among other qualifications, Dr. Graves brings to Akorn’s Board more than 30 years of ophthalmic pharmaceutical industry experience, business leadership skills, and a deep knowledge of pre-clinical and clinical development in this sector, regulatory affairs and pharmaceutical sales and marketing, as well as a vast network of leading clinicians and thought leaders in the ophthalmic space and a familiarity with corporate governance matters gained in part from serving as CEO and head of R&D at Santen and serving on other public company boards.

RONALD JOHNSON

Director Since: 2003

Age: 70

Committees: Audit, Compensation

Mr. Johnson was appointed a director by the Board in May 2003. Mr. Johnson served as President of Becker & Associates Consulting, a firm which provides consulting services to the pharmaceutical, biologics and medical device industries on FDA regulatory requirements, from 2011 until retiring from that firm in 2013, and currently continues to serve as an independent consultant. Previously, Mr. Johnson served as Executive Vice President of The Lewin Group, a subsidiary of Quintiles Transnational, Inc., which provides various healthcare consulting services to state and federal governments, healthcare insurers and healthcare institutions. Prior to joining The Lewin Group, Mr. Johnson served as Executive Vice President of Quintiles Consulting, a business unit of Quintiles Transnational, Inc. Quintiles Consulting provides consulting services to the pharmaceutical, medical device, biologic and biotechnology industries in their efforts to meet FDA regulatory requirements. Mr. Johnson also spent 30 years with the FDA, holding various senior level positions primarily in the compliance and enforcement areas.

Among other qualifications, Mr. Johnson brings to Akorn’s Board extensive experience in managing regulatory and compliance requirements of the FDA, particularly in pharmaceutical, medical device, biologic and biotechnology industries, as well as a deep knowledge and understanding of FDA policies and procedures regarding cGMP compliance, quality control processes and outcomes reporting gained from his years of providing specialized consulting services to governments, pharmaceutical companies and healthcare institutions and working at the FDA.

AKORN, INC. - 2016 Proxy Statement16

STEVEN MEYER

Director Since: 2005

Age: 59

Committees: Audit (chair), Nominating and Corporate Governance

Mr. Meyer was appointed a director by the Board in June 2009. Since 2005, Mr. Meyer has served as the Chief Financial Officer of JVM Realty, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company that provides renal and hospital products. Mr. Meyer served as the Corporate Treasurer and International Controller and VP of Global Operations during a 23-year career at Baxter International, Inc. Mr. Meyer serves on the board of directors and as chair of the audit committee of INSYS Therapeutics (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant.

Among other qualifications, Mr. Meyer brings to Akorn’s Board financial expertise, extensive knowledge of the healthcare industry, including an international perspective, as well as business leadership skills, which he gained in part from serving as CFO of an investment firm, as the corporate treasurer and international controller and vice president of global operations at a Fortune 500 healthcare company and his service on the board of a publicly held specialty pharmaceutical company.

TERRY ALLISON RAPPUHN

Director Since: 2015

Age: 59

Committees: Audit, Special Litigation (chair)

Ms. Rappuhn was appointed a director by the Board in April 2015. In February 2016, Ms. Rappuhn was elected to the board of directors of Span-America Medical Systems, Inc. (NASDAQ: SPAN), a manufacturer of beds and pressure management products for the medical market. From 2006 to 2010, she served on the board of AGA Medical Holdings, Inc. (previously a publicly held company that was acquired by St. Jude Medical), a medical device company, where she served as the audit committee chairperson. From 2003 to 2007, she served on the board of directors of SeQual TechnologiesGenesis HealthCare Corporation (previously a publicly held company that merged), an operator of skilled nursing and assisted living centers, where she served as the audit committee chairperson. From 1999 to April 2001, Ms. Rappuhn served as Senior Vice President and Chief Financial Officer of Quorum Health Group, Inc. (previously a publicly held company that was acquired by Triad Healthcare Corporation), an owner and currentlyoperator of acute care hospitals. From 1996 to 1999 and from 1993 to 1996, Ms. Rappuhn served as Quorum’s Vice President, Controller and Assistant Treasurer and as Vice President, Internal Audit, respectively. Ms. Rappuhn has 15 years of experience with Ernst & Young, LLP and is a Certified Public Accountant.

Among other qualifications, Ms. Rappuhn brings to Akorn’s Board expertise in the fields of finance and accounting in various segments of the healthcare industry, especially hospital operations, knowledge of information technology controls, including cybersecurity, and understanding of strategic, operational and financial issues of public companies, gained from serving as a board member and chief financial officer of rapidly expanding healthcare public companies that were building infrastructure, processes and teams.

AKORN, INC. - 2016 Proxy Statement     17

BRIAN TAMBI

Director Since: 2009

Age: 71

Mr. Tambi was appointed a director by the Board in June 2009. Mr. Tambi serves onas a member of the board of directors of Aciex Therapeutics.

Timothy A. Dick.   Insys Therapeutics (NASDAQ: INSY), a publicly held drug development company focused on pain and oncology. Since forming the company in 2006, Mr. DickTambi has served as the Chairman of its board, President and Chief Executive Officer of Atrium Pharmaceuticals, LLC, a pharmaceutical company focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From November 1995 to July 2006, Mr. Tambi was the Chairman of the board of directors, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc., a leading manufacturer and marketer of oral liquid and topical pharmaceuticals. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (previously a publicly held pharmaceutical company that was acquired by Teva). Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University. Under our April 13, 2009 Modification, Warrant and Investor Rights Agreement with EJ Funds, EJ Funds has the right to require us to nominate two directors to seats on our Board. Mr. Tambi was designated by EJ Funds for one of the seats (the other seat remains vacant).

Among other qualifications, Mr. Tambi brings to Akorn’s Board extensive pharmaceutical industry experience, particularly FDA knowledge and drug development and commercialization expertise, as well as business leadership skills gained from his experience as a founder, executive and board member of numerous public and private pharmaceutical companies.

ALAN WEINSTEIN

Director Since: 2009

Age: 73

Committees: Compensation, Nominating and Corporate Governance (chair), Special Litigation

Mr. Weinstein was appointed Chief Financial Officera director by the Board in JuneJuly 2009. Most recently, he was Vice President, Operations Improvement & Analysis of Option Care, Inc., a division of Walgreen Co.Since 2000, Mr. DickWeinstein has previously held various leadership positionsprovided consulting services to supplier clients in the areas of financial planning, analysis,hospital organization, hospital operations, and acquisitions at Option Care, Inc.  Prior to joining Option Care, Inc. in September 2001,working with GPOs. Mr. Dick held various management positions in financeWeinstein founded and acquisitions with both Johnson & Johnson and Peace Health, a Seattle-based regional health care system.

 Joseph Bonaccorsi.  Mr. Bonaccorsi joined Akorn in 2009 as Senior Vice President, Secretary and General Counsel.  Mr. Bonaccorsi came to Akorn from Walgreen Co., where he served as Senior Vice President Mergers & Acquisition and Counsel for the Walgreens-Option Care Home Care division. Mr. Bonaccorsi joined Option Care, Inc. in 2002, where he served as Senior Vice President, General Counsel, Secretary and Corporate Compliance Officer through 2007. Prior to joining Option Care,of Premier, Inc., hea national GPO providing services for hospitals nationwide. Mr. Weinstein serves as a director on the board of OpenMarkets, which provides a services and technology platform for efficiently purchasing healthcare equipment, and on the board of trustees of the Rosalind Franklin University of Medicine and Science. Previously, Mr. Weinstein served on the boards of privately companies in the healthcare industry whose primary customers were hospitals, including: Vascular Pathways, Inc. (a medical device company), Precyse (a healthcare services and technology company), SutureExpress (a healthcare services company) and Sterilmed, Inc. (a healthcare services company).

Among other qualifications, Mr. Weinstein brings to Akorn’s Board in-depth knowledge of the provider side of the healthcare industry, specifically hospital management, materials management and channel partner relationships, as well as business leadership and innovative and strategic planning skills gained from his years of service as a founder, and later a consultant, advisor and board member, for a number of privately held healthcare services/technology companies.

None of our directors or executive officers has a family relationship that is required to be disclosed under Item 401(d) of Regulation S-K of the Exchange Act. During the past ten years none of the persons currently serving as an executive officer and/or director of the Company has been the subject matter of any legal proceedings that are required to be disclosed pursuant to Item 401(f) of Regulation S-K, which include: (a) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (b) any criminal convictions or a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (c) any order, judgment, or decree permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in privateany type of business, securities or banking activities; (d) any finding by a court, the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, practiceany law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in Chicago, Illinois.  He received his BS degree from Northwestern Universityconnection with any business entity; or (e) any sanction or order of any self-regulatory organization or registered entity or equivalent exchange, association or entity. Further, no such legal proceedings are believed to be contemplated by governmental authorities against any director or executive officer.

The Board of Directors recommends a vote “FOR ALL” of the named nominees in Proposal 1.

The Company’s Board of Directors consists of nine seats, one of which is vacant and his Juris Doctorate from Loyola University Schoolis expected to remain vacant beyond the date of Law, Chicago.


Bruce Kutinsky, Pharm.D. Dr. Kutinsky joined Akorn in late 2009 as Senior Vice President of Corporate Strategy and was named President, Consumer Health Division following the Company’s acquisition2016 annual meeting. The vacant seat is reserved for a nominee to be named by EJ Funds, LP, a company controlled by our Chairman, in accordance with terms of Advanced Vision Research, Inc. in May 2011.  In September 2012, Dr. Kutinsky was appointeda Modification, Warrant and Investor Rights Agreement entered into on April 13, 2009. Proxies cannot be voted for a greater number of persons than the number of nominees.

AKORN, INC. - 2016 Proxy Statement     18

PROPOSAL 2RATIFICATION OF THE APPOINTMENT OF BDO USA, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016

The Board is seeking shareholder ratification of the Audit Committee’s selection of BDO USA, LLP (“BDO”) to serve as Akorn’s Chief Operating Officer.  Before joining Akorn, Dr. Kutinsky was Vice President – Strategic Solutionsour independent registered public accounting firm for Walgreens.  Priorthe fiscal year ending December 31, 2016. The Audit Committee initially engaged BDO on January 14, 2016 to that, Dr. Kutinsky served in various roles at Option Care from 1997 to 2007, most recent of which was as Executive Vice President, Specialty Pharmacy.  Dr. Kutinsky holds a Doctor of Pharmacy degree from the University of Michigan.

John R. Sabat.  Mr. Sabat assumed the position of Senior Vice President, National Accounts and Trade Relations in June 2009, after serving as Senior Vice President Sales, Marketing and National Accounts since February 2009.  He hadperform independent audit services. BDO has served as our Senior Vice President, National Accounts since October 2004.  He joinedindependent registered public accounting firm for the years ended December 31, 2013, December 31, 2014 December 31, 2015.

Although the Company is not required to submit the selection of independent registered public accountants for shareholder approval, if the shareholders do not ratify this selection, the Board may reconsider the selection of BDO. The Board considers BDO to be well qualified to serve as the independent auditors for the Company, and fully intends to retain BDO’s services throughout 2016. However, even if the selection is ratified, our Board reserves the right to direct the appointment of a different independent registered public accounting firm at any time during the year if the Audit Committee and Board determine that the change would be in our best interests.

Representatives of BDO will be in attendance at the 2016 annual meeting, will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions from shareholders regarding their engagement.

Change in Independent Registered Public Accounting Firm

The Audit Committee dismissed KPMG LLP (“KPMG”) as our independent registered public accounting firm on January 10, 2016. In a Form 8-K dated April 24, 2015, we reported that the Audit Committee, upon the recommendation of our management, concluded that our previously issued consolidated financial statements for the year ended December 31, 2014 and the previously issued unaudited condensed consolidated financial statements contained in our Quarterly Reports on Form 10-Q/A for the quarters ended June 30, 2014 and September 30, 2014 and the disclosures and related communications for each of these periods should not be relied upon because of errors in the financial statements for those associated periods. Furthermore, the Audit Committee concluded that our management’s report on the effectiveness of internal control over financial reporting as of December 31, 2014 should no longer be relied upon. Because of the then-pending restatement of the above referenced financial statements, the related audit reports and opinion of KPMG on the consolidated audited financial statements for the year ended December 31, 2014 as well as KPMG’s opinion on the effectiveness of our internal control over financial reporting as of December 31, 2014 were withdrawn. When originally issued, KPMG’s audit reports on the audited financial statements for the years ended December 31, 2013 and December 31, 2014 and on the effectiveness of internal control over financial reporting as of December 31, 2013 and December 31, 2014, did not contain any adverse opinion or disclaimer of opinion and such reports were not qualified or modified as to uncertainty, audit scope, or accounting principle, except that the reports on our internal control over financial reporting contained an adverse opinion due to material weaknesses. The Company acquired Hi Tech Pharmacal Co, Inc. (Hi Tech), and VPI Holdings Corp. Inc. (VersaPharm) during 2014, and we also excluded from our assessment of the effectiveness of internal control over financial reporting as of December 31, 2014, Hi Tech’s and VersaPharm’s internal control over financial reporting associated with total assets of $254,257,000 and $13,801,000, respectively, and total revenues of $164,825,000 and $9,173,000, respectively, included in the consolidated financial statements of Akorn, Inc. as of and for the year ended December 31, 2014. KPMG’s audit of internal control over financial reporting of Akorn, Inc. as of and for the year ended December 31, 2014 also excluded an evaluation of the internal control over financial reporting of Hi Tech and VersaPharm.

During our fiscal years ended December 31, 2013 and December 31, 2014 and during the interim period subsequent to December 31, 2014 to the date of the Audit Committee’s dismissal of KPMG, there were no “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between KPMG and us on any matter of accounting principle or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to KPMG’s satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its reports. During our fiscal years ended December 31, 2013 and December 31, 2014, and during the interim period subsequent to December 31, 2014 to the date hereof, there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K except for:

1.The identification of material weaknesses in our internal control over financial reporting as described in Item 9A of our Form 10-Ks for the annual periods ended December 31, 2013 and December 31, 2014.
2.KPMG advised us that information had come to its attention, that if further investigated may: (i) materially impact the fairness or reliability of either: a previously issued audit report or the underlying financial statements; or the financial statements issued or to be issued covering the fiscal period(s) subsequent to the date of the most recent financial statements covered by an audit report (including information that may prevent it from rendering an unqualified audit report on those financial statements), or (ii) cause it to be unwilling to rely on management’s representations or be associated with the registrant’s financial statements. KPMG also advised us that, in addition to the Audit Committee’s conclusion that our audited consolidated financial

AKORN, INC. - 2016 Proxy Statement     19

statements for the year ended December 31, 2014 and our unaudited condensed consolidated financial statements for the quarters ended June 30, 2014 and September 30, 2014 and the disclosures and related communications for each of these periods should not be relied, information has come to its attention, that if further investigated may significantly impact our unaudited condensed consolidated financial statements for the quarter ended March 31, 2014 and our audited consolidated financial statements for the year ended December 31, 2013.
3.Due to the dismissal, KPMG advised us that it did not have the opportunity to expand the scope of its audit, conduct further procedures, evaluate the investigation or complete its process. KPMG further advised us that, at the time of its dismissal, KPMG has not had an opportunity to conduct its procedures or conclude that it was satisfied with the investigation or that any remediation has taken place.

The Audit Committee has authorized KPMG to respond fully to the inquiries of our successor auditor, BDO.

The Company provided KPMG with a copy of its Form 8-K filed with the SEC on January 14, 2016 announcing the change in independent registered public accounting firm containing substantially the same disclosure as above and requested that KPMG provide the Company with a letter addressed to the SEC stating whether or not KPMG agrees with the disclosures contained therein. A copy of KPMG’s letter was attached as Exhibit 16.1 to our Form 8-K/A filed with the SEC on January 27, 2016.

On January 14, 2016 the Audit Committee approved the engagement of BDO as our independent registered public accounting firm effective immediately.

During our fiscal years ended December 31, 2014 and December 31, 2015, and from January 1, 2016 through the date of the engagement, neither we, nor anyone on our behalf, consulted BDO regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to our consolidated financial statements, and no written report or oral advice was provided us by BDO that BDO concluded was an important factor considered by us in June 2003reaching a decision as Vice President, National Accounts.  Prior to joiningany accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a “disagreement” or a “reportable event”.

Independent Registered Public Accounting Firm Fees

In 2016, the Company engaged BDO USA LLP (“BDO”) as its independent registered public accounting firm to audit its annual consolidated financial statements for fiscal years 2015, 2014 and 2013, as included in the Company’s Annual Report on Form 10-K, review interim condensed consolidated financial statements and audit the Company’s internal controls over financial reporting. It is not possible to break out the Audit Fees related to each of 2015, 2014 and 2013, and therefore the following table and footnotes present fees for professional audit services of BDO for the audit of Akorn’s annual financial statements for the years ended December 31, 2013, December 31, 2014 and December 31, 2015 and fees billed for other services rendered by BDO during 2014 and 2015:

  2015   2014  
Audit Fees  (1)    (1)  
Audit-Related Fees  —    —  
Tax Fees  26,428(2)    —  
All Other Fees  94,416(3)    133,496(4)  
TOTAL $(1)   $(1)  
(1)As of the date of this filing, BDO’s Audit Fees totaled $5.4 million for its services to audit the Company’s annual consolidated financial statements for fiscal years 2015, 2014 and 2013, review interim condensed consolidated financial statements and audit our internal controls over financial reporting. Also, although difficult to provide an estimate of the total fees, an estimated additional $1.2 million is expected to be billed for BDO’s audit services for these periods. It is not possible to break out the Audit Fees related to each of 2015, 2014 and 2013, and therefore the amounts represent fees for auditing all three years.
(2)The amount shown represents fees billed for tax services rendered in connection with the acquisition of VersaPharm.
(3)The amount shown represents fees billed for consulting services provided to AIPL, including training and related services.
(4)The amount shown represents fees billed for services in connection with the acquisition of VersaPharm.

Audit Committee Pre-Approval Policies and Procedures

The Audit Committee has considered whether the provision of services covered in the preceding paragraphs is compatible with maintaining independence of our registered public accounting firm. At their regularly scheduled and special meetings, the Audit Committee considered and pre-approved any audit and non-audit services to be performed for us he servedby our independent registered public accounting firm. The Audit Committee did not pre-approve all of the audit services, audit-related services and tax services that were performed by BDO in 2014 and 2015, because BDO was not its registered public accounting firm at that time. However, in 2016, prior to the Company engaging BDO as its independent registered public accounting firm to audit its annual consolidated financial statements for fiscal years 2015, 2014 and 2013, the Audit Committee reviewed the services provided by BDO to the Company in 2014 and 2015 in determining BDO’s independence.

The Board of Directors unanimously recommends that you vote “FOR” the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.

AKORN, INC. - 2016 Proxy Statement     20

PROPOSAL 3APPROVAL BY NON-BINDING ADVISORY VOTE OF THE COMPANY’S CURRENT EXECUTIVE COMPENSATION PROGRAM

You are being asked to vote on a proposal commonly known as a “say-on-pay” proposal, which gives you the opportunity to express your approval or disapproval, on a non-binding advisory basis, of our executive officer compensation program, policies and practices through the following resolution:

“RESOLVED, that the shareholders of Akorn, Inc. approve, on an advisory basis, the Company’s executive compensation program, as described in the Compensation Discussion and Analysis, the compensation tables and the accompanying narrative disclosure set forth, pursuant to Item 402 of Regulation S-K, in the Company’s proxy statement for the 2016 annual meeting of shareholders.”

We urge you to consider the various factors regarding our executive compensation program, policies and practices as detailed in the Compensation Discussion and Analysis. As discussed in the Compensation Discussion and Analysis, we believe that our executive compensation program is competitive and governed by pay-for-performance principles which emphasize compensation opportunities that reward results. Our use of stock-based incentives reinforces the alignment of the interests of our executives with those of our long-term shareholders, thereby supporting the Company’s strategic objectives and mission.

This advisory vote is in accordance with requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), adopted in mid-2010. The Dodd-Frank Act required that public companies give their shareholders the opportunity to cast advisory votes relating to executive compensation at the first annual meeting of shareholders held after January 21, 2011. Further, companies were required to hold an initial advisory vote on the frequency with which future advisory votes should be held – whether every one, two or three years – and must hold subsequent votes on the frequency of such advisory votes at least every six years. The SEC adopted rules to implement the provisions of the Dodd-Frank Act relating to this requirement.

In advance of the Company’s 2011 annual meeting of shareholders, the Board of Directors had recommended that future advisory votes on the Company’s executive officer compensation program should occur every year. At the 2011 annual meeting of shareholders, the majority of the Company’s shareholders voted in favor of holding future advisory votes every year, and the Company’s Board of Directors subsequently adopted this as its official position. Accordingly, this Proposal 3 is being submitted to you to obtain the advisory vote of the shareholders in accordance with the Dodd-Frank Act, Section 14A of the Exchange Act and the rules of the Securities and Exchange Commission. We expect that the next shareholder advisory vote on the Company’s executive compensation program will take place at the 2017 annual meeting of shareholders.

Because your vote is advisory, it will not be binding upon the Board of Directors. However, our Board of Directors (including our Compensation Committee) will take into account the outcome of the vote when considering future decisions affecting executive compensation as it deems appropriate.

The Board of Directors unanimously recommends that you vote “FOR” approval, on a non-binding advisory basis, of the Company’s executive compensation program.

AKORN, INC. - 2016 Proxy Statement     21

III.Executive Compensation and Other Information

EXECUTIVE SUMMARY

2015 Performance Highlights

Despite facing challenges, our financial performance in 2015 was solid and included the following highlights:

We generated net revenue of $985.1 million and maintained a consolidated gross margin of 60.5%.
We generated operating income of $294.6 million (or 29.9% of net revenues).
We received 15 product approvals and 2 tentative approvals from the FDA, including 11 ANDA approvals, 2 ANADA approvals, 1 NDA approval, 1 significant supplemental ANDA new product approval and 2 tentative ANDA approvals.
Our R&D organization submitted 18 ANDA filings and 1 NDA filing to the FDA for approval during 2015.
We launched 12 new products.
We completed the operational integrations of Hi-Tech Pharmacal Co., Inc. and VersaPharm, Inc.
We closed the acquisition of a sterile ophthalmic manufacturing facility in Hettlingen, Switzerland.
We invested in our organizational capital, significantly expanding our accounting and finance organization, manufacturing and operations leadership and commercial infrastructure.

Changes in Our Executive Team in 2015

In 2015, we made several changes and additions to our executive team, and we believe these changes have better situated our Company for growth and success. Among our Named Executive Officers (as defined below) these changes involved the addition of our new Chief Financial Officer and our Corporate Controller as well as the addition of our Executive Vice President, Sales and Marketing, with Major Pharmaceuticals, a division of Apotex, Inc., and a manufacturer and worldwide distributor of proprietary, multi-source prescription and over-the-counter pharmaceuticals.

Mark M. Silverberg.  Mr. Silverberg currently serves as our Executive Vice President, Global Quality Assurance and Alliance Management, after servingPharmaceutical Operations.

2015 Named Executive Officers

We refer to the following individuals as Senior Vice President, Global Quality Assurance since May 2006.  He joined us in April 2005 as Vice President, Global Compliance.  Prior to joining us, Mr. Silverberg served as Director of Division Quality for the Diagnostics Division of Abbott Laboratories.our 2015 “Named Executive Officers” or “NEOs”:

NEOPrincipal Position
Raj RaiChief Executive Officer
Duane A. PortwoodExecutive Vice President and Chief Financial Officer effective October 30, 2015
Randall E. PollardSenior Vice President, Corporate Controller and Chief Accounting Officer, also served as Interim Chief Financial Officer from August 3, 2015 to October 30, 2015
Timothy A. DickFormer Chief Financial Officer, resigned August 3, 2015
Joseph BonaccorsiSenior Vice President, General Counsel and Secretary
Bruce KutinskyChief Operating Officer
Steven LichterExecutive Vice President, Pharmaceutical Operations
Jonathan KaferExecutive Vice President, Sales and Marketing

AKORN, INC.- 2016 Proxy Statement     22

27

COMPENSATION DISCUSSION AND ANALYSIS

In this Compensation Discussion and Analysis

The following Compensation Discussion and Analysis presents section we present an overview of our compensation program, focusing on the elements of compensation awarded or paid to our executive officers, including our CEO, Chief Financial Officer and the other executive officers named in the Summary Compensation Table (collectively, “Named Executive Officers”).

Summary of 2013 Results

We are pleased with another year of progress that is due to management’s effective and successful execution of the management objectives established by Mr. Rai and the Board of Directors.  The key highlights and accomplishments for our 2013 fiscal year include the following:

●  Achieved record revenue of $317.7 million in 2013, up 24% over the prior year.
●  Net income for 2013 was $52.4 million, or $0.46 per diluted share, compared to net income of $35.4 million, or $0.32 per diluted share, in the prior year.
●  Produced 2013 non-GAAP Adjusted Net Income of $62.5 million, or $0.55 per diluted share.
●  Achieved an 84% increase in the Company’s common stock market price, from a closing price of $13.36 at December 31, 2012 to $24.62 at December 31, 2013.
●  Entered into an agreement to acquire Hi-Tech Pharmacal Co,, Inc. (“Hi-Tech”) for approximately $640 million, or $43.50 per share of Hi-Tech common stock.  This acquisition, which we believe will build scale, breadth of products and dosage forms and enhance the diversification of the Company’s product portfolio, is expected to close early in the second quarter of 2014.
●  Filed 12 Abbreviated New Drugs Applications (“ANDAs”) and completed the development on an additional 11 ANDAs with a combined annual IMS market size of approximately $2.3 billion.
●  Completed the acquisition of the U.S. rights to three branded ophthalmic products from Merck; AzaSite®, COSOPT® and COSOPT® PF.

In 2013, base cash compensation for Named Executive Officers increased by an average of 3% from the previous year.  Based on Company results and individual performance to MBOs, all Named Executive Officers qualified for bonus payouts.  Our CEO received a bonus equal to 135% of his base compensation, while our other Named Executive Officers received bonuses ranging from 21% to 40% of their base compensation.  All of the Named Executive Officers received equity awards in 2013.

The Compensation Committee considers shareholder input when setting compensation for the Company’s Named Executive Officers. At the 2013 annual meeting of shareholders, 99.5%Below is a roadmap of the votes cast on the advisory vote on executive compensation were in favordiscussion that follows.

Table of our executive compensation program.  The Board and the Compensation Committee reviewed these results and determined that, given the significant level of shareholder support, no major re-examination of our executive compensation program was deemed to be necessary at this time.  The Compensation Committee will continue to consider the outcome of the annual advisory votes to approve executive compensation when making future compensation decisions for the named executive officers.


Objectives and Role of the Compensation Committee

The Compensation Committee leads the development of our compensation philosophies and practices and attempts to ensureassure that the total compensation paid to our executive officers is fair and reasonable relative to the extremely competitive nature of the specialty pharmaceutical industry of which we are a part. For several years, our Company forged throughexperienced major business and financial challenges, and has more recently experienced a significant turn-aroundturnaround that is largely attributable to the success of our current management team. During the challenging downturn years, the Compensation Committee focused intently on attracting and rewarding executives with the unique intersection of industry and turnaround skills and made compensation decisions based on our objective of aligning the Company’s key executives’ goals and incentive pay with the goals of our shareholders in order to enable and encourage the turn-around effort. Consistent with our ongoing goal to keep the Company’s key executives’ objectives and incentive pay aligned with the goals of our shareholders, we continue to pursue a compensation philosophy that is intended to provide total compensation opportunities, which include base salary, performance-based cash bonus, long term equity compensation, and a health and welfare benefits packagepackage. These are intended to incentivize the uniquely skilled employees who will continue to carry out our strategic plan, mission and goals, while maintaining our required high quality standards and growth.

28

In 2012, we refined our compensation philosophy to reflect the Company’s current posture in the industry in order to align it with the achievement of the Company’s business strategies. Accordingly, we developed and adopted a philosophy that is intended to serve the foundation upon which the executive compensation program is structured and administered and to serve as a basis for guiding the continued development and evolution of the program.


Our compensation philosophy is based on the following goals and principles:

●  Attract and retain results-oriented executives with proven track records of success to ensure the Company has the caliber of executives needed to perform at the highest levels of the industry,
●  Support Company growth, alignment with shareholder interests and the achievement of other key corporate goals and objectives,
●  Be designedDesign packages to achieve external competitiveness, internal equity, and be cost-effective,
●  Focus attention on and appropriately balance current priorities and the longer-term strategy of the Company through short-andshort- and long-term incentives,
●  Encourage teamwork and cooperation while recognizing individual contributions by linking variable compensation to Company and individual performance based on position responsibilities and ability to influence financial and organizational results,
●  Promote ownership of Company stock by executives to enhance the alignment of interests with shareholders,

AKORN, INC.- 2016 Proxy Statement     23

Motivate and reward a prudent level of risk and decision making in an effort to drive reasonable performance,
●  Provide flexibility and some discretion in applying the compensation principles to appropriately reflect individual circumstances as well as changing healthcare and pharmaceutical industry conditions and priorities, and
●  Involve a limited use of perquisites and supplemental benefits which will only be provided if a compelling business rationale exists.

Role of Compensation Committee and Management

Our Compensation Committee is composed exclusively of independent directors and meets regularly both with and without management. The Compensation Committee annually setsapproves Named Executive Officer base salaries, establishes annual incentive compensation pay for performance objectives based on both goals for the company and individual and company goals,employees, makes actual awards of annual incentive compensation based on attainment of these goals and other factors the Compensation Committee deems appropriate and considers awards of long-term equity compensation. In connection with its review and determination, the Compensation Committee considers the input

Role of the Chairman of our Board, who conducts a detailed review of the performance of our CEO based on the Chairman’s substantial and meaningful experience in ownership and management of pharmaceutical and life science companies.  Our Chairman also presents his recommendation for any change in base salary or other compensation components for our CEO.  

The Compensation Committee also seeks input from the CEO, particularly related to the establishment and measurement of corporate and individual objectives and recommendations related to overall employee compensation matters. OurThe CEO provides the Board with a self-evaluation of his performance, but the CEO does not participate in discussions or make recommendations with respect to his own compensation.

Our CEO reviews the performance of, and proposes salary increases for, all managers who report to him, including the other Named Executive Officers. Any increases are generally based upon the individual’s performance during the previous year and any changes in responsibilities for the upcoming year. The Compensation Committee reviews the reasonableness of any proposed compensation for the Named Executive Officers. In conducting its review and making its determinations, the Compensation Committee reviews a history of base salary, cash incentive bonus targets and payouts, and equity awards, prepared by the Company’s Human Resources Department. During the year, our CEO may change the base salary of the managers who report to him, with the exception of our Chief Financial Officer (“CFO”), Chief Operating Officer (“COO”) and General Counsel, without prior approval of our Compensation Committee. He may do so in order to address significant changes in the individual’s responsibilities, to be competitive in the market or for other business reasons. The CEO exercised this authority during 2013.  Proposed compensation changes for the CFO, COO and General Counsel are submitted by our CEO to the Compensation Committee for review and approval.

29

Our Human Resources Department (“HR”) evaluates total compensation levels and compositionelements of compensation and fashions competitive pay packages on a company-wide basis. HR also works with the Compensation Committee and the CEO in planning for

AKORN, INC.- 2016 Proxy Statement     24

recruitment and retention of employees. Based on HR’s research and the CEO’s recommendations, we fix these salaries at rates that we believe are generally competitive, but we do not attempt to pay at the high end of our competition.

Role of the Compensation Consultants


The Compensation Committee has maintained a structured approach to compensation for our Named Executive Officers, and, since 2005,2012, has retained Willis Towers Watson as its own independent compensation consultants which have providedconsultant to provide the Compensation Committee with support, advice and recommendations. recommendations on our compensation program for our executive officers.

The Compensation Committee has analyzed whether the work of our compensation consultant Willis Towers Watson has raised any conflict of interest, taking into consideration the following factors: (i) the provision of other services to the Company by Willis Towers Watson; (ii) the amount of fees from the Company paid to Willis Towers Watson as a percentage of Willis Towers Watson’s total revenue; (iii) the policies and procedures of Willis Towers Watson that are designed to prevent conflicts of interest; (iv) any business or personal relationship of Willis Towers Watson or the individual compensation advisors employed by Willis Towers Watson with our CEO; (v) any business or personal relationship of the individual compensation advisors with any member of the Compensation Committee; and (vi) any stock of the Company owned by Willis Towers Watson or the individual compensation advisors employed by Willis Towers Watson. The Compensation Committee has determined, based on its analysis of the above factors, that the work of Willis Towers Watson and the individual compensation advisors employed by Willis Towers Watson as compensation consultants to the company has not created any conflict of interest.

In 2010, 2012addition, in 2016 in connection with our restatement process, the Compensation Committee engaged legal counsel to provide advice regarding the recovery of bonuses paid to our executive officers for 2014.

Role of Peer Group

In 2015, 2014 and 2013, our compensation consultant worked with the Compensation Committee in comparing our executive compensation with pertinent market data. The data was taken from published salary surveys reflecting a broad range of entities, both within and outside our own specialty pharmaceutical industry. The study also included publicly reported data fromfilings made with the SEC by a selected peer group, which peer group we updated and refined in 2012 to include Auxilium Pharmaceuticals Inc., Cornerstone Therapeutics Inc., DepoMed Inc., Hi Tech Pharmacal Co. Inc., Jazz Pharmaceuticals plc, Lannett Company, Inc., Nektar Therapeutics, Optimer Pharmaceuticals, Inc., Pozen Inc., Questcor Pharmaceuticals, Inc., Sagent Pharmaceuticals, Inc., and Santarus, Inc.  2015. The following companies comprised our selected peer group in 2015:

2015 Peer Group
Alkermes Plc.Pharmacyclics Inc.
Biomarin Pharmaceutical Inc.Prestige Brands Holdings, Inc.
Endo International Plc.Quintiles Transnational Inc.
Impax Laboratories Inc.Salix Pharmaceuticals Ltd.
Incyte CorporationThe Medicines Company
Jazz Pharmaceuticals CompanyUnited Therapeutics Corporation
Mallinckrodt Plc.

Specifically, the Compensation Committee requested the consultant to report base and annual salary incentive percentages for executives in similar sized companies based on revenue and market capitalization and/or similar industries. The Compensation Committee reviewed these surveys and informationthe data in order to obtain a general understanding of current compensation practices and trends for specific positions held versus justrather than focusing on the Named Executive Officers. This analysis was reviewed and updated in 2011, 20122015, 2014 and 2013 in order to confirm the appropriate data, measures and comparisons.


With respect to establishing the CEO and CFO compensation, we gather, analyze and evaluate the compensation mix provided by our peer group, as well as consider the other factors set forth in the Compensation Committee’s charter. We do not target or benchmark our Named Executive Officers’ compensation at a certain level or percentage based on other companies’ compensation arrangements. Based on our review

Role of these sources, we have determined that our total compensation and cashthe Shareholders

The Compensation Committee considers shareholder input when setting compensation for the Company’s Named Executive Officers falls nearOfficers.

At the aggregated medianslast annual shareholder meeting, which was held in 2014, the Company’s advisory vote on executive compensation was approved by the following vote:

ForAgainstAbstainBroker
Non-Votes
85,598,356204,544359,1346,673,489

This represents a 99% level of approval. Although the effect of the namedadvisory vote on executive officerscompensation is non-binding, the Board and the Compensation Committee considered these results and determined that, given the significant level of shareholder support, no major re-examination of our peer group. Our goal isexecutive compensation program was necessary at this time. The Compensation Committee will continue to structureconsider the outcome of the future advisory votes, as well as shareholder feedback that we receive from our shareholder outreach program, when making compensation in a manner where the largest increase in total direct compensationdecisions for our Named Executive Officers comes from appreciationand our compensation programs generally. Akorn values the opinions of its shareholders and is committed to considering their opinions in their Long Term Incentive Awards.making compensation decisions. See “Shareholder Outreach Program.”

AKORN, INC.- 2016 Proxy Statement     25

The Compensation Committee has analyzed whether the work of our current compensation consultant, Towers Watson, has raised any conflict of interest, taking into consideration the following factors: (i) the provision of other services to the Company by Towers Watson; (ii) the amount of fees from the Company paid to Towers Watson as a percentage of Towers Watson’s total revenue; (iii) the policies and procedures of Towers Watson that are designed to prevent conflicts of interest; (iv) any business or personal relationship of Towers Watson or the individual compensation advisors employed by Towers Watson with our CEO; (v) any business or personal relationship of the individual compensation advisors with any member of the Compensation Committee; and (vi) any stock of the Company owned by Towers Watson or the individual compensation advisors employed by Towers Watson. The Compensation Committee has determined, based on its analysis of the above factors, that the work of Towers Watson and the individual compensation advisors employed by Towers Watson as compensation consultants to the company has not created any conflict of interest.
Components of Compensation.  Our compensation program generally provides equivalent benefits for all salaried and hourly-paid employees.
Elements of our Compensation Program

For our managers, directors and vice presidents, including our executive officers, we provide additional compensation designed to reward performance.  For 2013,2015, the principal components of compensation for our Named Executive Officers were:

base salary, performance based annual cash incentive and long-term equity incentive. In addition, we offer health and welfare benefits and certain limited perquisites and separation benefits.

ElementTypeAt Risk
Base Salary,salaryCashNo, fixed
Performance-based annual incentive(1)CashYes, at risk based on Company and individual performance
Long-term incentives(2)EquityYes, at risk because time-based vesting occurs over a period of years

(1)We occasionally also provide non-recurring discretionary cash bonuses to reflect superior individual performance, new responsibilities or base Consulting Fee, as applicableto compensate new hires for amounts forfeited from their previous employer.
  
(2)Performance-Based Annual Bonus,
Long-Term Incentive Compensation, including periodic grants of long-term stock-based compensation, such as stockHistorically, we have awarded options which are subject to time-based vesting requirements, and
Health and Welfare Benefits.and/or RSUs.
30


Base Salary.  


Salary

The salaries for our Named Executive Officers are established to be competitive with market practices in order to allow us to attract and retain senior executive talent. Salary decisions are also influenced by internal equity taking into consideration the relationship between salaries among the executives and each executive’s role and responsibilities and the impact on Company performance. Other factors considered by the Compensation Committee include an executive’s experience, specific skills, tenure and individual performance. In setting base salaries for the CEO, CFO, COO and General Counsel, we also consider external equity based on analysis of peer group data. In 2013, no substantial increases toThe Compensation Committee typically reviews the base salaries were implemented.

of our Named Executive Officers annually in the first quarter with any increases effective as of January 1 of that year.

Performance-Based Annual Bonus.


Beginning in 2005, weIncentive Plan

Each year, the Compensation Committee adopts guidelines pursuant to which it calculates the annual performance-based cash incentive awards available to our Named Executive Officers. We have instituted formal management-by-objectives (MBO) annualto assess performance basedas a basis for determining awards for all of our Named Executive Officers.Officers paid out under our 2014 Plan. Our MBO based incentive program has continued to be a major component of our compensation strategy. It affords us the opportunity and framework for establishing both corporate and individual performance objectives while providing us the flexibility to reward superior performance in overcoming unforeseen circumstances and exceptional achievements.objectives. Individual MBOs extend beyond financial performance and include actions required for the continued turnaround and future growth of the company.


Each year, the Compensation Committee adopts guidelines pursuant to which it calculates the annual cash incentive awards available to our Named Executive Officers, subject toOfficer’s MBOs align with each of the Compensation Committee’s oversight and modification.corporate MBOs. The Compensation Committee believes that our annual incentive program provides our Named Executive Officers with a team incentive to both enhance our financial performance and perform at the highest level. The termsNo payments are made under the incentive plan unless a threshold Company objective, such as Adjusted EBITDA, is attained. See “2015 Performance-Based Annual Incentive Awards.”

In addition to cash bonus payments made under our annual cash incentive plan, the Compensation Committee may provide discretionary bonuses to reward an executive’s superior performance in overcoming unforeseen circumstances and exceptional achievements.

Long-Term Equity Incentive Plan

Under our 2014 Plan, the Compensation Committee has the flexibility to make equity awards based on the common stock of these programs are not containedthe Company, including time- and performance-based awards of stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares, and other equity based awards. Our Board developed a long-term equity incentive plan as part of our goal to structure our compensation in a formal writtenmanner where the largest increase in total direct compensation for our Named Executive Officers comes from appreciation in a long-term equity incentive award made under our 2014 Plan (“Long-Term Incentive Award”). Under the plan, the Long-Term Incentive Awards to executive officers would be awarded such that 75% of the grant-date fair value of each executive’s equity grant would be provided in the form of options and 25% in RSUs. We believe that Long-Term Incentive Awards should provide a large majority of compensation opportunity for our Named Executive Officers. The Company does not have any long-term cash incentives nor does it maintain a pension plan or a supplemental executive retirement plan. NoOur current Form of Non-Qualified Stock Option Award Agreement, Form of Incentive Stock Option Award Agreement and Form of Restricted Stock Unit Award Agreement were filed as exhibits to the Company’s Form 10-K filed with the SEC on May 10, 2016. The Company may from time to time grant other types of equity awards using other forms of award agreements.

Stock Options

Historically we have primarily awarded stock options as the long-term incentive awards. We grant non-qualified stock options (“NSOs”) to our Named Executive Officers as a means of rewarding past performance and encouraging continued efforts to achieve personal and Company objectives in the current and future years. Our options are awarded at the closing price of our stock on the date of grant. Options awarded to our executive officers vest at 25% of the award per year on each of the first four anniversaries of the date of grant and expire five or seven years from the date of grant, as determined by the Compensation Committee and set forth in the applicable award agreement.

AKORN, INC.- 2016 Proxy Statement     26

Restricted Stock Units

Beginning in 2014, based in part upon the recommendation of the compensation consultant, the Compensation Committee determined that the long-term incentive awards to executive officers would be awarded such that 75% of the grant-date fair value of each executive’s equity grant would be provided in the form of options and 25% in RSUs. Each RSU represents the right to receive one share of our common stock on a stated date (the “vesting date”) unless the award is partterminated earlier in accordance with terms and conditions established by the administrator of anour 2014 Plan. The RSUs generally vest in equal installments, 25% of the award per year on each of the first four anniversaries of the date of grant. Unless the Compensation Committee determines otherwise, RSUs that do not vest will be forfeited. Holders of RSUs have no voting, dividend or other rights as a shareholder until such units are vested.

Timing of Equity Grants and Equity Grant Practices

At the Board meeting held immediately after our annual meeting of shareholders, the Compensation Committee typically will recommend equity compensation, if any, to be awarded to our Named Executive Officers and all other Company employees. All awards are made based on the closing price of our stock on the date of grant. In addition, awards may be made to new employees upon their joining the Company, and to employees who are promoted during the year. The timing of such awards depends on those specific circumstances and is not tied to any other particular company event, anticipated events or announcements. Under our long-term equity incentive plan, that has any guaranteed bonus amounts.in 2015 each executive officer was eligible to receive an award with a value up to a certain percentage of the executive’s annual salary as follows: Mr. Rai 400%; Mr. Portwood 250%, Mr. Bonaccorsi 250%, Mr. Kutinsky 300%, Mr. Lichter 100%, Mr. Pollard 100%, Mr. Kafer 100% and Mr. Dick 250%.

In addition to awards made under our incentive plans, the Compensation Committee may provide discretionary bonuses to reward an executive’s superior performance in overcoming unforeseen circumstances and exceptional achievements.

Analysis of What We Paid

2015 Base Salaries

In 2015, the Compensation Committee reviewed the base salaries of our Named Executive Officers and increases to base salaries were implemented with the weighted average base salary of our Named Executive Officers increasing approximately 11% in comparison to 2014. The Compensation Committee again reviewed the base salaries of our Named Executive Officers in 2016 and increases to base salaries were implemented with the weighted average base salary of our Named Executive Officers increasing approximately only 2% in comparison to 2015.

  2016 Base
Salary
($)
 2015 Base
Salary
($)(1)
 2014 Base
Salary
($)
  
 
What We Took Into Consideration in Setting 2015 Salaries
 
Raj Rai 824,000  800,000 750,000 Mr. Rai’s performance in 2014 in completing the acquisitions of Hi-Tech Pharmacal and VersaPharm, as well as veterinary products from Lloyd, Inc. 
Duane A. Portwood 450,000  450,000(1) N/A Offering a competitive salary in connection with Mr. Portwood’s appointment as Chief Financial Officer of our Company in October 2015 
Joseph Bonaccorsi 437,750  425,000 350,000 Mr. Bonaccorsi’s performance in 2014 in handling special legal projects, managing increased growth in our legal department and outside counsels and contributing to increased compliance measures 
Bruce Kutinsky 484,100  470,000 425,000 Mr. Kutinsky’s performance in 2014 in obtaining 14 unique product approvals, launching 5 products, and integrating more than 62 products acquired through acquisitions 
Steven Lichter 309,000  300,000(1) N/A Offering a competitive salary in connection with Mr. Lichter’s appointment as Executive Vice President, Pharmaceutical Operations in April 2015 
Randall E. Pollard 275,000  275,000(1)(2) N/A Offering a competitive salary in connection with Mr. Pollard’s appointment as Vice President and Corporate Controller in April 2015 
Jonathan Kafer 309,000  300,000(1) N/A Offering a competitive salary in connection with Mr. Kafer’s appointment as Executive Vice President, Sales and Marketing in April 2015 
Timothy Dick (3)  385,000 385,000 It was decided that Mr. Dick’s salary was competitive with the market. 

AKORN, INC.- 2016 Proxy Statement     27

(1)The base salaries actually paid to Messrs. Portwood, Lichter, Pollard and Kafer were pro-rated to their respective start dates of October 30, February 16, April 20, and April 20, 2015.
(2)In connection with his promotion to Interim Chief Financial Officer, Mr. Pollard’s salary was increased to $275,000 as of August 3, 2015 from $235,000.
(3)Mr. Dick resigned as Chief Financial Officer as of August 3, 2015.

2015 Performance-Based Annual Incentive Awards

We structured specific annual incentive compensation payawards for 20132015 based upon MBOs for our CEO, CFO, COO and General Counsel, as well as the Company’s achievement of its overall goals. After the Board reviewed the strategic plan and budget for the year, the Compensation Committee set annual incentive compensation targets designed to induce achievement of that plan and budget.

For 2013,2015, we set the CEO’s bonus target at 100% of base compensation,salary, the CFO’s andbonus at 50% of base salary, the COO’s bonuses at 50% of base compensationsalary and the General Counsel’s bonus at 40%50% of base compensation.  Thesalary. These were the same bonus targets were set for the CEO, CFO and COO for 2014, and an increase for the General Counsel who had a bonus target of 40% of base salary for 2012.  The CEO, CFO, COO2014. Messrs. Lichter, Pollard and General CounselKafer had 2015 target bonus opportunities of 40% of base salary. In 2015, the Named Executive Officers each havehad additional opportunity for “stretch” bonus of between 20% to up to 50%60% of their base salary (as set forth below) if certain additional objectives were achieved.

In general, the Compensation Committee considered the experience, responsibilities, title and historical performance of each particular Named Executive Officer when determining the target and stretch bonus or 50%, 25%, 25%opportunities and 20% of their base compensation, respectively.  In addition to the bonuses available to the Company’s CEO, CFO, COO and General Counsel, we approved specific performance objectives and target percentages of compensation for the other Named Executive Officers based on the CEO’s recommendation and our review of the appropriate objectives for these individuals.  EachCompensation Committee’s review.

  2015 Target
Base Incentive
Bonus
Opportunity
as % of Base
Salary*
 2015 Target
Base Incentive
Bonus
Opportunity
as $
 2015 Stretch
Incentive
Bonus
Opportunity
as % of Base
Salary
 2015 Stretch
Incentive
Bonus
Opportunity
as $
 2015 Total
Incentive
Bonus
Opportunity
 Total Incentive
Bonus Earned
for 2015(1)
Raj Rai 100%  $800,000  50%   $ 400,000  $1,200,000  $724,399 
Duane A. Portwood (2)   (2)  (2)   (2)   (2)   (2) 
Joseph Bonaccorsi 50%   212,500  25%   106,250   318,750   218,510 
Bruce Kutinsky 50%   235,000  25%   117,500   352,500   122,200 
Steven Lichter 40%   103,846(3)  20%   51,923(3)   155,769(3)   90,865 
Randall E. Pollard 40%   110,000(3)  20%   55,000(3)   165,000(3)   110,000 
Jonathan Kafer(4) 40%   83,077(3)  60%   124,616(3)   207,693(3)   83,077 
Timothy Dick 50%   192,500  25%   96,250   288,750   (5) 

(*)For purposes of our performance-based incentive plan, bonus eligible Base Salary is defined as the officer’s base pay earnings as shown on the officer’s W-2 for the applicable year.
(1)Upon the recommendation of management, the Compensation Committee unanimously decided to delay the payment of all bonuses earned by our Named Executive Officers for 2015 until the Company filed the audited financial statements for 2014 and 2015, which the Company filed in its Form 10-K that it filed with the SEC on May 10, 2016.
(2)Mr. Portwood joined Akorn on October 30, 2015, and so did not receive bonus targets for 2015, however, the Company agreed to pay a bonus of $56,250 to partially compensate for the bonus opportunity he gave up at his prior employer when joining Akorn. See “Summary Compensation Table.”
(3)The bonus opportunities for Messrs. Lichter and Kafer are pro-rated to each executive’s start date of February 16 and April 20, 2015, respectively. Pursuant to his offer letter, Mr. Pollard was entitled to the bonus opportunity for the full year.
(4)Pursuant to his offer letter, Mr. Kafer was entitled to receive a bonus payment in the amount of 50%, 75% or 100% of his base salary if certain objectives were achieved, if the objectives were exceeded by 5% or if specified additional objectives were achieved. Mr. Kafer’s maximum bonus opportunity for 2015 was $207,693.
(5)Mr. Dick resigned from the Company as of August 3, 2015 and so did not receive a bonus for 2015.

For the year 2015, the Compensation Committee determined the above bonus amounts were earned by each Named Executive Officer has established MBOs that align with each of the corporate MBOs discussed below.

For the year 2013, we paid bonuses to each of our Named Executive Officers based on their achievement of personal MBOs and the Company’s achievement of its performance targets.  Sincetargets and each Named Executive Officer’s achievement of personal MBOs. However, upon the Company was not deemed to have exceeded its overall budget goals, “stretch” bonuses were not paid for 2013.  For 2013, our named executive officers’ received the following bonuses:

  
Base Pay
for Bonus
Calculation
(a)
  
Base Bonus Opportunity
(b)
   
Base Bonus Available
 (c)
  
Base Bonus
Paid
(d)
  
Discretionary Bonus Paid
(e)
  
Total Bonus
Paid
 (f)
 
Raj Rai $500,000   100%  $500,000  $500,000  $250,000  $750,000 
Timothy A. Dick  309,000   50%   154,500   77,250     77,250 
Joseph Bonaccorsi  286,000   40%   114,400   114,400     114,400 
Bruce Kutinsky (h)  313,000   50%   156,500   122,070     122,070 
John R. Sabat  280,000   30%   84,000   77,701     77,701 
Mark M. Silverberg  280,000   30%   84,000   58,800     58,800 
TOTALS $1,968,000       $1,093,400  $950,221  $250,000  $1,200,221 

(c)   Base Bonus Available = Base Pay (a) x Base Bonus Opportunity (b).
(d)   Base Bonus Paid = Base Pay (a) x Base Bonus Opportunity (b) x % Personal MBO Achievement.
(e)   Discretionary Bonus was awarded byrecommendation of management, the Compensation Committee unanimously decided to delay the payment of all bonuses earned by our Named Executive Officers for 2015 until the BoardCompany filed its audited financial statements for 2014 and 2015, which the Company filed in its Form 10-K that it filed with the SEC on May 10, 2016. For purposes of Directors.
(f)   Total Bonus Paid = Base Bonus Paid (d) + Discretionary Bonus Paid (e).
31


Annual Cash Incentive Awards for our Chiefdetermining the target bonus amount earned by each Named Executive Officer,
The Compensation Committee discussed the annual cash incentive program for Mr. Rai for fiscal year 2013. Additionally,Company objectives were weighted 50% as a group, and the individual MBOs were weighted 50% as a group. In addition, the Compensation Committee reviewed the Company’s performance and each individual executive’s performance against their respective objectives that were set in 2015 and then assigned the pre-determined financialCompany and each Named Executive Officer a performance rating from 0-100. An executive officer must have achieved at least 50% of his MBOs in order to receive a bonus under the incentive bonus plan. The Named Executive Officers were also eligible to receive a “stretch” bonus if certain objectives and personal objectives.  The 2013 cash incentive plan consistedwere achieved under the “stretch” portion of the following key components:

incentive bonus plan.

AKORN, INC.- 2016 Proxy Statement     28

A.  A base bonus tied to personal objectives linked to Company’s overall strategic plan and the achievement of the target Adjusted EBITDA, as defined by the Company.  The Adjusted EBITDA targets for Mr. Rai were established by the Compensation Committee at the commencement of the year and are the same targets applied to our annual cash bonus program for our other executive officers. A reconciliation of Adjusted EBITDA to net income for the year ended December 31, 2013 can be found on our Current Report on Form 8-K filed with the SEC on March 3, 2014.  The personal objectives were not specifically assigned percentages.

B.  An “over-achievement” bonus which equals 50% of the base bonus, provided the Company achieves its “stretch” Adjusted EBITDA.

For 2013, the Company’s overall corporate MBOs were as follows:
Achieve a determined level of sales and adjusted EBITDA
Complete development of a certain number of new moleculesBack to Contents
Submit a determined number of ANDA / ANADA filings
Increase annual adjusted EBITDA by a certain percentage through various growth opportunities
Complete identified infrastructure improvement projects
Maintain and achieve defined FDA related compliance standards at domestic and international facilities

The Compensation Committee adopted an annual cash

Under the 2015 incentive program pursuant to which Mr. Rai was eligible to receive a target cash bonus of up to $500,000, attributable to his achievement of personal objectives and Company MBOs, or up to $750,000plan, if the Company exceedingdid not achieve its “stretch” Adjusted EBITDA target for 2013.  Based upon its reviewthe year, no bonuses would be paid even if other objectives were achieved.

2015 Performance-Based Annual Incentive Award for our Chief Executive Officer

For 2015, the Company achieved the following financial metrics: Sales of Mr. Rai’s performance toward achievement$985 million, Adjusted EBITDA of $460 million and Adjusted EPS of $2.02.

In addition to reviewing the corporate MBOs listed above,Company’s financial metrics, the Compensation Committee awardedevaluated the Company’s performance against key strategic initiatives designed to promote the Company’s long-term success, as well as significant events during 2015. We continue to make progress on our plan to prepare Akorn India Private Limited (AIPL) for FDA certification. We submitted 18 ANDAs and 1 NDA to the FDA, and we launched 12 new products. We also have concentrated our efforts to enhance our culture and develop organizational talent.

The Compensation Committee determined that Mr. Rai a baseshould be awarded an incentive bonus of $500,000 for 2013.  In addition, althoughbased on the following achievements in 2015. Mr. Rai led the Company did not exceed its “stretch” Adjusted EBITDA target for 2013,to deliver $985 million in sales and $151 million (GAAP) net earnings. Additionally, Mr. Rai provided the Compensation Committee believedleadership and direction during the unstable restatement environment that enabled the company to have these business successes. He significantly strengthened the talent of the organization through the hiring of key executives across all functions. He personally negotiated with lenders and regulatory agencies to ensure the Company achieved other significant milestones in 2013 and awardedmaintained its ability to operate effectively. Mr. Rai a discretionary additional bonusensured that all of $250,000 as a result of his and the Company’s various achievements during the year, including the signing of a definitive agreementoperations maintained regulatory compliance so that we could continue to acquire Hi-Tech.


manufacture, distribute and sell our products.

2015 Performance-Based Annual Cash Incentive AwardsAward for our Other Named Executive Officers


In 2013,

Similar to prior years, for fiscal year 2015, Mr. Rai recommended and the Compensation Committee approved financialcorporate goals and personal MBOs required for incentive payout to other Named Executive Officers. The goals for the other Named Executive Officers were significantly aligned with the Company’s overall stated goals and objectives, and were tailored to each Named Executive Officer’s role and responsibilities within the Company. The plan required achievement of financial goals, including exceeding net revenue andthe Adjusted EBITDA targets, as well as Company’s overall corporate MBOstarget before any individual payouts wouldcould be earned.  These financial and corporate goals were achievedearned as well as achievement of at base bonus level, allowingleast 50% of the incentive payouts to be made.executive’s individual MBOs. The amounts of actual individual payouts to the other Named Executives Officers varied based on achievement of their personal MBOs andwhich were in the range of 50%0% to 100% of individual goal achievement.

Mr. Dick resigned from the Company as of August 3, 2015 and so did not receive a bonus for 2015.

The Compensation Committee determined that Mr. Kutinsky should be awarded an incentive bonus based on the following achievements. Mr. Kutinsky provided leadership across our Pharmaceutical Operations and Sales and Marketing organizations during 2015. He greatly increased the effectiveness of our Sales, Marketing and Operations organizations through the addition new talent, especially at the senior levels, and the establishment of new business processes. The teams launched new products that contributed $36.0 million of revenue (growth of $31.0 million over the year ended December 31, 2014) to the company, negotiated contracts with major customers to increase our revenue opportunity, and responded to over 150 inquiries from regulatory agencies to ensure they had the information to review our ANDA, ANADA and NDA filings.

The Compensation Committee determined that Mr. Bonaccorsi should be awarded an incentive bonus based on the following achievements. In 2015, Mr. Bonaccorsi managed diverse litigation and regulatory challenges that not only required the deployment of the Company’s legal team, but more so the breadth of outside counsel required to meet the demands of regulators, board committees and litigation. In addition, he and his team provided outstanding legal services to the Company on a wide range of legal and regulatory matters.

The Compensation Committee determined that Mr. Pollard should be awarded an incentive bonus based on the following achievements. Mr. Pollard joined the Company on April 20, 2015 and much of his year was focused on addressing the issue of the financial restatement and establishing processes, fixing weaknesses, partnering with our auditors and investigators while at the same time dramatically increasing the size and caliber of our Finance organization. Mr. Pollard also served as the interim CFO for three months following the resignation of Mr. Dick. Mr. Pollard’s leadership in managing the Company’s debt was important to maintaining efficiency in our operations.

The Compensation Committee determined that Mr. Lichter should be awarded an incentive bonus based on the following achievements in 2015. Mr. Lichter ensured all manufacturing facilities maintained their regulatory compliance to operate. Additionally, he led the reduction of our weekly backorders by almost 60% from Q1 to year-end. Much of his effort and his success was focused on the creation of the Pharmaceutical Operations function within the Company and the associated organizational structure and the recruiting of talent and implementation of business processes such as S&OP, technical transfers and cost management programs.

AKORN, INC.- 2016 Proxy Statement     29

Long Term

Mr. Kafer’s bonus for 2015 was directly linked to the sales performance of the Company and targets established by the Compensation Committee and the Board of Directors. In 2015, the Company achieved $985 million in sales, and while not a factor in the determination of Mr. Kafer’s bonus amount, the Compensation Committee noted Mr. Kafer’s successful implementation of business processes for new product launches and the evaluation of commercial viability of products, and the streamlining of the commercial organization.

2015 Long-Term Incentive Compensation.


We grant NSOsGrants

Due to the restatement process, no equity awards were granted in 2015 under our long-term incentive plan. However, the following grants were made to our Named Executive Officers in connection with their joining the Company in 2015: Mr. Lichter was awarded 200,000 options on February 23, 2015, Mr. Pollard was awarded 50,000 options May 1, 2015, Mr. Kafer was awarded 125,000 options on May 1, 2015 and Mr. Portwood was awarded 300,000 options on October 30, 2015. In addition, Mr. Pollard was awarded 10,000 options on October 30, 2015 in recognition for his service as a meansInterim Chief Financial Officer. The stock options vest in four equal installments of rewarding past performance25% of the award per year beginning on the first anniversary of the grant date.

The long-term incentive awards that were intended to be made in 2015 were delayed until 2016 and encouraging continued efforts to achieve personal and Company objectiveswere granted 100% in the current and future years.  options.

During 2013,2015, the Board approvedmade the following grantgrants of stock options to our Named Executive Officers.  All options were granted at existing market price, vest one quarter per year on eachOfficers:

  Number of Options
Granted in 2015(1)
 Grant Date Fair Value
$
Raj Rai  
Duane A. Portwood 300,000 $3,186,270
Joseph Bonaccorsi  
Bruce Kutinsky  
Steven Lichter 200,000 $3,641,160
Randall E. Pollard 60,000 $941,269
Jonathan Kafer 125,000 $2,087,650
Timothy A. Dick  
TOTAL 685,000 $9,856,349

(1)Long-term incentive awards were scheduled to be granted in May 2015 to our executive officers with 75% of the grant-date fair value of each executive’s equity grant to be provided in the form of options and 25% in RSUs. However, due to the restatement process, the grants were delayed until early this year and were awarded 100% in options as follows: on March 24, 2016, Mr. Rai was awarded 191,387 options; Mr. Kutinsky was awarded 26,058 options and Mr. Bonaccorsi was awarded 65,453 options.

In addition to the first four anniversaries ofincentive awards described above, the grant date, and expire five years from the date of grant:

32

      
Number of
Options Granted
in 2013
  
Grant Date
Fair Value
 
Raj Rai  65,200  $443,725 
Timothy A. Dick  19,600   133,390 
Joseph Bonaccorsi  12,100   82,348 
Bruce Kutinsky  21,200   144,279 
John R. Sabat  11,900   80,987 
Mark M. Silverberg  11,900   80,987 
   141,900  $965,715 
Stock options granted in 2013 reflect the Company’s belief that Long Term Incentives should provide a large majority of compensation opportunity for our Named Executive Officers.  The Company does not have any Long Term Cash Incentives nor does it maintain a pension plan or a supplemental executive retirement plan.

While the Company has not yet adopted any stock ownership guidelines, as of March 7, 2014, each of ourCompensation Committee made discretionary cash bonuses to Named Executive Officers beneficially ownedfor their extraordinary contributions in 2015. See the “Summary Compensation Table” for the amounts of those awards.

2016 Performance Objectives

For the 2016 performance-based annual incentive plan, the following Company equity with a valuefinancial goals were set at Sales of at least 5 times his base salary$1.08 billion, Adjusted EBITDA of $499 million and Adjusted EPS of $2.15, as well as individual MBOs for 2013.


Benefits.

Employment and Consultant Agreements.  The Company has entered intoeach executive officer.

Other Elements of Compensation

Below are additional elements of compensation that we provide to our executive officers. For information regarding employment agreements with its CEO, CFO, COO and General Counsel.  The Company does not have employment agreements with its other Named Executive Officers.


The Company entered into an Employment Agreement with its CEO, Mr. Rai, effective January 1, 2014. Previously, Mr. Rai had been compensated pursuant to a consulting agreement.  Under the terms of his employment agreement, Mr. Rai receives an annual base compensation in the amount of $725,000 for his service as CEO, with the opportunity to earn bonus equal to 100% of his annual compensation beginning in fiscal year 2014.  The Compensation Committee and the Board felt that the financial achievements under Mr. Rai’s leadership merited this level of compensation.  Mr. Rai’s employment agreement also defines the amounts payable to Mr. Rai upon termination of his services following a change in control of the Company.  There is not a single trigger for his change of control provision.  The agreement with our CEO provides for post-termination benefits under certain circumstances following a change of control of ownership of the Company, which would include accelerated vesting of equity compensation awards, and a multiple of base salary and past bonus compensation.  

The Company entered into an employment agreement with its COO effective January 1, 2014.  This agreement has an initial term of one-year and is automatically renewed for successive one (1) year periods unless written notice of non-extension is provided.  The employment agreements describe payments due to the officer upon termination under various scenarios, including his termination following a change in control.  The agreement does not have a change of control provision with a single trigger.  The employment agreement with our COO provides for post-termination benefits under certain circumstances.  Further, in the event of a termination for good cause by the COO or for no cause following a change of control of ownership of the Company, post-termination benefits and compensation would include accelerated vesting of equity compensation awards, and a multiple of base salary and past bonus compensation.  

The Company entered into employment agreements with its CFO and its General Counsel on December 22, 2010.  Each employment agreement has an initial term of one-year and is automatically renewed for successive one (1) year periods unless written notice of non-extension is provided.  The employment agreements describe payments due to the officer upon termination under various scenarios, including his termination following a change in control.  Neither of these agreements has a change of control provision with a single trigger.  The employment agreements with our CFO and General Counsel provide for post-termination benefits under certain circumstances.  Further, in the event of a termination for good cause by the CFO or General Counsel or for no cause following a change of control of ownership of the Company, post-termination benefits and compensation would include accelerated vesting of equity compensation awards, and a multiple of base salary and past bonus compensation.  

33

Perquisites. The Company has eliminated all perquisites including company cars. None of our executives is eligible for any tax gross-ups.
executive severance plan, see “Potential Payments Upon Termination.”

Company-Wide Benefits.  

The Company does not have a pension plan and does not have a supplemental executive retirement plan. Executive officers and all full-time employees are eligible to participate in the Company’s standard benefit program,programs, which includesinclude health insurance (which is partially funded by the employee), 401(k), disability and life insurance (separate programs for executives and all other employees), flexible spending accounts, an employee stock purchase plan, an employee assistance program, an education assistance program, travel assistance, paid time off and holidays. Part-time employees are eligible to participate in a limited benefits program which includes a 401(k), plan, an employee stock purchase plan, and limited holiday and paid time off.   At the recommendation of management, the Board of Directors may elect to approve matching 401(k) contributions. Since January 1, 2011, the Company has been matching employee 401(k) contributions at a rate of 50% of the first 6% contributed by the employee.

Perquisites

In 2009, the Company largely eliminated perquisites for its executive officers. However, in 2015, the Company made several additions to its team of executive officers, and in doing so paid moving, temporary housing and related relocation costs to some of its Named Executive Officers. See “Summary Compensation Table” and “All Other Compensation Table.”

AKORN, INC.- 2016 Proxy Statement     30

ESPP.  The Akorn, Inc. Employee Stock Purchase Plan permits

Historically, the ESPP has permitted eligible employees to acquire shares of our common stock at a 15% discount from market price, through payroll deductions not exceeding 15% of base wages. Purchases under the ESPP arewere subject to an annual maximum purchase of $25,000 in market value of our common stock.

Other Considerations.
Tax Considerations.  It has been Due to our restatement process, however, we were required to suspend purchases under and continuesterminate our prior ESPP. Once our restatement process is complete, we intend to develop and obtain shareholder approval of a new employee stock purchase plan.

Executive Share Retention and Ownership Guidelines

In order to promote equity ownership and further align the interests of management with the Company’s shareholders, the Company adopted stock ownership guidelines for the Company’s executive officers. The executive officers are expected to achieve the ownership level associated with their position within five years of their respective appointments.

RoleGuideline
Chief Executive Officer5 times base salary
All Other Executive Officers3 times base salary

Until the specified ownership levels are met, an executive officer will be our intent thatrequired to retain 50% of all non-equity incentive paymentsshares acquired upon option exercises and the vesting of RSUs (in both cases, less shares withheld to pay taxes or cost of exercise). The value of a share shall be deductible unless maintaining such deductibility would undermine our ability to meet our primary compensation objectives or is otherwise not in our best interest. At this time, essentially all compensation (except certain equity incentives) paid tomeasured as the Named Executive Officers is deductible under Section 162(m)greater of the Internal Revenue Code.  We also regularly analyze the tax effects of various forms of compensation and the potential for excise taxes to be imposed on the executive officers which might have the effect of frustrating the purposes of such compensation.

Accounting Treatment Considerations.  We are especially attuned to the impact of Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation, with respect to the grant and vesting of equity compensation awards.  Prior to the granting of such awards, we analyze the short and longer-term effects of any particular award on our budget for the year of grant and anticipated financial impact in future years.  This information is taken into account in determining the type and vesting parameters for equity-based compensation awards.
Timing of Equity Grants and Equity Grant Practices.  The Compensation Committee recommends to the Board equity compensation to all of the Named Executive Officers and all other Company employees.  All awards are made based onthen current market price or the closing price of oura share of the Company’s common stock on the dateacquisition date. For purposes of approved award.  the stock ownership guidelines, stock ownership includes:

shares purchased on the open market,
shares owned jointly with, or separately, by the officer’s spouse and dependent children,
shares held in trust for the officer or immediate family member,
shares held through any Company-sponsored plan, including specifically the Employee Stock Purchase Plan,
shares obtained through the exercise of stock options, and
50% of unvested restricted shares of stock.

As of December 31, 2015, Messrs. Rai, Bonaccorsi, Kutinsky and Dick had all met the minimum ownership guidelines, and Messrs. Portwood, Lichter, Pollard and Kafer have until five years from their respective appointments to attain the required ownership levels.

Hedging Policy

Under the Company’s hedging policy, executive officers are discouraged from engaging in the purchase of puts, calls or other hedging transactions involving Company stock.

Clawback Policy

In addition, awards may be made to new employees upon their joiningFebruary 2016, the company, and to employees who are promoted during the year.  The timing of such awards depends on those specific circumstances and is not tied to any other particular company event, anticipated events or announcements.


Clawback Policy. The Company has not adopted a compensation clawback policy but(“Clawback Policy”) that applies to all executive officers and incentive-based compensation (including discretionary bonuses) awarded to such officers. Under the policy, the Company may require the forfeiture and repayment of incentive-based compensation if (1) the Company is monitoring developmentsrequired to prepare an accounting restatement due to material noncompliance with financial reporting requirements under the federal securities laws, (2) an executive officer received incentive-based compensation based on materially inaccurate financial statements or materially inaccurately determined performance metrics, (3) an action or omission by an executive officer results in material financial or reputational harm to the Company, or (4) an executive officer violated a non-compete or non-solicit provision or engaged in a felony or professional conduct injurious to the Company, its customers, employees, suppliers, or shareholders. In any such event, the Compensation Committee may require that an executive officer forfeit or repay all or any portion of any outstanding unpaid incentive-based compensation that was awarded to the officers and any incentive-based compensation that was paid to the officers during the 36 months prior. If a restatement occurs or an award is based on materially inaccurate financial statements or performance metrics, the Compensation Committee will consider all facts and circumstances that it determines relevant, including whether anyone responsible engaged in misconduct and issues of accountability. Any amount repaid by an executive officer shall not exceed the amount of incentive-based compensation awarded by the Company in excess of what would have been awarded to such employee under the circumstances reflected by the accounting restatement since the effective date of the policy. Pursuant to the provisions of the Clawback Policy, the Company shall amend the policy as necessary to satisfy the requirements of the Dodd Frank Wall Street Reform and Consumer Protection Act and intendsthe NASDAQ. In order to adopt a clawback policy that satisfiesensure the requirementsenforceability of the actClawback Policy, the Company is inserting appropriate language regarding the policy into applicable award agreements and other documents.

In addition to the SEC’s rules thereunder once such rules have been adopted. TheClawback Policy, the Company’s CEO and CFO are currently subject to statutory clawback requirements under the Sarbanes Oxley Act of 2002, which generally requires public company chief executive officers and chief financial officers to disgorge bonuses, other incentive- or equity-based compensation and profits on sales of company stock that they receive within the 12-month period following the public release of financial information if there is a restatement because of material noncompliance, due to misconduct, with financial reporting requirements under the federal securities laws.

Recovery of Bonuses in Connection with the Restatement

In light of our restatement, and as referenced in the Form 10-K/A filed in April 2015, in May 2016 the Compensation Committee re-evaluated the base, “stretch” and discretionary bonuses paid to the individuals listed as “named executive officers” for fiscal year 2014 (the “2014 NEOs”). Under our performance-based annual incentive plan in which the 2014 NEOs participated, if we do not achieve our Adjusted EBITDA target for a year, no awards are to be paid under the plan, even if other objectives were achieved. As a result of our restatement, it was determined that the Adjusted EBITDA that we actually achieved for 2014 did not meet the target threshold for that year. As a result, the Compensation Committee determined, and the Board approved, that the Company would seek repayment of 100% of the after-tax bonuses (base, “stretch” and

AKORN, INC.- 2016 Proxy Statement     31

discretionary) that were paid to each of the 2014 NEOs who are still employed by the Company for their service in 2014. Although the Company’s Clawback Policy generally applies to incentive payments prospectively since its adoption in February 2016, the steps taken by the Compensation Committee with respect to the 2014 bonuses are consistent with such policy. The Compensation Committee indicated that the recovery of bonuses is not tied to any determination of fault on the part of the 2014 NEOs and results solely from the financial restatement. The 2014 NEOs are cooperating with the Company, and the Company and the 2014 NEOs will be implementing repayment terms.

Tax Considerations

Section 162(m) of the Internal Revenue Code generally prohibits publicly held companies from deducting more than $1.0 million per year in compensation paid to each of certain of the Company’s highest paid executive officers, unless, in general, the compensation is paid pursuant to a plan which is performance-related, non-discretionary and has been approved by our shareholders, such as our 2014 Plan. It has been and continues to be our intent that all non-equity incentive payments be deductible unless maintaining such deductibility would undermine our ability to meet our primary compensation objectives or is otherwise not in our best interest. In general, historically the Compensation Committee has structured awards to the executive officers under the Company’s non-equity incentive program to qualify for this exemption. However, in 2015, due to the restatement process and hiring of new executive officers, the Company set its performance objects later in the year than is typical and thus was unable to structure its non-equity incentive program to meet the strict compliance requirements of Section 162(m) for the 2015 performance period. As a result, the CEO’s total compensation exceeded the Section 162(m) deductibility limit by approximately $1,400,000, which represented a cost to the Company of approximately $526,000 as a result of the lost tax deduction. The Compensation Committee believes that this amount, including the cost of the lost tax deduction was justifiable in order to be able to hire and retain key strategic executives through the restatement process and set meaningful objectives. However, going forward, it is our intent that we will continue to strive to structure compensation (excluding certain equity incentives) paid to the Named Executive Officers so that it is deductible under Section 162(m) of the Internal Revenue Code to the extent practical, but we may award non-deductible compensation in certain circumstances as we deem appropriate.

We also regularly analyze the tax effects of various forms of compensation and the potential for excise taxes to be imposed on the executive officers which might have the effect of frustrating the purposes of such compensation.

Accounting Treatment Considerations

We are especially attuned to the impact of ASC 718 - Stock Compensation, with respect to the granting and vesting of equity compensation awards. Prior to the granting of such awards, we analyze the short and longer-term effects of any particular award on our budget for the year of grant and anticipated financial impact in future years. This information is taken into account in determining the type and vesting parameters for equity-based compensation awards.

COMPENSATION COMMITTEE REPORT

Management of the Company has prepared the Compensation Discussion and Analysis describing the Company’s compensation program for senior executives, including the named executive officers. The Compensation Committee of Akorn has reviewed and discussed with management the Compensation Discussion and Analysis for fiscal year 20132015 and, based on such review and discussions, the Compensation Committee recommended to the Company’s Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.

This report is submitted by the Compensation Committee, consisting of:

Adrienne L. Graves, Ph.D., Chair
Ronald Johnson
Alan Weinstein

AKORN, INC.- 2016 Proxy Statement     32

Ronald M. Johnson, Chair
Adrienne L. Graves, Ph.D.
Alan Weinstein

35


Executive Compensation Tables

EXECUTIVE COMPENSATION TABLES

2015 Summary Compensation Table

The following table includessets forth information concerning compensation paid to or earned by our Named Executive Officers for the years ended December 31, 2013, 20122015, 2014 and 2011.

SUMMARY COMPENSATION TABLE 
Name and principal position
Year
 
 
Salary
($)
  
Bonus
($) (1)
  
Stock
Awards
($) (2)
  
Option
Awards
($) (3)
  
Non-Equity
Incentive Plan
Compensation
($) (4)
 
Nonqualified
Deferred
Compensation
Earnings
 ($)
 
All Other
Compen-
sation
($) (5)
  
Total
($)
 
                        
Raj Rai2013  -0-   250,000   -0-   443,725   500,000    500,000   1,250,000 
Chief Executive Officer2012  -0-   -0-   -0-   -0-   675,000    500,000   1,175,000 
 2011  -0-   250,000   -0-   2,962,720   750,000    500,000   4,462,720 
                               
Timothy A. Dick2013  309,000   -0-   -0-   133,390   77,250    12,860   532,500 
Chief Financial Officer2012  299,808   -0-   -0-   -0-   180,000    12,610   492,418 
 2011  289,712   -0-   -0-   462,925   195,750    12,135   960,522 
                               
Joseph Bonaccorsi2013  286,340   -0-   -0-   82,348   114,400    13,040   496,128 
Senior Vice President,2012  278,170   -0-   -0-   -0-   150,120    12,790   441,080 
General Counsel and Secretary2011  269,808   -0-   -0-   277,755   162,000    12,537   722,100 
                               
Bruce Kutinsky2013  313,685   -0-   -0-   144,279   122,070    10,203   590,237 
Chief Operating Officer2012  260,769   -0-   -0-   799,140   130,174    9,468   1,199,551 
 2011  240,000   -0-   -0-   462,925   108,000    9,231   820,156 
                               
John R. Sabat2013  280,160   -0-   -0-   80,987   77,701    11,968   450,816 
Senior Vice President, National2012  271,769   -0-   -0-   -0-   110,160    11,821   393,750 
Accounts & Trade Relations2011  263,900   -0-   -0-   370,340   117,000    11,846   763,086 
                               
Mark M. Silverberg2013  280,160   -0-   -0-   80,987   58,800    14,876   434,823 
Executive  Vice President,2012  271,846   -0-   -0-   -0-   97,920    13,798   383.564 
Global Quality Assurance &2011  264,000   -0-   -0-   370,340   106,515    13,545   754,400 
Alliance Management                              

2013.

Name and principal position Year Salary
($)
 Bonus*
($)
 Stock
Awards
($)(1)
 Option
Awards
($)(2)
 Non-Equity
Incentive Plan
Compensation*
($)(3)
 All Other
Compensation
($)(4)
 Total*
($)

Raj Rai

Chief Executive Officer

 

 2015 800,000 391,400   724,399 3,211 1,919,010
 2014 750,000 375,000(*) 4,412,253 1,948,882 1,125,000(*) 3,721 8,614,856
 2013  250,000  443,725 500,000 500,000 1,693,725

Duane A. Portwood

Executive Vice President

and Chief Financial Officer

 2015 70,962(5) 56,250(6)  3,186,270  104 3,313,586
 2014       
 2013       

Joseph Bonaccorsi

Senior Vice President, General

Counsel and Secretary

 2015 425,000 100,000   218,510 8,810 752,320
 2014 350,000  3,913,930 389,703 168,000(*) 10,769 4,832,402
 2013 286,340   82,348 114,400 9,290 492,378

Bruce Kutinsky

Chief Operating Officer

 2015 470,000    122,200 8,511 600,711
 2014 425,000  184,140 552,102 255,000(*) 4,668 1,420,910
 2013 313,685   144,279 122,070 6,453 586,487

Steven Lichter

Executive Vice President,

Pharmaceutical Operations

 2015 259,616(5) 94,854(7)  3,641,160 90,866 8,925 4,095,421
 2014       
 2013       

Randall E. Pollard

Former Interim CFO. Current

Executive Vice President,

Corporate Controller and

Chief Accounting Officer

 2015 178,846(8) 127,000(7)  941,269 132,000 30,284 1,409,399
 2014       
                
                
 2013       

Jonathan Kafer

Executive Vice President,

Sales and Marketing

 2015 207,692(5) 39,100  2,087,650 83,077 20,786 2,438,305
 2014       
 2013       

Timothy A. Dick

Former Chief Financial Officer

 

 2015 232,480(9)     175,050 407,530
 2014 385,000  1,669,754 428,737  9,007 2,492,498
 2013 309,000   133,390 77,250 9,110 528,750

(*)In light of our restatement, the Compensation Committee re-evaluated the base, “stretch” and discretionary bonuses paid to our 2014 NEOs. Consistent with the terms of the Company’s new Clawback Policy, the Compensation Committee determined, and the Board approved, that the Company would seek repayment of 100% of the after-tax bonuses (base, “stretch” and discretionary) in respect of 2014 service that were paid to each of the 2014 NEOs who are still employed by the Company. See “Recovery of Bonuses in Connection with the Restatement.”
(1)The amounts shown in this column are discretionary cash bonus awards earned in the applicable year and paid to the Named Executive Officers in the following year.  See “Performance-Based Annual Bonus” for additional information.

(2)
This column shows the grant-dategrant date fair value of restricted stock awardsRSUs granted during the applicable year. Additional information regarding restricted stock awards is included in the notesDue to the “Grants of Plan-Based Awards”restatement process, no RSUs were awarded under our long-term incentive plan in 2015. Such long-term incentive awards were delayed until 2016 and “Outstanding Equity Awards” tables.
were granted 100% in options. See “Long-Term Incentive Plan” and “2015 Long-Term Incentive Grants.”
(2)(3)This column shows the grant-date fair value of stock options granted during the applicable year. These amounts were determined as of the options’ grant dates in accordance with FASB ASC Topic 718.718 using the Black Scholes-Merton valuation model. The assumptions used were the same as those reflected in Note 911 – “Stock Options, Employee Stock Purchase Plan and Restricted Stock.” Due to the restatement process, no stock options were awarded under our consolidated financial statementslong-term incentive plan in 2015. However, in connection with joining the Company, Mr. Lichter was awarded 200,000 options on February 23, 2015, Mr. Pollard was awarded 50,000 options May 1, 2015, Mr. Kafer was awarded 125,000 options on May 1, 2015 and Mr. Portwood was awarded 300,000 options on October 30, 2015. In addition, Mr. Pollard was awarded 10,000 options on October 30, 2015 in recognition for his service as Interim Chief Financial Officer. The stock options vest in four equal installments of 25% of the award per year ended December 31, 2013.beginning on the first anniversary of the grant date. The long-term incentive awards intended to be granted in 2015 were delayed until 2016 and were granted 100% in options. See “Long-Term Incentive Plan,” “2015 Long-Term Incentive Grants” and the notes to the “Grants of Plan-Based Awards” and “Outstanding Equity Awards” tables.

AKORN, INC. - 2016 Proxy Statement     33

 

(4)(3)The amounts shown in this column are performance-based annual cash incentive awards earned in the applicable year andyear. Annual performance-based incentive awards are typically paid to the Named Executive Officers in the following year.first quarter of the subsequent year in which they were earned. However, upon the recommendation of management, the Compensation Committee unanimously decided to delay payment of all bonuses earned by the Named Executive Officers for 2015 until the Company filed its Annual Report on Form 10-K for 2015. See “Performance-Based Annual Bonus”Incentive” for additional information.
36

(5)(4)The amounts reported in this column represent the dollar amount for each Named Executive Officer as set forth in more detail in the “All Other Compensation Table” below.
(5)The amounts shown represent the base salaries of Messrs. Portwood, Lichter and Kafer - $450,000, $300,000 and $300,000, respectively, pro-rated to their respective start dates of October 30, February 16 and April 20, 2015.
(6)Mr. Portwood joined Akorn on October 30, 2015, and so did not receive bonus targets for 2015; however, he received a guaranteed payment of $56,250 to partially compensate for the bonus opportunity he gave up at his prior employer when joining Akorn.
(7)Messrs. Lichter and Pollard were granted signing bonuses of $46,154 and $50,000, respectively. Messrs. Lichter and Pollard were also awarded discretionary bonuses in the amounts of $48,700 and $55,000, respectively. In addition, for his service as Interim Chief Financial Officer, Mr. Pollard was awarded a bonus in the amount of $22,000.
(8)In connection with his promotion to Interim Chief Financial Officer, Mr. Pollard’s salary was increased from his starting salary of $235,000 to $275,000 as of August 3, 2015.
(9)This amount represents Mr. Dick’s base salary of $385,000 pro-rated through his resignation date of August 3, 2015.

All Other Compensation Table

Name Year  Fees for
Consulting
Services
($)
  401(k)
Match
($)
  Group
Term Life
Insurance
Premium
($)
  All
Other
($)
  Total
($)
Raj Rai 2015      2,650   561      3,211
Duane A. Portwood 2015         104      104
Joseph Bonaccorsi 2015      7,950   860      8,810
Bruce Kutinsky 2015      7,950   561      8,511
Steven Lichter 2015      7,615   1,310      8,925
Randall E. Pollard 2015         249   30,035(b)   30,284
Jonathan Kafer 2015      4,846   573   15,367(b)   20,786
Timothy A. Dick 2015   160,417(a)   7,950   395   6,288(c)   175,050

(a)These consulting services (CEO only), perquisitesfees were paid pursuant to a consulting arrangement entered into between the Company and other personal benefits, tax reimbursements, our matching contributionsMr. Dick upon his resignation from the Company. See “Potential Payments Upon Termination.”
(b)The amount shown reflects moving, temporary housing and related relocation costs reimbursed to the Akorn 401(k) savings plan, insurance premiums, and other benefits as follows:
NameYear
Fess for Consulting
Services
($)
401(k)
Match
($)
Group
Term Life
Insurance
Premium
($)
All
Other
($) (1)
Total
($)
executive.
Raj Rai
(c)
2013
2012
2011
500,000
500,000
500,000
-0-
-0-
-0-
-0-
-0-
-0-
-0-
-0-
-0-
500,000
500,000
500,000
Timothy A. Dick
2013
2012
2011
-0-
-0-
-0-
8,750
8,500
8,028
360
360
360
3,750
3,750
3,747
12,860
    12,610
12,135
Joseph Bonaccorsi
2013
2012
2011
-0-
-0-
-0-
8,750
8,500
8,250
540
540
540
3,750
 3,750
3,747
13,040
12,790
 12,537
Bruce Kutinsky
2013
2012
2011
-0-
-0-
-0-
5,913
5,178
4,985
540
540
499
3,750
3,750
3,747
10,203
9,468
9,231
John R. Sabat
2013
2012
2011
-0-
-0-
-0-
5,842
5,695
5,723
2,376
2,376
  2,376
3,750
3,750
3,747
11,968
11,821
11,846
Mark M. Silverberg
2013
2012
2011
-0-
-0-
-0-
8,750
8,250
8,250
2,376
  1,548
  1,548
3,750
3,750
3,747
14,876
13,798
13,545
The amount shown represents the cost paid for continued health coverage after Mr. Dick’s resignation in 2015. See “Potential Payments Upon Termination.”

AKORN, INC. -2016 Proxy Statement34

 
(1)This column represents the discount from market value on shares purchased through the Employee Stock Purchase Plan for Messrs. Bonaccorsi, Dick, Sabat and Silverberg, and Dr. Kutinsky.Back to Contents

37


2013 Grants of Plan-Based Awards

 2015 Grants of Plan-Based Awards

The following table provides additional information about non-equity incentive compensation and stock and option awards granted to our Named Executive Officers during the year ended December 31, 2013.



GRANTS OF PLAN-BASED AWARDS 
Name
Grant
Date
Estimated Future Payouts
Under
Non-Equity Incentive Plan
Awards (1)
 
 
Estimated Future Payouts
Under
Equity Incentive Plan Awards
 
 
 
All Other Stock Awards: Number
of Shares
of Stocks 
 
All Other
Option
Awards:
Number of
Securities
Underlying
Options
  
Exercise
or Base
Price of
Option
Awards
(2)
($/Sh)
  
Grant Date
 Fair Value
of Stock
and Option
Awards($)
(3)
 
  
 
Threshold
($)
 
 Target
($)
 Maxi-mum
($)
 Thresh-old
($)
 Target
($)
 Maximum
($)
          
Raj Rai5/3/13         65,200  $15.36  $443,725
 
 
 
 
Timothy A. Dick
 
5/3/13         19,600  $15.36  $133,390 
 
Joseph Bonaccorsi
 
5/3/13         12,100  $15.36  $82,348 
 
Bruce Kutinsky
 
5/3/13         21,200  $15.36  $144,279 
 
John R. Sabat
 
5/3/13         11,900  $15.36  $80,987 
 
Mark M. Silverberg
 
5/3/13         11,900  $15.36  $80,987 
in 2015 under our 2014 Plan.

                  All Other    
    Estimated Possible Payouts Estimated Future Payouts All Other Option Exercise  
    Under Non-Equity Incentive Under Equity Incentive Stock Awards: or Base Grant Date
    Plan Awards(1) Plan Awards Awards: Number of Price of Fair Value
    Thres-     Thres-     Number Securities Option of Stock
  Grant hold Target Maximum hold Target Maximum of Shares Underlying Awards(3) and Option
Name Date ($) ($) ($) ($) ($) ($) of Stocks Options(2) ($/Sh) Awards($)(4)
Raj Rai                      
Non-Equity Incentive                      
Compensation 07/30/2015   800,000 1,200,000              
Duane A. Portwood                      
Stock Option 10/30/2015               300,000 26.74 3,186,270
Joseph Bonaccorsi                      
Non-Equity Incentive                      
Compensation 07/30/2015   212,500 318,750              
Bruce Kutinsky                      
Non-Equity Incentive                      
Compensation 07/30/2015   235,000 352,500              
Steven Lichter                      
Non-Equity Incentive
Compensation
 07/30/2015   103,846(5) 155,769(5)         200,000 48.05 3,641,160
Stock Option 02/23/2015                    
Randall E. Pollard                      
Non-Equity Incentive
Compensation
 07/30/2015   110,000(5) 165,000(5)              
Stock Option 05/01/2015               50,000 43.00 835,060
Stock Option 10/30/2015               10,000 26.74 106,209
Jonathan Kafer                      
Non-Equity Incentive
Compensation
 07/30/2015   83,077(5) 207,693(5)              
Stock Option 05/01/2015               125,000 43.00 2,087,650
Timothy A. Dick                      
Non-Equity Incentive                      
Compensation(6) 07/30/2015   192,500 288,750              

(1)
(1)
(2)
For information on performance-based annual bonusincentive awards granted in 2013,2015, see “Performance-Based Annual Bonus”Incentive” and “Summary Compensation Table - Non-Equity Incentive Plan Compensation.”
(2)The stock options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Due to the restatement process, no equity awards were granted in 2015 under our long-term incentive plan. However, the following grants were made to Named Executive Officers in connection with their joining the Company in 2015: Mr. Lichter was awarded 200,000 options on February 23, 2015, Mr. Pollard was awarded 50,000 options May 1, 2015, Mr. Kafer was awarded 125,000 options on May 1, 2015 and Mr. Portwood was awarded 300,000 options on October 30, 2015. In addition, Mr. Pollard was awarded 10,000 options on October 30, 2015 in recognition for his service as Interim Chief Financial Officer. The long-term incentive awards that were intended to be granted in 2015 were granted earlier this year on March 24, 2016, as follows: Mr. Rai was awarded 191,387 options; Mr. Kutinsky was awarded 26,058 options and Mr. Bonaccorsi was awarded 65,453 options.
(3)The per-share exercise or base price of the options granted in the fiscal year is based on the closing price of our common stock on the grant date of each respective option.
(4)
(3)
The grant date fair value of the option award granted during 20132015 was based on the closing prices of our common stock on the grant date, and was calculated in accordance with FASB ASC Topic 718. The assumptions used for this grant were the same as those reflected in Note 911 – “Stock Options, Employee Stock Purchase Plan and Restricted Stock.”
(5)The amounts shown for Messrs. Lichter and Kafer are pro-rated to our consolidated financial statements in our Annual Report on Form 10-Ktheir respective start dates of February 16 and April 20, 2015. Pursuant to his offer letter, Mr. Pollard was entitled to the bonus opportunity for the year ended December 31, 2013.
full year.
(6)(4)The options vest one quarter per year on eachMr. Dick resigned from the Company as of the first four anniversaries of the grant date.August 3, 2015 and so did not receive a bonus for 2015.
38

Outstanding Equity Awards at 2013 Year-End

The following table provides a summary of equity awards outstanding at December 31, 2013, for each of our Named Executive Officers.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
OPTION AWARDS (1)STOCK AWARDS
Name
Number of
Securities
Underlying
Unexercised
Options
Exercisable
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
Option
Exercise
Price
($)
Option
Expiration
Date
 (8)
Number of
Shares or
Units of
Stock That
Have Not
Vested
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other Rights
That Have
Not Vested
Raj Rai250,000 (2)-0- 1.006/8/2014    
 2,000,000 (3)-0- 1.348/7/2014    
 150,000 (4)-0- 1.462/22/2015    
 750,000 (5)-0- 2.615/21/2015    
 533,333 (6)266,667 6.624/29/2016    
 -0- (13)65,200 15.365/3/2018    
          
Timothy A. Dick100,000 (6)-0- 1.006/12/2014    
 183,333 (4)-0- 1.462/22/2015    
 366,667 (5)-0- 2.615/21/2015    
 83,333 (6)41,667 6.624/29/2016    
 -0- (13)19,600 15.365/3/2018    
          
Joseph Bonaccorsi250,000 (7)-0- 0.815/6/2014    
 100,000 (4)-0- 1.462/22/2015    
 100,000 (5)-0- 2.615/21/2015    
 50,000 (6)25,000 6.624/29/2016    
 -0- (13)12,100 15.365/3/2018    
          
Bruce Kutinsky250,000 (11)-0- 5.4312/10/2015    
 83,333 (6)41,667 6.624/29/2016    
 25,000 (12)75,000 13.358/3/2017    
 -0- (13)21,200 15.365/3/2018    
          
 John R. Sabat25,000 (4)-0- 1.462/22/2015    
 18,173 (5)-0- 2.615/21/2015    
 66,666 (6)33,334 6.624/29/2016    
 -0- (13)11,900 15.365/3/2018    
          
39

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END (continued)
OPTION AWARDS (1)STOCK AWARDS
Name
Number of
Securities
Underlying
Unexercised
Options
Exercisable
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
Option
Exercise
Price
($)
Option
Expiration
Date
 (8)
Number of
Shares or
Units of
Stock That
Have Not
Vested
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other Rights
That Have
Not Vested
Mark M. Silverberg50,000 (9)-0- 1.115/26/2014    
 50,000 (8)-0- 1.6011/19/2014    
 35,000 (10)-0- 1.6011/19/2014    
 75,000 (10)-0- 1.6011/19/2014    
 80,000 (4)-0- 1.462/22/2015    
 60,000 (5)-0- 2.615/21/2015    
 66,666 (6)33,334 6.624/29/2016    
 -0- (13)11,900 15.365/3/2018    

AKORN, INC. -2016 Proxy Statement     35

 
Outstanding Equity Awards at 2015 Year-End

The following table sets forth information with respect to outstanding equity awards held by our Named Executive Officers as of December 31, 2015. Market values have been determined based on the closing price of our common stock on December 31, 2015 of $37.31.

  OPTION AWARDS(1) STOCK AWARDS
Name Number of
Securities
Underlying
Unexercised
Options
Exercisable
 Number of
Securities
Underlying
Unexercised
Options
Unexercisable
 Equity
Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
 Option
Exercise
Price
($)
 Option
Expiration
Date
 Number of
Shares or
Units of
Stock That
Have Not
Vested
 Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
 Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights That
Have Not
Vested
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
Raj Rai                  
Option(1) 32,600 32,600   15.36 5/3/2018         
Option(2) 52,923 158,767   24.74 5/2/2019         
RSU(3)           19,703 735,128    
RSU(4)           73,944 2,758,879    
Duane A. Portwood                  
Option(5)  300,000   26.74 10/30/2022         
Joseph Bonaccorsi                  
Option(6) 100,000    2.61 (6)         
Option 75,000    6.62 (6)         
Option(1) 6,050 6,050   15.36 5/3/2018         
Option(2) 10,583 31,747   24.74 5/2/2019         
RSU(3)           3,940 147,020    
RSU(4)           74,370 2,774,775    
Bruce Kutinsky                  
Option(6) 250,000    5.43 (6)         
Option 125,000    6.62 (6)         
Option(7) 75,000 25,000   13.35 8/3/2017         
Option(1) 10,600 10,600   15.36 5/3/2018         
Option(2) 14,493 44,977   24.74 5/2/2019         
RSU(3)           5,582 208,274    
Steven Lichter                  
Option(8)  200,000   48.05 2/23/2022         
Randall E. Pollard                  
Option(9)  50,000   43.00 5/1/2022         
Option(5)  10,000   26.74 10/30/2022         
Jonathan Kafer                  
Option(9)  125,000   43.00 5/1/2022         
Timothy A. Dick                  
Option 125,000    6.62 (6)         
Option(1) 9,800    15.36 5/3/2018         
Option(2) 11,643    24.74 5/2/2019         
RSU(3)           4,334 161,711    
RSU(4)           30,008 1,119,543    

AKORN, INC. -2016 Proxy Statement36

NOTES:

(1)Outstanding stockThe amounts shown represent the number of options atgranted to each executive officer May 3, 2013 that had not vested as of December 31, 2013, become exercisable2015. These options vest in accordance withfour equal installments of 25% of the vesting schedule below:
Grant Date                   Vesting Schedule                                                                              .
(2)6/8/2009Vested immediately upon grant.
(3)8/7/2009250,000 options vested on 12/8/2009 and 250,000 options to vest every six months thereafter, until 6/8/2013, for as long as and providing that Mr. Rai continues to render CEO consulting services to the Company.
(4)2/22/20101/3award per year beginning on the first anniversary of the grant date. Mr. Dick’s remaining 9,800 options were forfeited as of his resignation August 3, 2015. Subsequent to December 31, 2015, the following options vested: Mr. Rai 3,025, Mr. Bonaccorsi 16,300 and Mr. Kutinsky 5,300.
(2)
(5)5/21/20101/3The amounts shown represent the number of options granted to each executive officer May 2, 2014 that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Mr. Dick’s remaining 34,927 options were forfeited as of his resignation August 3, 2015. Subsequent to December 31, 2015, the following options vested: Mr. Rai 52,923, Mr. Bonaccorsi 10,583 and Mr. Kutinsky 14,993.
(3)
(6)6/12/20091/3The amounts shown represent the number of RSUs granted to each executive officer May 2, 2014 that had not vested as of December 31, 2015. These RSUs vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. RSUs that were scheduled to vest in 2015 are treated as vested for accounting purposes and purposes of determining diluted earnings per share. However, due to the Company’s restatement process, no shares could be issued with respect to any RSUs that vested in 2015 and the Company intends to issue such shares as soon as it is allowed. Subsequent to December 31, 2015, the following RSUs vested: Mr. Rai 6,568, Mr. Bonaccorsi 1,314 and Mr. Kutinsky 1,861. In accordance with his letter agreement, Mr. Dick’s remaining 4,334 RSUs vested on February 3, 2016.
(4)
(7)5/6/20091/3The amounts shown represent the number of RSUs granted to each executive officer September 5, 2014 that had not vested as of December 31, 2015. These RSUs vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. RSUs that were scheduled to vest in 2015 are treated as vested for accounting purposes and purposes of determining diluted earnings per share. However, due to the Company’s restatement process, no shares could be issued with respect to any RSUs that vested in 2015 and the Company intends to issue such shares as soon as it is allowed. In accordance with his letter agreement, Mr. Dick’s remaining 30,008 RSUs vested on February 3, 2016.
(5)
(8)11/19/20091/3The amounts shown represent the number of options granted on October 30, 2015 to Mr. Pollard in connection with his service as our Interim Chief Financial Officer and to Mr. Portwood in connection with his hire as our new Chief Financial Officer that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date.
(6)These options are fully vested and were scheduled to expire if not exercised. However, due to legal restrictions under the securities laws, during the restatement process the options could not be exercised. Once the restrictions are lifted, the executives will have 30 days to exercise such options before they expire.
(9)(7)5/26/20091/The amounts shown represent the number of options granted to each executive officer August 3, 2012 that had not vested as of December 31, 2015. These options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. The remaining options vest August 3, 2016.
(8)
(10)11/19/20091/4 vesting immediately and 1/4The amounts shown represent the number of options granted on eachFebruary 23, 2015 to Mr. Lichter in connection with his hire that had not vested as of next three anniversariesDecember 31, 2015. These options vest in four equal installments of grant
(11)12/10/20101/325% of the award per year beginning on the first anniversary of the grant date. Subsequent to December 31, 2015 50,000 of Mr. Lichter’s options vested.
(9)
(12)8/3/20121/4The amounts shown represent the number of options granted on May 1, 2015 to Mr. Pollard and Mr. Kafer in connection with their hires. The options vest in four equal installments of 25% of the award per year beginning on the first anniversary of the grant date. Subsequent to December 31, 2015, the following options vested: Mr. Pollard 12,500 and Mr. Kafer 31,250.

AKORN, INC. -2016 Proxy Statement     37

 
(13)5/3/20131/4 per year beginning on the first anniversary of the grant
 See “2013 Grants of Plan-Based Awards” for more information on outstanding stock options.
40

 2013 Option Exercises and Stock Vested Table

 2015 Option Exercises and Stock Vested Table

The following table provides a summary of the value realized by our Named Executive Officers from the exercise of option awards or the vesting of stock awards during the year ended December 31, 2013.


2015.

  OPTION AWARDS STOCK AWARDS
Name Number of
Shares
Acquired
on Exercise
(#)
 Value
Realized
on
Exercise ($)(1)
 Number of
Shares
Acquired
on
Vesting
(#)(2)
 Number of
Shares Withheld
to Cover Tax
Liability(2)
 Value Realized
on Vesting
($)(2)
Raj Rai(3) 1,700,000 64,090,976 31,216  1,261,183
Duane A. Portwood     
Joe Bonaccorsi(4) 100,000 4,661,094 26,104  1,045,060
Bruce Kutinsky(5)   1,861  78,542
Steven Lichter    ��� 
Randall E. Pollard     
Jonathan Kafer     
Timothy A. Dick(6) 122,222 4,526,517 11,447  460,283

OPTION EXERCISES AND STOCK VESTED(1)The stock option exercises included above were either same-day sales or were sales to cover the exercise price and taxes due upon exercise of the options. The value realized on exercise of these options equaled the difference between the average sales prices and the exercise prices for the underlying shares.
(2)OPTION AWARDSSTOCK AWARDSAs a result of the Company’s restatement process, no shares associated with vesting RSUs were issued in 2015 and accordingly, no shares could be withheld. For disclosure purposes, the Company has still reported the number of shares and value realized associated with the vesting of the RSUs.
Name(3)
NumberOf the 1,700,000 options exercised by Mr. Rai during the year ended December 31, 2015, 873,985 shares were sold to cover the exercise price and taxes due upon exercise of
Shares
Acquired
options and the remaining 826,015 shares were held by Mr. Rai. Of the $1.3 million of value realized on Exercise
(#)
Value
Realized
vesting of RSUs during the year ended December 31, 2015, $0.3 million of value was based on
Exercise ($)
Number the vesting of
Shares
Acquired
6,568 shares at the closing price of our common stock on
Vesting
(#)
Number the first trading day following the annual vesting on May 4, 2015 of
Shares Withheld
to Cover Tax
Liability
Value Realized $42.21 per share and $1.0 million of value was based on
Vesting
($)
the vesting of 24,648 shares at the closing price of our common stock on the first trading day following the annual vesting on September 8, 2015 of $39.92 per share.
No Named Executive Officers(4)Of the 100,000 options exercised by Mr. Bonaccorsi during the year ended December 31, 2015, 40,827 shares were sold to cover the exercise price and taxes due upon exercise of options and the remaining 59,173 shares were held by Mr. Bonaccorsi. Of the $1.0 million of value realized on vesting of RSUs during the year ended December 31, 2015, $0.1 million of value was based on the vesting of 1,314 shares at the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share and $1.0 million of value was based on the vesting of 24,790 shares at the closing price of our common stock on the first trading day following the annual vesting on September 8, 2015 of $39.92 per share.
(5)The value for Mr. Kutinsky was based on the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share.
(6)Of the 122,222 options exercised by Mr. Dick during 2013.the year ended December 31, 2015, 60,300 shares were sold to cover the exercise price and taxes due upon exercise of options and the remaining 61,922 shares were held by Mr. Dick. Of the $0.5 million of value realized on vesting of RSUs during the year ended December 31, 2015, $0.1 million of value was based on the vesting of 1,445 shares at the closing price of our common stock on the first trading day following the annual vesting on May 4, 2015 of $42.21 per share and $0.4 million of value was based on the vesting of 10,003 RSUs at the closing price of our common stock on the first trading day following the annual vesting on September 8, 2015 of $39.92 per share and $0.9 million of value was based on the accelerated vesting of the remaining 34,342 outstanding RSUs in connection with his resignation as discussed above, based on the price of our common stock on the first trading day following the vesting date of February 3, 2016 of $25.41 per share.

Potential Payments Upon Termination or Change of Control


Employment Agreements and Offer Letters

We have entered into employment agreements with our CEO, CFO, COO and General Counsel which include severance andthat, in addition to providing bonus opportunity, provide the officers with compensation if they are terminated without cause, they leave the Company with good reason or their employment terminates in certain circumstances in connection with a change of control provisions that may require us to make payments to these individuals in the eventcontrol. The agreements renew automatically for a one-year period unless written notice of the termination of the CEO’s, CFO’s, COO’s and General Counsel’s employment, and increased payments and acceleration of unvested equity grants, such as stock options, following a change in control.


Underis provided. We believe the terms of the employment agreements wepromote stability and continuity of senior management. Specifically, these common protections promote our ability to attract and retain management and assure us that our executive officers will continue to be dedicated and available to provide certain financial protections forobjective advice and counsel notwithstanding the possibility, threat or occurrence of a periodchange in their circumstances or in the control of one year for the Company. All of the employment agreements are listed in the Exhibit Index to our 2015 Annual Report on Form 10-K.

Each of our CEO, CFO, COO and General Counsel followingis entitled to receive benefits under the employment agreements if (1) we terminate the executive’s employment without cause, (2) the

AKORN, INC. -2016 Proxy Statement38

executive resigns for good reason or (3) if there is a change of control. Incontrol during the eventterm of the agreement and within the 90 days prior to and 12 months following the change of control we terminate the executive’s employment without cause or he resigns for good reason. Under these scenarios, each of the executives is entitled to receive (1) any accrued but unpaid salary and pro-rata bonus, (2) reimbursement for any outstanding reasonable business expense, (3) vacation pay, (4) continued life and health insurance as described below and (5) a severance payment calculated as described below.

The term “cause” includes termination due to willful and continued failure to substantially perform assigned duties, the conviction of any felony or crime involving fraud, and breach of any material term of the employment of the CEO, CFO, COO or General Counsel is terminated involuntarily by the Company or successor or for good reason by the individual officer during such period, he would then be provided with severance benefits under the terms of the agreement. The agreement does not provide for any tax gross-up of severance pay.

A “change of control” as defined in the employment agreements generally means (i) any other person or entity acquires ownership of 40 % or more of our outstanding common stock or the combined voting power over our outstanding voting securities;  (ii) the incumbent directors, as defined in the agreements, ceaseterm “good reason” includes termination due to constitute at least a majority of the board; or (iii) the completion of certain corporate transactions including a reorganization, merger, statutory share exchange, consolidation or similar transaction, a sale or other disposition of all or substantially all of our assets, or the acquisition of assets or stock of another entity, subject to certain exceptions.

“Good reason” generally means the occurrence of any of  (a) amaterial adverse change in officer’s status or responsibilities, which represents a material and adverse changerelocation beyond fifty (50) miles from officer’s status or responsibilities, or the assignment to officer of any duties or responsibilities which are materially inconsistent with officer’s status or responsibilities; (b) a reduction in officer’s base salary to a level below that in effect at any time previously; (c) the Company’s requiring officer to be based at any place outside a 50-mile radius from officer’sexecutive’s job location or residence, without the officer’s consent; (d)a substantial reduction in base salary that is not comparable to that of other executives and is not part of a comprehensive reduction, and the failure of the Company to obtain an agreement satisfactory to the officer,executive from any successorssuccessor entities to assume the employment agreement.

If we terminate the executive without cause or the executive resigns for good reason, the severance payment will be equal to one times his then current base salary plus his total bonus opportunity most recently approved under the Company’s annual bonus incentive plan. In addition, the executive is eligible to receive payment of life and agree to perform the agreement.


With respect to the CEO’s Employment Agreement, if,health insurance coverage for a period of 12 months following such executive’s termination of employment.

If there is a change of control during the term of the agreement and within the agreement is terminated within ninety (90)period from 90 days prior to or twelve (12)and 12 months following athe change in control we terminate the CEO then would be entitled toexecutive without cause or the following compensation and benefits:


i.  If the CEO’s Employment Agreement is terminated by the Companyexecutive resigns for good cause, due toreason, the CEO’s disability or death, due to CEO’s retirement, or by CEO for any other than for Good Reason, the Company would pay to CEO accrued compensation.
41


ii. If the CEO’s Employment Agreement is terminated by the Company without good cause, or by the CEO for Good Reason, the CEO wouldseverance payment will be entitled to (a) the Company would pay CEO all accrued compensation and a pro-rata bonus amount; (b) the Company would pay CEO as a liquidated sum in lieu of any further compensation for periods subsequent to the termination date, an amount in cash equal to three (3) times in the case of the CEO and two times in the case of the CFO, COO or General Counsel, the sum of the greater of (a) the executive’s then current base annual compensationsalary and (b) his base salary immediately prior to the change of control, plus his total bonus amount; (c) until the second (2nd) anniversary of the termination date, officer would have such rights with respect to benefits provided by the Company, including without limitation car allowance, life insurance, disability, medical, dental and hospitalization benefits as were provided to officer within ninety (90) days preceding the date of the Change in Control,and (d) the restrictions on any outstanding incentive awards (including restricted stock and granted performance shares or units) granted to CEOopportunity most recently approved under the Company’s stock optionannual bonus incentive plan. In addition, the executive will be eligible to receive payment of life and other stock incentive plans or under any other incentive plan or arrangement would lapse and such incentive award would become 100% vested, all stock options and stock appreciation rights granted tohealth insurance coverage for a period of 36 months for the CEO would become immediately exercisable and would become 100% vested and all performance units granted to the CEO would become 100% vested.

Under the Employment Agreement with our CEO, he is subject to certain restrictive covenants including non-compete provisions that obligate the CEO to not compete with the business24 months for each of the Company during the term of his employment.  The CEO is specifically prohibited from engaging in any business activity that is, or may reasonably be found to be, in competition with the business of the Company.  Further, the CEO is prohibited during the term and for twelve months following the termination of the Consulting Agreement from soliciting, enticing or inducing any Company employees or business away from the Company to be employed by any competitor of the Company.

With respect to the CFO, COO and General Counsel, if, during the termfollowing such executive’s termination of their respective agreements, the agreement is terminated within 90 days prior to or 12 months following a change in control, the officer would then be entitled to the following compensation and benefits:

i.  If the officer’s employment were terminated by the Company for good cause, due to the officer’s disability or death, due to officer’s retirement, or by the officer for any other than for Good Reason, the Company would pay to officer accrued compensation.

ii. If the officer’s employment is terminated by the Company without good cause, or by the officer for Good Reason, the officer would be entitled to: (a) the Company would pay officer all accrued compensation and a pro-rata bonus amount; (b) the Company would pay officer an amount in cash equal to two (2) times the sum of  base annual compensation and bonus amount; (c) until the second (2nd) anniversaryas well as vesting (as of the termination date, officer would have such rights with respect to benefits provided by the Company, including without limitation car allowance, life insurance, disability, medical, dental and hospitalization benefits as were provided to officer within ninety (90) days preceding the dateexecutive’s last day of the Change in Control; and (iv) the restrictions onemployment) of any outstanding incentive awards (including restricted stock and granted performance sharesunvested options or units) granted to officer under the Company’s stock option and other stock incentive plans or under any other incentive plan or arrangement would lapse and such incentive award would become 100% vested, all stock options and stock appreciation rights granted to officer would become immediately exercisable and would become 100% vested and all performance unitsRSUs previously granted to the officer would become 100% vested.

Any change of control severance payment amountsexecutive.

Severance payments will be made to the CEO, CFO, COO or General Counsel would be paid in a singleone lump sum cash payment within 30 days, ofor as soon as administratively practicable, following the termination and would bedate, subject to all applicable tax and other withholdings.

If the executive’s employment is terminated by the Company for cause, or by the executive without good reason, or due to the executive’s death or disability or retirement pursuant to the Company’s policies applicable to executive officers, the executive is not entitled to severance pay or continuation of payment of life and health insurance but will receive accrued, but unpaid salary, reimbursement for any outstanding reasonable business expense and pro-rata pay for unused vacation time.

The employment agreements contain non-competition and non-solicitation covenants that apply during the term and until the sooner to occur of 12 months following the executive’s termination date and 12 months following the change of control.

In the event that any payment or benefit received or to be received by the CEO, CFO, COO or General Counsel in connection with termination of his Employment Agreementemployment agreement would constitute a parachute payment within the meaning of Section 280G of the Internal Revenue Code or any similar or successor provision to 280G would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code, then such Severance Parachute Paymentsamounts would be reduced to the largest amount which would result in no portion of the Severance Parachute Paymentsamounts being subject to the Excise Tax.  excise tax. The agreements do not provide for any tax gross-up of severance pay.

Termination Other Than

In connection with his promotion to Chief Accounting Officer and Interim Chief Financial Officer, Mr. Pollard entered into a letter agreement dated August 25, 2015, which entitles Mr. Pollard to severance in an amount equal to twelve months of his then current base salary if his employment is terminated prior to August 3, 2016 without cause or due to a change in control that occurs within 60 days of August 3, 2016. Eligibility for Cause or Disability; Voluntary Terminationthis severance benefit is dependent upon execution of a termination and severance agreement at the time of termination of his employment.

A copy of each of the employment agreements and letter agreements we have with our Named Executive Officers has been filed with the SEC. Please see the exhibit list at Item 15.Exhibits, Financial Statement Schedules.

Executive and Key Management Change in Control Severance Plan

The severance and change in control arrangements for Good Reason.


Further, with respect to theour CEO, CFO, COO and General Counsel,GC are set forth in their individual employment agreements, as set forth above. Severance and change in control arrangements for our other Named Executive Officers and key executives is set forth in the Executive Change in Control Severance Plan (the “Executive CIC Plan”) that has been instituted by our Compensation Committee. Participants in the Executive CIC Plan are selected by the Company’s Compensation Committee or Board of Directors. Under the Executive CIC Plan, if any such officer is terminated other than for cause or disability, ora Named Executive Officer, within the officer terminates employment for “good reason” either more than 90 days prior to orand 12 months following a change of control of the Company, experiences an involuntary termination without cause or voluntarily terminates his employment for good reason, then he wouldwill be entitled to receive (i) a lump sumlump-sum cash severance payment equal to the amountone year of the officer’s accrued compensationhis then current base salary, (ii) continued payment of health insurance coverage for a period of one year following termination of employment and pro-rated bonus, plus:

(i) an amount in cash equal to one (1) times the sum of the base annual compensation and bonus; and
42

(ii) until the first (1st) anniversary of the termination, the officer would have such rights with respect to all benefits provided by the Company as were provided to the officer(iii) vesting as of the executive’s last day of employment of any unvested options or RSUs previously granted to the executive. See “Payments in Connection with Various Termination Scenarios.”

The Executive CIC Plan provides the Company with assurance that it will have the continued dedication of, and the availability of objective advice and counsel from, key executives of the Company and its affiliates and to promote certainty and minimize potential disruption for key executives of the Company in the event the Company is faced with or undergoes a change in control. The Company updated its equity award agreements for its Named Executive Officers. Each of the Company’s equity award agreements for Named Executive Officers now provides for this “double trigger” vesting of equity awards in the event the

AKORN, INC. -2016 Proxy Statement39

Company undergoes a change in control transaction in which the awards are continued or assumed – that is, the award will vest if the recipient experiences an involuntary termination datewithout cause or if greater, at any timevoluntarily terminates his employment for good reason within the 90 days preceding the termination date,prior to and (iii) the amounts provided would be paid12 months following a change in a single lump sum cash payment within 30 days after the termination plus accrued pay in lieu of unused vacation.

Termination for Death or Disability or for Cause.

If the Company’s employmentcontrol of the CFO, COO or General Counsel wouldCompany. Our current Form of Non-Qualified Stock Option Award Agreement, Form of Incentive Stock Option Award Agreement, and Form of Restricted Stock Unit Award Agreement were filed as exhibits to our Form 10-K that we filed with the SEC on May 10, 2016. Other equity awards may be terminated (i)granted under our 2014 Stock Option Plan using other forms of award agreements as may be determined from time to time in the form approved by the Compensation Committee.

The Executive CIC Plan does not provide for any tax gross-up of severance pay. In addition, payment of any cash severance under the Executive CIC Plan is contingent upon the participant’s execution of a separation agreement containing a release of claims in favor of the Company for Cause, (ii) dueand its affiliates and covenants restricting the executive officer’s competition, solicitation of employees, disparagement of the Company and its affiliates and disclosure of confidential information.

Payments in Connection with Various Termination Scenarios

The following table indicates the cash amounts, accelerated vesting and other payments and benefits that each Named Executive Officer would have been entitled to officer’s Disability or death, (iii) due to officer’s retirementreceive upon termination under various circumstances pursuant to the terms of their respective employment agreements, the 2003 Plan and 2014 Plan, the award agreements made under the 2003 Plan and the 2014 Plan and the Company’s policies applying to executive officers generally, or (iv) by officer other than for Good Reason,Executive CIC Plan. The table assumes that the executive’s termination of employment with the Company would pay to officerunder the accrued compensation. Cause generally means an officer’s willful and continued failure to perform substantially his duties.


Each of the agreements with the CFO, COO and General Counsel contains non-compete provisions pursuant to which the CFO, COO and General Counsel shall not compete with the business of the Company during the term of their employment and for twelve months following their employment termination. Specifically, the officers will not engage in any business activity that is or may reasonably be found to be in competition with the business of the Company.  Further, the CFO, COO and General Counsel are prohibited from soliciting, enticing or inducing any Company employees or business away from the Company to be employed by any competitor of the Company.

The following table sets forth the estimated amounts payable to each of our Named Executive Officers upon a “change in control” of the Company:

  Raj Rai  
Timothy A.
Dick
  
Joseph
Bonaccorsi
  
Bruce
Kutinsky
  
John R.
Sabat
  
Mark M.
Silverberg
 
Cash Severance Payments $2,175,000  $618,000  $572,680  $650,000  $-0-  $-0- 
Cash Bonus Payments  2,175,000   463,500   343,608   487,500   -0-   -0- 
Accelerated Vesting of Stock Options (1)  5,403,758   931,502   562,046   1,791,568   -0-   -0- 
Employee Benefits Continuation (2)  24,000   16,000   16,000   16,000   -0-   -0- 
Tax Gross-Up  -0-   -0-   -0-   -0-   -0-   -0- 
TOTAL $9,777,758  $2,029,002  $1,494,334  $2,945,068  $-0-  $-0- 

scenario shown occurred on December 31, 2015.

Executive / Termination Event(1)(2) Cash Severance
Payment
 Acceleration of
Equity Awards(3)
 Life/Health
Insurance Benefits
 Total Termination
Benefits
Raj Rai            
without cause or with good reason, $2,000,000  —  $11,250(4) $2,011,250
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $6,000,000 $6,205,284  $33,750(5) $12,239,034
Duane A. Portwood            
without cause or with good reason, $787,500  —  $11,250(4) $798,750
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $1,575,000 $3,171,000  $22,500(5) $4,768,500
Joseph Bonaccorsi            
without cause or with good reason $680,000  —  $11,250(4) $691,250
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $1,360,000 $3,453,628  $22,500(5) $4,836,128
Bruce Kutinsky            
without cause or with good reason, $822,500  —  $11,250(4) $833,750
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $1,645,000 $1,605,311  $22,500(5) $3,272,811
Steven Lichter            
without cause or with good reason    —     
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $300,000  (6)  $11,250(4) $311,250
Randall E. Pollard            
without cause(7) $275,000  —    $275,000
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $275,000 $105,700(6)  $11,250(4) $391,950
Jonathan Kafer            
without cause or with good reason    —     
without cause or with good reason within 90 days prior            
to or 12 months following a change of control $300,000  (6)  $11,250(4) $311,250

(1)RepresentsThe table does not give effect to any reduction in payments to any executive that might occur under his employment agreement in the event that the payment would become subject to additional taxes under Section 4999 of the Internal Revenue Code for receipt of excess parachute payments in the event of a termination or resignation following a change in control. In addition, the amounts shown in this table do not include accrued but unpaid salary, reimbursement for any outstanding reasonable business expense or vacation pay.
(2)If the executive’s employment is terminated by the Company for cause, or by the executive without good reason, or due to the executive’s death or disability or retirement pursuant to the Company’s policies, the executive will receive all accrued but unpaid salary, reimbursement for any outstanding reasonable business expense and vacation pay.
(3)The amount represents the intrinsic value of “in-the-money” unvested stock options and unvested RSUs based on $24.62$37.31 per share, which was the closing stock price of Akorn, Inc. common stock on December 31, 2013.2015.
(2)  (4)For Messrs. Dick and Bonaccorsi and Dr. Kutinsky, theThe amount represents the estimated cost to continue health and life insurance coverage for 2 years after a change in control.  For Mr. Rai, the1 year.

AKORN, INC. -2016 Proxy Statement40

(5)The amount represents continuedthe estimated cost to continue health and life insurance coverage for Mr. Rai for 3 years, after changefor Messrs. Portwood, Bonaccorsi and Kutinsky for 2 years.
(6)All of Messrs. Lichter’s and Kafer’s stock options were out of the money as of December 31, 2015. The amount shown for Mr. Pollard does not include 50,000 of his stock options which were out of the money as of December 31, 2015.
(7)Pursuant to his letter agreement dated August 25, 2015, Mr. Pollard is entitled to severance in control.an amount equal to twelve months of base salary if his employment is terminated prior to August 3, 2016 without cause.

Director Compensation

Mr. Dick’s Resignation

On August 3, 2015, Mr. Dick tendered his resignation to pursue other opportunities. In connection with his departure, the Company entered into a letter agreement with Mr. Dick. Pursuant to the letter agreement, Mr. Dick agreed to serve as a consultant to the Company until February 3, 2016, all of Mr. Dick’s unvested stock options were immediately forfeited, his RSUs continued to vest through the consulting period, and the Company agreed to continue paying health coverage for one year. The table below shows the total amounts paid or to be paid to Mr. Dick in connection his resignation.

  Cash
Severance
Payment
 Acceleration
of Equity
Awards(1)
  Life/Health
Insurance
Benefits(2)
  Consulting
Payments(3)
  Total
Termination
Benefits
Timothy A. Dick $  $872,624  $19,589  $256,667  $1,148,880

(1)Represents the intrinsic value as of December 31, 2015 of unvested RSUs based on the closing stock price of Akorn, Inc. common stock on February 4, 2016 or $25.41.
(2)The amount represents the cost to continue health coverage for one year following Mr. Dick’s resignation - $6,288 in 2015 and $13,202 in 2016.
(3)The Company paid Mr. Dick $160,417 for consulting services he provided in 2015, and an additional $96,250 for consulting services provided in 2016.

DIRECTOR COMPENSATION

Director compensation is set by the Compensation Committee in coordination with management and submitted to the Board for approval. Each year, the Compensation Committee works with its independent compensation consultant to review current director compensation using published survey data of companies of similar size based on revenue and market capitalization and in the pharmaceutical industry, as well as director compensation of companies in our self-selected peer group, in order to guide the Compensation Committee towards establishing director compensation that falls in an appropriate rangerange. In 2015, based upon the recommendations of the compensation consultant, the Compensation Committee revised our director compensation program to better align the program with median peer group practices to compensate for a companyadditional time commitment and risk associated with participation on Board committees.

 Amount
Annual Compensation Element Chair  Member
Annual Cash Retainer $125,000  $75,000
Annual Equity Award Grant Value $230,000  $230,000
Audit Committee - Cash Compensation $25,000  $12,500
Compensation Committee - Cash Compensation $20,000  $10,000
Nominating and Governance Committee - Cash Compensation $15,000  $7,500
Special Litigation Committee - Cash Compensation $20,000  $12,500
Special Committee - Cash Compensation(1) $15,000  $7,500
Stock Ownership Guidelines5x annual equity 5x annual equity
 and cash retainer and cash retainer

(1)From time to time, the Board may create one or more special committees. Generally, a chair of a special committee is paid $15,000 and a member $7,500 for his or her services, however, the compensation paid may vary and is approved on a case-by-case basis by the Compensation Committee.

AKORN, INC. -2016 Proxy Statement     41

All retainers are paid quarterly in arrears. Annual equity awards are generally made immediately following the annual meeting of its sizeshareholders. In addition to the above fees, we reimburse our directors for reasonable and necessary expenses they incur in performing their duties as directors.

Annual equity awards are typically made to our directors at the Pharmaceutical Industry.


UponBoard meeting held immediately after our annual meeting of shareholders. In 2014, the annual equity awarded to our directors was 100% in options, vesting one year from the date of grant and expiring five years from the date of grant if not exercised. Beginning in 2015, the Compensation Committee determined that the annual equity awarded to our directors would be awarded 50% in options and 50% in RSUs. However, due to the Company’s restatement process, the Company paid each director cash in lieu of their annual equity award for 2015.

In connection with her appointment to the Board in March 2012, Dr. Graveson May 1, 2015, Ms. Rappuhn was granted the option to purchase 20,000 shares of our common stock at the market pricesprice in effect on the date of grant. The optionsoption vested immediately100% upon the anniversary of the date of grant and expireexpires five years from grant date if not exercised.  Our directors currently receive fees paid in cash and each has stock or stock options.  While the Company has not yet adopted any stock ownership guidelines for its Board, given the number of shares beneficially owned by Board members as of March 7, 2014, the Company is confident each independent director could currently fulfill a requirement to beneficially own Company’s stock with a value that is a multiple of 3 – 5 times his annual director’s fees.  The Compensation Committee has discussed adding this requirement.

43

In 2012, the Compensation Committee revised annual cash compensation schedule for our Board members that was previously adopted on April 19, 2011.  The revised cash compensation schedule was adopted as of May 4, 2012 and has remained unchanged since that date.  The cash portion of Board compensation is paid quarterly.  Accordingly, for their service on the Board during 2013, our Chairman received cash compensation of $90,000 and our other Board members received cash compensation of $70,000 apiece.

Set forth below are the current and previous cash compensation schedules for our Board members:

  
Fee schedule adopted
on April 29, 2011
  
Fee schedule adopted
on May 4, 2012
 
Board Fees:      
   Chairman of the Board $70,000  $90,000��
   Board Members $50,000  $70,000 
         
In addition to the cash compensation detailed above, each Director is to receive an annual equity award.  The quantity and type of equity award to be granted is determined annually and takes into account the estimated grant-date fair value of the award.   Each continuing director received a grant of 4,557 shares of restricted stock on May 8, 2013 for his or her annual service as a director, with half of the shares vesting on the grant date and the remainder vesting on the one year anniversary of grant.

In connection with their service as our directors, we have provided to each of our independent directors supplemental indemnity assurances with respect to any claims associated with their serving as one of our directors, as a director of any of our subsidiaries, as a fiduciary of any of our employee benefit plans and in other positions held at our request.

Director Stock Ownership Guidelines

The Compensation Committee believes that it is in the best interests of the Company and its shareholders to align the financial interests of the Company’s directors with those of the shareholders. Accordingly, the Compensation Committee established the following stock ownership guidelines for directors. Each director is expected to acquire and retain shares of the Company’s common stock having a value equal to at least five times the total value of the director’s annual stock and cash retainer. Directors shall have three years from the date of election or appointment to attain such ownership levels. The Nominating and Governance Committee in its discretion may extend the period of time for attainment of such ownership levels in appropriate circumstances. In the event a director’s annual retainer increases, he or she will have one year from the date of the increase to acquire any additional shares needed to meet the guidelines.

As of May 1, 2016, Messrs. Kapoor, Abramowitz, Johnson, Meyer, Tambi and Weinstein had all met the minimum ownership guidelines. Ms. Graves has not yet achieved the required level, largely because the Company paid the equity portion of the directors’ 2015 retainer fee in cash rather than equity. Ms. Rappuhn has until April 20, 2018 (three years from the date of her appointment) to attain the required ownership level. The following table sets forth compensation paid to our directors for the year 2013:

2013 DIRECTOR COMPENSATION 
 
Name
(a)
  
 
 
Fees Earned
or Paid
in Cash
($)
(b) (1)
   
 
Stock
Awards
($)
(c) (2)
  
Option
Awards
($)
(d) (3)
  
Non-equity incentive plan compensation
($)
(e)
  
Change in pension value and nonqualified deferred compensation earnings
(f)
  
All other compensation
($)
(g)
   
Total
($)
(h)
 
Dr. John N. Kapoor (Chairman) $90,000  $69,996  -0-  -0-  -0-  -0-  $159,996 
Kenneth S. Abramowitz  70,000   69,996  -0-  -0-  -0-  -0-   139,996 
Dr. Adrienne Graves  70,000   69,996  -0-  -0-  -0-  -0-   139,996 
Ronald M. Johnson  70,000   69,996  -0-  -0-  -0-  -0-   139,996 
Steven Meyer  70,000   69,996  -0-  -0-  -0-  -0-   139,996 
Brian Tambi  70,000   69,996  -0-  -0-  -0-  -0-   139,996 
Alan Weinstein  70,000   69,996  -0-  -0-  -0-  -0-   139,996 
2015:

2015 DIRECTOR COMPENSATION TABLE

Name Fees Earned or
Paid in Cash
($)(1)
  Bonus  Option
Awards
($)(2)
  Total
($)
Dr. John N. Kapoor (Chairman) $355,000  $  $  $355,000
Kenneth S. Abramowitz  314,375         314,375
Dr. Adrienne Graves  336,938         336,938
Ronald M. Johnson  335,625         335,625
Steven Meyer  336,250   100,000(3)      436,250
Terry Allison Rappuhn  293,750   100,000(3)   362,994   756,744
Brian Tambi  305,000         305,000
Alan Weinstein  340,000         340,000

(1)The dollar amount of allamounts shown in this column represent the retainer fees earned or paid in cashby each for servicesserving as a director, including annualany retainer fees for serving as a chair or committee and/or chairmanship fees,member. The amounts shown in this column also include $230,000 paid in cash to each director in lieu of their 2015 annual equity award. The amounts shown for Ms. Rappuhn and meeting fees.Mr. Weinstein each include $7,500, and for Mr. Johnson $15,000, for their service on a special committee in 2015.
(2)This column presents the aggregate grant date fair value of restricted stock awards issued during 2013.
(3)No stock options were awarded to any of our directors in 2013.  Had such awards been granted, this column would presentrepresents the aggregate grant date fair value of stock options granted during the year. Ms. Rappuhn was awarded 20,000 options on May 1, 2015, in connection with her appointment to the Board. The options were granted pursuant to our 2014 Plan and vest one year from the grant date. The grant date fair values wouldare be determined in accordance with FASB ASC Topic 718 using the Black Scholes-Merton valuation model, and the assumptions used would be the same as those reflected in Note I to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013.11 – “Stock Options, Employee Stock Purchase Plan and Restricted Stock. As of December 31, 2013,May 1, 2016, each director had the following number of vested options outstanding: Dr. Kapoor – none;- 10,753; Mr. Abramowitz – 51,585;- 35,753; Dr. Graves – 20,000;- 30,753; Mr. Johnson – 120,000;- 60,753; Mr. Meyer – 40,000;- 35,753; Mr. Tambi – 70,000; and- 60,753; Mr. Weinstein – 70,000.- 60,753; and Ms. Rappuhn - 20,000.
(3)Mr. Meyer and Ms. Rappuhn were each awarded a discretionary bonus of $100,000 for leading the Audit Committee’s independent investigation related to the Company’s restatement.

AKORN, INC. -2016 Proxy Statement42

44

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

Ronald M.  Johnson,

Dr. Adrienne Graves, Chair, Alan Weinstein and Dr. Adrienne Graves,Ronald M. Johnson, who currently comprise the Compensation Committee, are each independent, non-employee directors of the Company. No executive officer (current or former) of the Company served as a director or member of (i) the compensation committee of another entity in which one of the executive officers of such entity served on our Compensation Committee, (ii) the board of directors of another entity in which one of the executive officers of such entity served on our Compensation Committee, (iii) the compensation committee of any other entity in which one of the executive officers of such entity served as a member of our Board, or (iv) were directly or indirectly the beneficiary of any related transaction required to be disclosed under the applicable regulations of the Exchange Act, during the year ended December 31, 2015.

EQUITY COMPENSATION PLANS

Equity Compensation Plans

Options granted under the 2003 Plan have exercise prices equivalent to the market value of our common stock on the date of grant and expire five years from that date. Options granted to our Directors typically vest one year from the date of grant and expire five years from the date of grant. All options granted from May 4, 2012 through November 6, 2013 vest annually over a four-year period. All existing option and restricted stock awards as of November 6, 2013, the date of expiration of the 2003 Option Plan, remain intact through their various expiration dates, but no further awards can be granted pursuant to the 2003 Option Plan.

On May 2, 2014, the Company obtained shareholder approval of the 2014 Option Plan, which was adopted by the Board of Directors on December 30, 2013. Under this plan, which replaced the expired 2003 Option Plan, 7,500,000 shares of common stock may be issued pursuant to options and other stock-based awards. The 7,500,000 shares set aside for issuance under the 2014 Option Plan is inclusive of the 6,816,500 shares authorized but unissued from the terminated 2003 Option Plan. Options granted under the 2014 Plan have exercise prices equivalent to the market value of our common stock on the date of grant. They vest over four years and expire five or seven years from the date of grant. As of May 1, 2016, 4,066,317 shares remain available for issuance under the 2014 Option Plan.

Historically, the Akorn, Inc. Employee Stock Purchase Plan (the “ESPP”) permitted eligible employees to acquire shares of our common stock through payroll deductions in whole percentages from 1% to 15% of eligible wages, at a 15% discount from the market price of our common stock, subject to an annual maximum purchase of $25,000 in market value of common stock. However, due to our restatement process, we were required to suspend purchases under and terminate our ESPP.

Summary Table

The following table sets forth certain information as of December 31, 2015, with respect to compensation plans under which shares of Akorn common stock were issuable as of that date. We do not have any equity compensation plans that have not been approved by our shareholders.

Plan Category Number of securities to
be issued upon exercise
of outstanding options,
warrants
and rights
 Weighted-average
exercise price of
outstanding options,
warrants and rights
 Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
the first column)
Equity Compensation plans approved by security holders: 5,014,379(1) $21.49 4,066,317

(1)This amount reflects 2,444,151 outstanding options and 252,764 unvested restricted stock unit awards under the 2003 Plan, and 2,317,464 options under the 2014 Plan.

AKORN, INC. -2016 Proxy Statement     43


45


 ANNUAL REPORT
A COPY
IV.Security Ownership of Certain Beneficial Owners and Management

As of April 29, 2016, the following persons were directors, nominees, Named Executive Officers or others with beneficial ownership of 5% or more of our common stock. The information set forth below has been determined in accordance with Rule 13d-3 under the Exchange Act based upon information furnished to us or to the SEC by the persons listed. Unless otherwise noted, the address of each of the following persons is 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

BENEFICIAL OWNERSHIP OF THE 2013 ANNUAL REPORT ACCOMPANIES THIS PROXY STATEMENT. WE WILL PROVIDE, WITHOUT CHARGE, A COPYHOLDERS OF 5% OR MORE OF OUR FORM 10-K, INCLUDING FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES, AS FILED WITH THE SEC, UPON REQUEST IN WRITING FROM ANY PERSON WHO WAS A HOLDER OF RECORD OR WHO REPRESENTS IN GOOD FAITH THAT SUCH PERSON WAS A BENEFICIAL OWNER OF COMMON STOCK, AS OF MARCH 7, 2014.  REQUESTS SHOULD BE MADE TO DIRECTORS, AND NAMED EXECUTIVE OFFICERS:

  Shares Percent
  Beneficially of
Beneficial Owner Owned(1) Class
Holders of 5% or more of our common stock (excluding Directors and Named Executive Officers):    
BlackRock, Inc. 7,230,228(2) 6.1%
Directors:    
John N. Kapoor, Ph.D. 31,457,558(3) 26.3%
Kenneth S. Abramowitz 72,068(4) *
Adrienne L. Graves, Ph.D. 30,753(5) *
Ronald M. Johnson 147,560(6) *
Steven J. Meyer 109,309(7) *
Terry Allison Rappuhn 20,500(8) *
Brian Tambi 94,344(9) *
Alan Weinstein 139,810(10) *
Named Executive Officers:    
Raj Rai 2,315,980(11) 1.9%
Duane A. Portwood -0- *
Joseph Bonaccorsi 576,102(12) *
Bruce Kutinsky, Pharm. D. 512,580(13) *
Steven Lichter 50,000(14) *
Randall E. Pollard 12,500(15) *
Jonathon Kafer 31,250(16) *
Timothy A. Dick 350,556(17) *
Directors and Executive Officers as a group (16 persons) 35,920,870 30.1%
(*)indicates Beneficial Ownership of less than 1%.
(1)Includes all shares beneficially owned, whether directly and indirectly, individually or together with associates, jointly or as community property with a spouse, as well as any shares as to which beneficial ownership may be acquired within 60 days of April 29, 2016 by the vesting of RSUs or the exercise of options, warrants or other convertible securities. Unless otherwise specified in the footnotes that follow, the indicated person or entity has sole voting power and sole investment power with respect to the shares.
(2)The stock ownership of BlackRock, Inc. is as of December 31, 2015 as reflected in the Schedule 13G/A filed with the SEC on January 25, 2016. The address of BlackRock, Inc. is 40 East 52ndStreet, New York, New York 10022.
(3)Includes (i) 4,907,524 shares of common stock owned by the Kapoor Trust, of which Dr. Kapoor is the sole trustee and beneficiary, (ii) 500,730 shares of common stock owned directly by Dr. Kapoor, and (iii) 10,753 shares of common stock issuable upon exercise of options. The total also includes (a) 15,050,000 shares of common stock owned by Akorn Holdings, L.P., a Delaware limited partnership, of which Dr. Kapoor is the indirect managing general partner, (b) 2,970,644 shares of common stock owned EJ Financial / Akorn Management L.P., of which Dr. Kapoor is the indirect managing general partner, (c) 3,590,445 shares of common stock owned by EJ Funds LP., of which Dr. Kapoor is the indirect managing general partner, and (d) 4,427,462 shares of common stock held through several trusts, the trustee of which is employed by a company controlled by Dr. Kapoor and the beneficiaries of which include Dr. Kapoor’s children and various other family members, all of which shares in (a) – (d) Dr. Kapoor disclaims beneficial ownership of to the extent of his actual pecuniary interest therein. Dr. Kapoor holds sole voting and dispositive power over 31,457,558 beneficially-owned shares and holds shared voting and dispositive power over 31,457,558 beneficially owned shares.
(4)Beneficial ownership for Mr. Abramowitz includes 35,753 shares of common stock issuable upon exercise of options.
(5)Beneficial ownership for Dr. Graves includes 30,753 shares of common stock issuable upon exercise of options.
(6)Beneficial ownership for Mr. Johnson includes 60,753 shares of common stock issuable upon exercise of options.
(7)Beneficial ownership for Mr. Meyer includes 35,753 shares of common stock issuable upon exercise of options.
(8)Beneficial ownership for Ms. Rappuhn includes 20,000 shares of common stock issuable upon exercise of options.

AKORN, INC.- 2016 Proxy Statement     44

(9)Beneficial ownership for Mr. Tambi includes 60,753 shares of common stock issuable upon exercise of options and excludes 6,026 RSUs scheduled to vest in three equal installments on September 5, 2016, September 5, 2017 and September 5, 2018.
(10)Beneficial ownership for Mr. Weinstein includes (i) 60,753 shares of common stock issuable upon exercise of options.
(11)Beneficial ownership for Mr. Rai includes 2 million shares owned by the Rajat Rai 2016 GRAT. The total also includes 154,745 shares of common stock issuable upon the exercise of options and excludes; (i) 13,136 RSUs scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (ii) 73,945 RSUs scheduled to vest in three equal installments on September 5, 2016, September 5, 2017 and September 5, 2018, (iii) 16,300 shares of common stock issuable upon the exercise of stock options scheduled to vest on May 3, 2017 and (iv) 105,485 shares of common stock issuable upon the exercise of stock options scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018.
(12)Beneficial ownership for Mr. Bonaccorsi includes 205,240 shares of common stock issuable upon the exercise of options and excludes (i) 2,627 RSUs scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (ii) 74,370 RSUs scheduled to vest in three equal installments on September 5, 2016, September 5, 2017 and September 5, 2018, (iii) 3,025 shares of common stock issuable upon the exercise of stock options scheduled to vest on May 3, 2017 and (iv) 21,165 shares of common stock issuable upon the exercise of stock options scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018.
(13)Beneficial ownership for Dr. Kutinsky includes 495,885 shares of common stock issuable upon the exercise of stock options and excludes (i) 3,722 RSUs scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018, (ii) 5,300 shares of common stock issuable upon the exercise of stock options scheduled to vest on May 3, 2017 and (iv) 29,985 shares of common stock issuable upon the exercise of stock options scheduled to vest in two equal installments on May 2, 2017 and May 2, 2018.
(14)Beneficial ownership for Mr. Lichter includes 50,000 shares of common stock issuable upon the exercise of stock options and excludes 150,000 shares of common stock issuable upon the exercise of stock options schedule to vest in three equal installments on February 23, 2017, February 23, 2018 and February 23, 2019.
(15)Beneficial ownership for Mr. Pollard includes 12,500 shares of common stock issuable upon the exercise of stock options and excludes (i) 37,500 shares of common stock issuable upon the exercise of stock options schedule to vest in three equal installments on May 1, 2017, May 1, 2018 and May 1, 2019 and (ii) 10,000 shares of common stock issuable upon the exercise of stock options scheduled to vest in four equal installments on October 30, 2016, October 30, 2017, October 30, 2018 and October 30, 2019.
(16)Beneficial ownership for Mr. Kafer includes 31,250 shares of common stock issuable upon the exercise of stock options and excludes 93,750 shares of common stock issuable upon the exercise of stock options schedule to vest in three equal installments on May 1, 2017, May 1, 2018 and May 1, 2019.
(17)Beneficial ownership for Mr. Dick includes (i) 146,443 shares of common stock issuable upon the exercise of stock options and (ii) 45,789 RSUs.

AKORN, INC.- 2016 Proxy Statement   �� 45

V.Questions and Answers

Why have I received these materials? What is included in the proxy materials?

This proxy statement was provided to you because our Board is soliciting your proxy to vote at the annual meeting of shareholders to be held on July 1, 2016. The proxy materials for our 2016 annual meeting of shareholders include the Notice of Annual Meeting, this proxy statement and our Form 10-K filed for fiscal year 2015. If you received a paper copy of these materials, the proxy materials also include a proxy card or voting instruction form.

 Who may attend the 2016 Annual Meeting? Are there procedures for attending?

Only shareholders as of May 11, 2016 or their legal proxy holders may attend the 2016 annual meeting. Due to space constraints and other security considerations, we will not be able to accommodate the guests of either shareholders or their legal proxy holders.

To be admitted to the 2016 annual meeting, you must present valid proof of ownership of the Company’s common stock as of May 11, 2016 or a valid legal proxy. All attendees must also provide a form of government-issued photo identification. If you arrive at the 2016 annual meeting without the required items, we will admit you only if we are able to verify that you are a shareholder of the Company as of May 11, 2016.

Shareholders of record may gain admittance to the 2016 annual meeting by providing proof of ownership of the Company’s common stock as of May 11, 2016. If your shares are held in the name of a bank, broker, trustee or other nominee and you plan to attend the 2016 annual meeting, you will need to bring proof of ownership as of May 11, 2016, such as a recent bank or brokerage account statement, and if you wish to vote in person, you must obtain a legal proxy issued in your name from your broker or other nominee. If you are not a shareholder but attending as proxy for a shareholder, you may attend the 2016 annual meeting by presenting a valid legal proxy. Shareholders may appoint only one proxy holder to attend on their behalf.

If you are representing an entity that is a shareholder, you must provide evidence of your authority to represent that entity at the 2016 annual meeting. Shareholders holding shares in a joint account will be admitted to the 2016 annual meeting if they provide proof of joint ownership.

 Who is entitled to vote at the 2016 Annual Meeting?

Shareholders of record as of the close of business on May 11, 2016 will be entitled to vote at the annual meeting. On May 11, 2016, there were 119,427,471 shares of common stock outstanding and entitled to vote.

If on May 11, 2016 you were a “record” shareholder of common stock (that is, if you held common stock in your own name in the stock records maintained by our transfer agent, Computershare), ATTENTION: INVESTOR RELATIONS,you may vote in person at the annual meeting or by proxy. Whether or not you intend to attend the annual meeting, we encourage you to vote now, online, by phone, or proxy card to ensure that your vote is counted.

If on May 11, 2016, you were the beneficial owner of shares of common stock held in “street name” (that is, a shareholder who held common stock through a broker or other nominee) then these materials are being forwarded to you by the broker or other nominee. You may direct your broker or other nominee how to vote your shares of common stock. However, you will have to obtain a proxy form from the institution that holds your shares and follow the voting instructions on the form. If you wish to attend the annual meeting and vote in person, you may attend the meeting but may not be able to vote in person unless you first obtain a legal proxy issued in your name from your broker or other nominee.

A list of shareholders entitled to vote at the meeting will be open to the examination of any shareholder, for any purpose germane to the meeting, on and during ordinary business hours for 10 days prior to the date of the meeting at our principal offices located at 1925 WEST FIELD COURT, SUITEWest Field Court, Suite 300, LAKE FOREST, ILLINOISLake Forest, Illinois 60045.

 What am I voting on?

There are three matters scheduled for a vote:

Election of eight directors;
Ratification of the appointment by our Audit Committee of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
Approval by non-binding advisory vote of the Company’s executive compensation program.

AKORN, INC.- 2016 Proxy Statement     46

 How do I cast my vote?

You may either vote “FOR ALL” or “WITHHOLD ALL” or “FOR ALL EXCEPT” for any or all of the Company’s nominees for Director. There is no cumulative voting with respect to the election of directors. You may vote “FOR” or “AGAINST” or “ABSTAIN” from voting to ratify the Company’s appointment of BDO USA, LLP as its independent registered public accounting firm and on the voting to approve by non-binding advisory vote the Company’s executive compensation program.

If you are a shareholder of record, vote over the Internet at www.proxyvote.com or vote by telephone at 1 (800) 690-6903. You may also vote by proxy card, voter instruction form or in person at the annual meeting.

Whether or not you plan to attend the annual meeting, we urge you to vote now to ensure your vote is counted. You may still attend the annual meeting and vote in person if you have already voted by proxy.

If you hold your shares in street name, the name of your broker, bank, or other agent, you should have received a proxy card and voting instructions with these proxy materials from that organization rather than from Akorn. In order to vote, complete and mail the proxy card received from your broker or bank to ensure that your vote is counted. Alternatively, you may vote by telephone or over the Internet as instructed by your broker, bank or such other applicable agent. To vote in person at the annual meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker, bank, or other agent included with these proxy materials, or contact your broker, bank, or such other agent to request a proxy form.

Each share of common stock is entitled to one vote with respect to each matter to be voted on at the annual meeting.

 What constitutes a quorum for purposes of the annual meeting?

A quorum of shareholders is necessary to hold a valid meeting. The presence at the annual meeting in person or by proxy of the holders of a majority of the voting power of all outstanding shares of common stock entitled to vote, or 59,713,736 votes, shall constitute a quorum for the transaction of business at the meeting. Proxies marked as abstaining (including proxies containing broker non-votes) on any matter to be acted upon by shareholders will be treated as present at the meeting for purposes of determining a quorum but will not be counted as votes cast on such matters. If there is no quorum, a majority of the votes present at the meeting may adjourn the meeting to another date.

 How does the Board recommend that I vote my shares?

The Board’s recommendation is set forth together with the description of each item in this proxy statement. In summary, the Board recommends a vote:

FOR ALL for the election of the eight nominees for director (Proposal 1).
FOR the ratification of the appointment by our Audit Committee of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016 (Proposal 2).
FOR the approval, by non-binding advisory vote, of the Company’s executive compensation program (Proposal 3).

With respect to any other matter that properly comes before the annual meeting, the proxies will vote as recommended by the Board or, if no recommendation is given, in their own discretion. As of the date of this proxy statement, the Board had no knowledge of any business other than that described herein that would be presented for consideration at the 2016 annual meeting.

 What if I return a proxy card but do not make specific choices?

If you are the shareholder of record and return a signed and dated proxy card without marking any voting selections, your shares will be voted “FOR ALL” for the election of all eight nominees for director, “FOR” the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016 and “FOR” the approval by non-binding advisory vote of our executive compensation program. If any other matter is properly presented at the annual meeting, your proxy (the individual named on your proxy card) will vote your shares using his or her best judgment.

If you hold your shares in street name, and do not provide your nominee instruction with respect to any voting selections, your shares cannot be voted by your nominee for the election of any of the eight nominees for director or the approval by non-binding advisory vote of our executive compensation program. In such case, your vote will be considered a “broker non-vote.” However, your shares may be voted by your nominee for the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.

AKORN, INC.- 2016 Proxy Statement     47

HOUSEHOLDING OF PROXY MATERIALS
Back to Contents
 How many votes are needed to approve each proposal?

Proposal 1. The election of directors will be determined by a plurality of the votes cast at the annual meeting by shares represented in person or by proxy and entitled to vote for the election of directors. A plurality means the highest number of “FOR” votes. Therefore, the eight nominees receiving the most proper “FOR” votes will be elected. Abstentions and broker non-votes will have no effect on the outcome.

Proposal 2. The ratification of the appointment by our Audit Committee of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016 requires a “FOR” vote from a majority of the votes cast. Abstention and broker non-votes will have no effect on the outcome.

Proposal 3. The approval by advisory vote of the Company’s executive compensation program is non-binding to the Company. Abstentions and broker non-votes will have no effect on the outcome. Since this vote is non-binding, the Company maintains the right to adopt or maintain an executive compensation plan that has not been ratified by affirmative vote of its shareholders. However, our Board of Directors (including our Compensation Committee) will take into account the outcome of the vote when considering future decisions affecting executive compensation as it deems appropriate.

 Can I revoke or change my vote after I return my proxy card?

Yes.For shareholders of record, any time after you have submitted a proxy card and before the proxy card is exercised, you may revoke or change your vote in one of three ways:

You may submit a written notice of revocation to Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.
You may submit a proxy bearing a later date.
You may attend the annual meeting and vote in person. Attendance at the meeting will not, by itself, revoke a proxy.

If you hold your shares in street name,you will need to revoke or resubmit your proxy through your nominee and in accordance with its procedures. In order to attend the annual meeting and vote in person, you will need to obtain a proxy from your nominee, the shareholder of record.

 Who will bear the expense of soliciting proxies in connection with this proxy statement?

Akorn will bear the cost of soliciting proxies in the form enclosed. In addition to the solicitation by mail, proxies may be solicited personally or by telephone, facsimile, online posting or electronic transmission by our employees. Our employees will not receive any additional compensation for participating in proxy solicitation. We may reimburse brokers holding common stock in their names or in the names of their nominees for their expenses in sending proxy materials to the beneficial owners of such common stock.

 What does it mean if I receive more than one proxy?

If you receive more than one proxy, it means you have multiple accounts with brokers and/or our transfer agent. Please vote all of these shares. We recommend that you contact your broker and/or our transfer agent to consolidate as many accounts as possible under the same name and address. Our transfer agent is Computershare – Essential Registry Team, located at 350 Indiana Street, Suite 750, Golden, Colorado 80401 and may be reached at (303) 262-0678.

 What is householding of proxy materials?

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more shareholders sharing the same address by delivering a single proxy statement addressed to those shareholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for shareholders and cost savings for companies.

Brokers with account holders who are Akorn shareholders may be “householding” our proxy materials. A single proxy statement will be delivered to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders.

Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate proxy statement and annual report, please notify your broker and direct your written request to Akorn, Inc., Attention: Investor Relations, 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045, or call (847) 279-6156. Shareholders who currently receive multiple copies of the proxy statement at their address and would like to request “householding” of their communications should contact their broker.

AKORN, INC.- 2016 Proxy Statement     48

OTHER MATTERS
As
 How can I get a copy of the 2015 annual report or other proxy materials?

The Notice of Annual Meeting, proxy statement and our Form 10-K for 2015 are available at proxyvote.com and at the Company’s website akorn.com.

We will provide, without charge, a copy of our Form 10-K, including financial statements and financial statement schedules, as filed with the SEC, upon request in writing from any person who was a holder of record or who represents in good faith that such person was a beneficial owner of common stock as of May 11, 2016. Requests should be made to Akorn, Inc., Attention: Investor Relations, 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045.

 What are the deadlines for submitting shareholder proposals for the 2017 annual meeting?

Any proposal that a shareholder of our common stock wishes to submit for inclusion in the Akorn Proxy Statement for the 2017 annual meeting (“2017 Proxy Statement”) pursuant to Rule 14a-8 must be received by Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045 not later than November 24, 2016, or if such year’s annual meeting does not take place within 30 days from May 5, 2017, then the deadline is a reasonable time before Akorn begins to print and send its proxy materials. Such proposals must comply with SEC regulations under Rule 14a-8 regarding the inclusion of shareholder proposals in company-sponsored proxy materials. In addition, notice of any proposal that a holder of our common stock wishes to propose for consideration at the 2017 annual meeting, but does not seek to include in the 2017 Proxy Statement pursuant to Rule 14a-8, must be delivered to the Company no later than November 24, 2016 if the proposing shareholder of our common stock wish for Akorn to describe the nature of the date of this proxy statement, management is unaware of any matter for action by shareholders at the meeting other than those describedproposal in the accompanying notice.  The enclosed proxy, however, will confer discretionary authorityits 2017 Proxy Statement. Any shareholder proposals or notices submitted to Akorn in connection with respect to any other matter that may properly come before theour 2017 annual meeting should be addressed to: Akorn’s Corporate Secretary at 1925 West Field Court, Suite 300, Lake Forest, Illinois 60045. Any notice of a shareholder proposal submitted after November 24, 2016, or any adjournment thereof.  It is the intention of the persons named in the enclosedif such year’s annual meeting does not take place within 30 days from May 5, 2017, a reasonable time before Akorn begins to print and send its proxy to vote in accordance with their best judgment on any such matter.

materials, will be considered untimely.

By Order of the Board of Directors


/s/ S/Joseph Bonaccorsi


Joseph Bonaccorsi

Secretary


Lake Forest, Illinois

April 4, 2014

46


APPENDIX A




May 20, 2016

AKORN, INC. 2014 STOCK OPTION PLAN

47

TABLE OF CONTENTS
   
Page
  
ARTICLE 1 PURPOSE OF THE PLAN1
    
ARTICLE 2 DEFINITIONS1
 2.1
"Administrator"
1
 2.2
"Affiliate"
1
 2.3
"Applicable Laws"
1
 2.4
"Award"
1
 2.5
"Award Agreement"
1
 2.6
"Awarded Stock"
1
 2.7
"Beneficially Owned" and "Beneficial Ownership"
1
 2.8
"Board"
1
 2.9
"Change in Control"
1
 2.10
"Code"
2
 2.11
"Committee"
2
 2.12
"Common Stock"
2
 2.13
"Consultant"
2
 2.14
"Corporation"
2
 2.15
"Director"
2
 2.16
"Disability"
2
 2.17
"Effective Date"
3
 2.18
"Employee"
3
 2.19
"Exchange Act"
3
 2.20
"Exchange Program"
3
 2.21
"Fair Market Value"
3
 2.22
"Fiscal Year"
3
 2.23
"Incentive Stock Option"
3
 2.24
"Non-Qualified Stock Option"
3
 2.25
"Officer"
3
 2.26
"Option"
3
 2.27
"Other Stock Based Awards"
4
 2.28
"Outside Director"
4
 2.29
"Participant"
4
 2.30
"Performance Share"
4
 2.31
"Performance Unit"
4
 2.32
"Period of Restriction"
4
 2.33
"Plan"
4
 2.34
"Restricted Stock"
4
 2.35
"Rule 16b-3"
4
 2.36
"Section 16(b)"
4
 2.37
"Service Provider"
4
 2.38
"Share"
4
 2.39
"Stock Appreciation Right" or "SAR"
4
 2.40
"Unrestricted Stock"
4
i

ARTICLE 3 PLAN ADMINISTRATION5
 3.1Procedure5
 3.2Powers of the Administrator5
 3.3Effect of Administrator's Decision7
    
ARTICLE 4 STOCK SUBJECT TO THE PLAN7
 4.1Stock Subject to the Plan7
 4.2Lapsed Awards7
 4.3Adjustments for Changes in Capitalization and Similar Events7
    
ARTICLE 5 PARTICIPATION8
 5.1Eligibility8
 5.2Termination of Participation8
    
ARTICLE 6 STOCK OPTIONS8
 6.1Option Grant8
 6.2Exercise Price9
 6.3Waiting Period and Exercise Dates9
 6.4Exercise of Option9
 6.5Form of Consideration11
    
ARTICLE 7 RESTRICTED STOCK11
 7.1Grant of Restricted Stock11
 7.2Restricted Stock Agreement11
 7.3Transferability12
 7.4Removal of Restrictions12
 7.5Voting Rights12
 7.6Dividends and Other Distributions12
 7.7Return of Restricted Stock to Corporation12
    
ARTICLE 8 UNRESTRICTED STOCK12
    
ARTICLE 9 STOCK APPRECIATION RIGHTS12
 9.1Grant of SARs12
 9.2Number of Shares12
 9.3Exercise Price and Other Terms12
 9.4SAR Agreement12
 9.5Expiration of SARs13
 9.6Payment of SAR Amount13
 9.7Buyout Provisions13
ii

ARTICLE 10 PERFORMANCE UNITS AND PERFORMANCE SHARES13
 10.1Grant of Performance Units/Shares13
 10.2Value of Performance Units/Shares13
 10.3Performance Objectives and Other Terms13
 10.4Performance Measures13
 10.5Earning of Performance Units/Shares14
 10.6Form and Timing for Payment of Performance Units/Shares14
 10.7Cancellation of Performance Units/Shares14
    
ARTICLE 11 OTHER STOCK BASED AWARDS14
    
ARTICLE 12 DISSOLUTION OR LIQUIDATION; OR CHANGE IN CONTROL14
 12.1Dissolution or Liquidation14
 12.2Change in Control14
    
ARTICLE 13 MISCELLANEOUS PROVISIONS15
 13.1No Uniform Rights to Awards15
 13.2Share Certificates15
 13.3No Rights as a Service Provider15
 13.4No Rights as Shareholder15
 13.5No Trust or Fund Created15
 13.6No Fractional Shares15
 13.7Requirement of Consent and Notification of Election Under Code § 83(b) or Similar Provision16
 13.8Requirement of Notification Upon Disqualifying Disposition Under Code § 421(b)16
 13.9Leaves of Absence16
 13.10Notices16
 13.11Non-Transferability of Awards16
 13.12Date of Grant16
 13.13Amendment and Termination of Plan16
 13.14Conditions Upon Issuance of Shares17
 13.15Severability17
 13.16Inability to Obtain Authority17
 13.17Shareholder Approval17
 13.18Governing Law17
 13.19Section 409A.  It is the intention of the Corporation that no Award shall be “deferred compensation” subject to Code § 409A, unless and to the extent that the Administrator specifically determines otherwise, and this Plan and the terms and conditions of all Awards shall be interpreted accordingly.  The terms and conditions governing any Awards that the Administrator determines will be subject to Code § 409A, including, without limitation, any rules for elective or mandatory deferral of the delivery of cash or shares of Common Stock pursuant thereto and any rules regarding treatment of such Awards in the event of a Change in Control, shall be set forth in the applicable Award Agreement and rules established by the Administrator, and shall comply in all respects with Code § 409A.  The following rules will apply to Awards intended to be subject to Code § 409A (“409A Awards”):17
iii

(a)If a Participant is permitted to elect to defer an Award or any payment under an Award, such election will be permitted only at times in compliance with Code § 409A, including, without limitation, applicable transition rules thereunder.18
(b)The Corporation shall have no authority to accelerate distributions relating to Code § 409A Awards in excess of the authority permitted under Code § 409A.18
(c)Any distribution of a Code § 409A Award following a separation from service that would be subject to Code § 409A(a)(2)(A)(i) as a distribution following a separation from service of a “specified employee” as defined under Code § 409A(a)(2)(B)(i), shall occur no earlier than the expiration of the six-month period following such Separation.18
(d)In the case of any distribution of a Code § 409A Award, if the timing of such distribution is not otherwise specified in this Plan or an Award Agreement or other governing document, the distribution shall be made not later than the end of the calendar year during which the settlement of the Code § 409A Award is specified to occur.18
(e)In the case of an Award providing for distribution or settlement upon vesting or the lapse of a risk of forfeiture, if the time of such distribution or settlement is not otherwise specified in this Plan or an Award agreement or other governing document, the distribution or settlement shall be made not later than March 15 of the year following the year in which the Award vested or the risk of forfeiture lapsed.18
- 2016 Proxy Statement     49

 
This Plan is hereby adopted on this _____ day of __________________, 2014.
AKORN, INC.
By: ___________________________
Title:__________________________
Back to Contents
iv

AKORN, INC. 2014 STOCK OPTION PLAN
ARTICLE 1
PURPOSE OF THE PLAN
The purpose of this Akorn, Inc. 2014 Stock Option Plan is to promote the interests of Akorn, Inc. and its shareholders by: (i) attracting and retaining exceptional Directors, Employees and Consultants (including prospective Directors, Employees and Consultants) of the Corporation, and (ii) enabling such individuals to participate in the long-term growth and financial success of the Corporation.
Accordingly, the Plan provides for the granting of Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Stock Appreciation Rights, Performance Unit Awards, Performance Share Awards, and Other Stock Based Awards.
ARTICLE 2
DEFINITIONS
2.1"Administrator" means the Board, the Committee, or any Officer or Employee of the Corporation to whom the Board or the Committee has delegated authority to administer the Plan.
2.2"Affiliate" means a "parent" or "subsidiary" corporation as defined in Code §§ 424(e) and (f), or that the Board has designated as participating in the Plan.
2.3"Applicable Laws" means the requirements relating to the administration of equity-based awards or equity compensation plans under U.S. federal and state laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.
2.4"Award" means, individually or collectively, a grant under the Plan of Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Stock Appreciation Rights, Performance Unit Awards, Performance Share Awards or Other Stock Based Awards.
2.5"Award Agreement" means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan.  The Award Agreement is subject to the terms and conditions of the Plan.
2.6"Awarded Stock" means the Common Stock subject to an Award.
2.7"Beneficially Owned" and "Beneficial Ownership" means as set forth in Rule 13d-3 of the Exchange Act, provided that the exercise of voting rights by a nominee or proxy holder of the Board in connection with a meeting or proposed action by shareholders of the Corporation shall not be deemed to constitute such ownership and any ownership or voting power of the trustee under an employee benefit plan of the Corporation shall not be deemed to constitute such ownership.
2.8"Board" means the Board of Directors of the Corporation.
2.9"Change in Control" means, unless otherwise defined under Code § 409A and reflected in the Award Agreement, the occurrence of any of the following events:
1

(a)the consummation of a merger or consolidation of the Corporation with any other entity which thereby becomes the beneficial owner of more than 50% of the outstanding "Voting Securities" (defined as securities the holders of which are entitled to vote for the election of Directors) of the surviving entity;
(b)Directors who were members of the Board immediately prior to a meeting of the shareholders of the Corporation which meeting involves a contest for the election of at least one directorship, do not constitute at least a majority of the Directors following such meeting or election;
(c)an acquisition, directly or indirectly, of more than 50% of the outstanding shares of any class of "Voting Securities" of the Corporation by any "Person;"
(d)the shareholders of the Corporation approve a sale of all or substantially all of the assets of the Corporation or the liquidation of the Corporation; OR
(e)there is a change, during any period of two consecutive years or less of a majority of the Board as constituted as of the beginning of such period, unless the election of each Director who is not a Director at the beginning of such period was approved by a vote of at least two-thirds of the Directors then in office who were Directors at the beginning of the period.
Notwithstanding the foregoing, a Change in Control shall not be deemed to have occurred in the event the Corporation forms a holding company as a result of which the holders of the Corporation's "Voting Securities" immediately prior to the transaction, hold, in approximately the same relative proportions as they held prior to the transaction, substantially all of the "Voting Securities" of a holding company owning all of the Corporation's "Voting Securities" after the completion of the transaction.
2.10"Code" means the Internal Revenue Code of 1986, as amended, and the Treasury regulations promulgated thereunder.  Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code.
2.11"Committee"  means a committee of Directors or other individuals satisfying Applicable Laws and appointed by the Board in accordance with Article 3 of the Plan. If the Committee is comprised of two Directors, both Directors shall be "non-employee directors" as that term is defined in Rule 16b-3.
2.12"Common Stock" means the Common Stock of the Corporation, or in the case of Awards not based on Shares, the cash equivalent thereof.
2.13"Consultant" means any person, including an advisor, engaged by the Corporation or an Affiliate to render services to such entity.
2.14"Corporation" means Akorn, Inc., a Louisiana corporation.
2.15"Director" means a member of the Board.
2.16"Disability" means, unless otherwise defined under Code § 409A and reflected in the Award Agreement, total and permanent disability as defined in Code § 22(e)(3), provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.
2

2.17"Effective Date" means December30, 2013.
2.18"Employee" means any person, including Officers and Directors, employed by the Corporation or an Affiliate.  Neither service as a Director nor payment of a director's fee by the Corporation will be sufficient to constitute "employment" by the Corporation.
2.19"Exchange Act" means the Securities Exchange Act of 1934, as amended.
2.20"Exchange Program" means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for Awards of the same type (which may have lower exercise prices and different terms), Awards of a different type, and/or cash; or (ii) the exercise price of an outstanding Award is reduced.  The terms and conditions of any Exchange Program will be determined by the Administrator.
2.21"Fair Market Value" means, as of any date and unless the Administrator determines otherwise, the value of Common Stock determined as follows:
(a)If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the American Stock Exchange, the NASDAQ National Market or the NASDAQ SmallCap Market of the NASDAQ Stock Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system for the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable;
(b)If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share of Common Stock will be the mean between the high bid and low asked prices for the Common Stock for the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or
(c)In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.
Notwithstanding the preceding, for federal, state, and local income tax reporting purposes and for such other purposes as the Administrator deems appropriate, the Fair Market Value shall be determined by the Administrator in accordance with uniform and nondiscriminatory standards adopted by it from time to time.
2.22"Fiscal Year" means the fiscal year of the Corporation.
2.23"Incentive Stock Option" means an Option intended to qualify as an incentive stock option within the meaning of Code § 422 and the Treasury regulations promulgated thereunder.
2.24"Non-Qualified Stock Option" means an Option that by its terms does not qualify, or is not intended to qualify, as an Incentive Stock Option.
2.25"Officer" means a person who is an officer of the Corporation within the meaning of § 16 of the Exchange Act and the rules and regulations promulgated thereunder.
2.26"Option" means an Incentive Stock Option or a Non-Qualified Stock Option or both, as the context requires.
3

2.27"Other Stock Based Awards" means any other awards not specifically described in the Plan that are valued in whole or in part by reference to, or are otherwise based on, Shares and are created by the Administrator pursuant to Article 12.
2.28"Outside Director" means a Director who either: (i) is not a current Employee of the Corporation or an "affiliated corporation" (within the meaning of the Treasury regulations promulgated under Code § 162(m)), is not a former employee of the Corporation or an "affiliated corporation" receiving compensation for prior services (other than benefits under a tax qualified retirement plan), was not an officer of the Corporation or an "affiliated corporation" at any time, and is not currently receiving direct or indirect remuneration (within the meaning of the Treasury regulations promulgated under Code § 162(m)) from the Corporation or an "affiliated corporation" for services in any capacity other than as a Director; or (ii) is otherwise considered an "outside director" for purposes of Code § 162(m).
2.29"Participant" means the holder of an outstanding Award granted under the Plan.
2.30"Performance Share" means, pursuant to Article 10, an Award granted to a Service Provider under which, upon the satisfaction of predetermined individual or Corporation performance goals and/or objectives, shares of Common Stock are paid to the Participant.
2.31"Performance Unit" means, pursuant to Article 10, an Award granted to a Service Provider under which, upon the satisfaction of predetermined individual or Corporation performance goals and/or objectives, a cash payment shall be paid to the Participant based on the number of "units" awarded to the Participant.  For this purpose, the term "unit" means bookkeeping units, each of which represents such monetary amount as shall be designated by the Administrator in each Award Agreement.
2.32"Period of Restriction" means the period during which the transfer of Shares of Restricted Stock are subject to restrictions.  Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.
2.33"Plan" means the Akorn, Inc. 2014 Stock Option Plan, as amended from time to time.
2.34"Restricted Stock" means shares of Common Stock issued pursuant to a Restricted Stock Award under the Plan or issued pursuant to the early exercise of an Option.
2.35"Rule 16b-3" means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan.
2.36"Section 16(b)" means Section 16(b) of the Exchange Act.
2.37"Service Provider" means an Employee, Director or Consultant.
2.38"Share" means a share of the Common Stock, as adjusted in accordance with Section 4.3 and Article 13 of the Plan.
2.39"Stock Appreciation Right" or "SAR" means an Award that is designated as a SAR, and represents an unfunded and unsecured promise to deliver Shares, cash, other securities, other Awards or other property equal in value to the excess, if any, of the Fair Market Value per Share over the exercise price per Share of the SAR, subject to the terms of the applicable Award Agreement.
2.40"Unrestricted Stock" means as defined in Article 8 of the Plan.
4

ARTICLE 3
PLAN ADMINISTRATION
3.1Procedure.
(a)Board's Delegation.  The Board may delegate administration of the Plan to a Committee or multiple Committees.  If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers possessed by the Board, subject, however, to such resolutions, not inconsistent with the provisions of this Plan, as may be adopted from time to time by the Board.  The Board may abolish the Committee at any time and vest in the Board the administration of the Plan.  Different Committees with respect to different groups of Service Providers may administer the Plan.
(b)Code § 162(m).  To the extent that the Administrator determines it to be desirable and necessary to qualify Awards granted hereunder as "performance-based compensation" within the meaning of Code § 162(m), the Plan will be administered by a Committee of two or more Outside Directors.
(c)Rule 16b-3.  To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.
(d)Other Administration.  Other than as provided above, the Plan will be administered by: (i) the Board, or (ii) a Committee, which committee will be constituted to satisfy Applicable Laws.
(e)Delegation of Authority for Day-to-Day Administration.  Except to the extent prohibited by Applicable Law, the Administrator may delegate to one or more individuals the day-to-day administration of the Plan and any of the functions assigned to it in this Plan.  Such delegation may be revoked at any time.
3.2Powers of the Administrator.  Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:
(a)To determine the Fair Market Value;
(b)To select the Service Providers to whom Awards may be granted hereunder;
(c)To determine the number of Shares to be covered by each Award granted hereunder;
(d)To approve forms of agreement for use under the Plan;
(e)To determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture or repurchase restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine in its sole discretion;
5

(f)Subject to shareholder approval, to reduce the exercise price of any Award to the then current Fair Market Value if the Fair Market Value of the Common Stock covered by such Award shall have declined since the date the Award was granted;
(g)Subject to shareholder approval, to institute an Exchange Program;
(h)To construe and interpret the terms of the Plan and Awards granted pursuant to the Plan, and to establish, amend and revoke rules and regulations for its administration;
(i)To prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws and/or qualifying for preferred tax treatment under applicable foreign tax laws;
(j)To modify or amend each Award (subject to Section 14.13(c) of the Plan), including the discretionary authority to extend the post-termination exercise period of Awards longer than is otherwise provided for in the Plan ;
(k)To allow Participants to satisfy withholding tax obligations by electing to have the Corporation withhold from the Shares or cash to be issued upon exercise or vesting of an Award that number of Shares or cash having a Fair Market Value equal to the minimum amount required to be withheld.  The Fair Market Value of any Shares to be withheld will be determined on the date that the amount of tax to be withheld is to be determined.  All elections by a Participant to have Shares or cash withheld for this purpose will be made in such form and under such conditions as the Administrator may deem necessary or advisable;
(l)To authorize any person to execute on behalf of the Corporation any instrument required to affect the grant of an Award previously granted by the Administrator;
(m)To allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant under an Award;
(n)To determine whether Awards will be settled in Shares, cash or in any combination thereof;
(o)To create Other Stock Based Awards for issuance under the Plan;
(p)To establish a program whereby Service Providers designated by the Administrator can reduce compensation otherwise payable in cash in exchange for Awards under the Plan;
(q)To impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any re-sales by a Participant or other subsequent transfers by the Participant of any Shares issued as a result of or under an Award, including without limitation, (i) restrictions under an insider trading policy, and (ii) restrictions as to the use of a specified brokerage firm for such re-sales or other transfers; and (ii) restrictions as to the use of a specified brokerage firm for such re-sales or other transfers ; and
(r)To make all other determinations deemed necessary or advisable for administering the Plan.
6

3.3Effect of Administrator's Decision.  The Administrator’s decision shall be binding on Participants and any other holders of Awards.
ARTICLE 4
STOCK SUBJECT TO THE PLAN
4.1Stock Subject to the Plan.  Subject to the provisions of this Article 4 and Article 13 of the Plan, the maximum aggregate number of Shares that may be issued under the Plan is 7,500,000, of which the maximum number of Shares that may be delivered pursuant to Incentive Stock Options granted under the Plan shall be 1,500,000.  The Shares may be authorized and unissued, or reacquired Common Stock. Shares shall not be deemed to have been issued pursuant to the Plan with respect to any portion of an Award that is paid in cash.  Upon payment in Shares pursuant to the exercise of an Award, the number of Shares available for issuance under the Plan shall be reduced only by the number of Shares actually issued in such payment.  If a Participant pays the exercise price (or purchase price, if applicable) of an Award through the tender of Shares, or if Shares are tendered or withheld to satisfy any Corporation withholding tax obligations, the number of Shares so tendered or withheld shall again be available for issuance pursuant to future Awards under the Plan.
4.2Lapsed Awards.  If any outstanding Award expires or is terminated or canceled without having been exercised or settled in full, or if Shares acquired pursuant to an Award subject to forfeiture or repurchase are forfeited or repurchased by the Corporation, the Shares allocable to the terminated portion of such Award or such forfeited or repurchased Shares shall again be available for grant under the Plan.
4.3Adjustments for Changes in Capitalization and Similar Events.  In the event the Administrator determines that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of Shares or other securities of the Corporation, issuance of warrants or other rights to purchase Shares or other securities of the Corporation, or other similar corporate transaction or event affects the Shares resulting in an  adjustment, then the Administrator shall:
(a)in such manner as it may deem equitable or desirable, adjust any or all of (i) the number of Shares or other securities of the Corporation (or number and kind of other securities or property) with respect to which Awards may be granted, including (1) the aggregate number of Shares that may be delivered pursuant to Awards granted under the Plan, as provided in Section 4.1 of the Plan, and (2) the maximum number of Shares or other securities of the Corporation (or number and kind of other securities or property) with respect to which Awards may be granted to any Participant in any fiscal year of the Corporation, and (ii) the terms of any outstanding Award, including (1) the number of Shares or other securities of the Corporation (or number and kind of other securities or property) subject to outstanding Awards or to which outstanding Awards relate, and (2) the exercise price with respect to any Award; or
(b)if deemed appropriate or desirable, make provision for a cash payment to the holder of an outstanding Award in consideration for the cancellation of such Award, including, in the case of an outstanding Option or SAR, a cash payment to the holder of such Option or SAR in consideration for the cancellation of such Option or SAR in an amount equal to the excess, if any, of the Fair Market Value (as of a date specified by the Administrator) of the Shares subject to such Option or SAR over the aggregate exercise price of such Option or SAR (it being understood that, in such event, any Option or SAR having a per Share exercise price equal to, or in excess of, the Fair Market Value of a Share subject to such Option or SAR may be cancelled and terminated without any payment or consideration therefore).
7

(c)Any such adjustments shall be made by the Administrator in its absolute discretion, and the decision of the Administrator shall be final, binding and conclusive
Any Shares issuable as a result of any such adjustment shall be rounded to the next lower whole Share; no fractional Shares shall be issued.  Any adjustment to the exercise price of an Award shall be rounded to the nearest penny.
4.4  Substitute Awards.  The Administrator in its sole discretion shall have the right to substitute or assume Awards in connection with a share combination, share exchange, merger, consolidation, reorganization, or like corporate transaction which affects the number or nature of the Shares ("Substitute Awards").  The number of Shares underlying any Substitute Awards shall be counted against the aggregate number of Shares available for Awards under the Plan; provided, however, that Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding awards previously granted by an entity that is acquired by the Corporation or its Affiliate through a merger or acquisition shall not be counted against the aggregate number of Shares available for Awards under the Plan; provided further, however, that Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding stock options intended to qualify for special tax treatment under Code §§ 421 and 422 that were previously granted by an entity that is acquired by the Corporation or an Affiliate through a merger or acquisition shall be counted against the aggregate number of Shares available for Incentive Stock Options under the Plan.

ARTICLE 5
PARTICIPATION
5.1Eligibility.  Any Director, Employee or Consultant (including any prospective Director, Employee or Consultant) of the Corporation and any Affiliate shall be eligible to be designated a Participant in the Plan for purposes of receiving Awards.  However, Incentive Stock Options may only be granted to Employees.
5.2Termination of Participation.  If a Participant is no longer a Service Provider due to a termination for "Cause," then all Awards granted to the Participant shall expire upon the earlier of: (i) the date of the occurrence giving rise to such termination, or (ii) the natural expiration of the Award according to its underlying terms.  Thereafter, the Participant shall have no rights with respect to any Awards under the Plan.
(a)Defining "Cause”.  For purposes of the Plan, "Cause" shall mean a Participant's personal dishonesty; misconduct; breach of fiduciary duty; incompetence; intentional failure to perform stated obligations; willful violation of any law, rule, regulation or final cease and desist order; or any material breach of any provision of this Plan, Award Agreement, or any employment agreement.
ARTICLE 6
STOCK OPTIONS
6.1Option Grant.  Subject to the provisions of the Plan, the Administrator shall have sole and plenary authority to determine the Service Providers to whom Options shall be granted, the number of Shares to be covered by each Option, whether for Employees the Option will be an Incentive Stock Option or a Non-Qualified Stock Option, and the conditions and limitations applicable to the vesting and exercise of the Option.   In the case of Incentive Stock Options, the terms and conditions of such grants shall be subject to and comply with such rules as may be prescribed by Code § 422 and any regulations related thereto, as may be amended from time to time. All Options granted under the Plan shall be Non-Qualified Stock Options unless the applicable Award Agreement expressly states that the Option is intended to be an Incentive Stock Option. If an Option is intended to be an Incentive Stock Option, and if for any reason such Option (or any portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such non-qualification, such Option (or portion thereof) shall be regarded as a Non-Qualified Stock Option appropriately granted under the Plan, provided that such Option (or portion thereof) otherwise complies with the Plan's requirements relating to Non-Qualified Stock Options.
8

(a)Term of Option.  The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option, the term will be 10 years from the date of grant or such shorter term as may be provided in the Award Agreement. Moreover, in the case of an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than 10% of the total combined voting power of all classes of stock of the Corporation or any Affiliate, the term of the Incentive Stock Option will be five years from the date of grant or such shorter term as may be provided in the Award Agreement.
(b)$100,000 Limitation for Incentive Stock Options.  Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Non-Qualified Stock Option.  However, notwithstanding such designation, to the extent the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Corporation and any Affiliate) exceeds $100,000, such Options will be treated as Non-Qualified Stock Options.  For purposes of this Section 6.1(b), Incentive Stock Options will be taken into account in the order in which they were granted.  The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted.
6.2Exercise Price.  Except as otherwise established by the Administrator at the time an Option is granted and set forth in the applicable Award Agreement, the exercise price of each Share covered by an Option shall be not less than 100% of the Fair Market Value of such Share (determined as of the date the Option is granted); provided, however, that in the case of an Incentive Stock Option granted to an Employee who, at the time of the grant of such Option, owns stock representing more than 10% of the voting power of all classes of stock of the Corporation and any Affiliate, the per Share exercise price shall be no less than 110% of the Fair Market Value per Share on the date of the grant.  Options are intended to qualify as "qualified performance-based compensation" under Code § 162(m).
Notwithstanding the foregoing, Options may be granted with an exercise price of less than 100% of the Fair Market Value per Share on the date of grant if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Code § 424(a) (involving a corporate reorganization).
6.3Waiting Period and Exercise Dates.  At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.
6.4Exercise of Option.
(a)Procedure for Exercise; Rights as a Shareholder.  Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement.  An Option may not be exercised for a fraction of a Share.
9

An Option will be deemed exercised when the Corporation receives: (i) written or electronic notice of exercise (in accordance with the Award Agreement) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised.  Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan.  Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse.  Until the Shares are issued (as evidenced by the appropriate entry on the books of the Corporation or of a duly authorized transfer agent of the Corporation), no right to vote or receive dividends or any other rights as a shareholder will exist with respect to the Awarded Stock, notwithstanding the exercise of the Option. The Corporation will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Articles 4 and 13 of the Plan or the applicable Award Agreement.
Exercising an Option in any manner will decrease the number of Shares thereafter available for purchase under the Option, by the number of Shares as to which the Option is exercised.
(b)Termination of Relationship as Service Provider.  If a Participant ceases to be a Service Provider, other than upon the Participant's death or Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3) months following the Participant's termination.
(c)Disability of Participant.  If a Participant ceases to be a Service Provider as a result of the Participant's Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for 12 months following the Participant's termination.
(d)Death of Participant.  If a Participant dies while a Service Provider, the Option may be exercised following the Participant's death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award Agreement), by the Participant's designated beneficiary, provided such beneficiary has been designated prior to Participant's death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant's estate or by the person(s) to whom the Option is transferred pursuant to the Participant's will or in accordance with the laws of descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant's death.
10

(e)Buyout Provisions.  The Administrator may at any time offer to buy out for a payment in cash or Shares an Option previously granted based on such terms and conditions as the Administrator shall establish and communicate to the Participant at the time that such offer is made.
(f)Reversion to Plan.  Unless otherwise provided by the Administrator, if on the date of termination, Disability or death as provided in Sections 6.4(b), (c), and (d) of the Plan, Participant is not fully vested as to his or her Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan following the Participant's termination, Disability or death.  If the vested portion of the Option is not exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.
6.5Form of Consideration.  The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. To the extent permitted by Applicable Laws, consideration may consist entirely of:
(a)cash;
(b)check;
(c)other Shares which meet the conditions established by the Administrator to avoid adverse accounting consequences (as determined by the Administrator);
(d)consideration received by the Corporation under a cashless exercise program implemented by the Corporation in connection with the Plan;
(e)a reduction in the amount of any Corporation liability to the Participant, including any liability attributable to the Participant's participation in any Corporation-sponsored deferred compensation program or arrangement;
(f)any combination of the foregoing methods of payment; or
(g)such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws.
ARTICLE 7
RESTRICTED STOCK
7.1Grant of Restricted Stock.  Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.
7.2Restricted Stock Agreement.  Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator will determine in its sole discretion. Unless the Administrator determines otherwise, Shares of Restricted Stock will be held by the Corporation as escrow agent until the restrictions on such Shares have lapsed.
11

7.3Transferability.  Except as provided in this Article 7, Shares of Restricted Stock may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.
7.4Removal of Restrictions.  Except as otherwise provided in this Article 7, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction.  The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.
7.5Voting Rights.  During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder shall not have voting rights with respect to those Shares, unless the Administrator determines otherwise.
7.6Dividends and Other Distributions.  During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares unless otherwise provided in the Award Agreement.  If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.
7.7Return of Restricted Stock to Corporation.  On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Corporation and again will become available for grant under the Plan.
ARTICLE 8
UNRESTRICTED STOCK
Pursuant to the terms of the applicable Award Agreement, a Service Provider may be awarded (or sold at a discount) shares of Common Stock that are not subject to a Period of Restriction, in consideration for past services rendered thereby to the Corporation and any Affiliate or for other valid consideration.
ARTICLE 9
STOCK APPRECIATION RIGHTS
9.1Grant of SARs.  Subject to the terms and conditions of the Plan, a SAR may be granted to Service Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.
9.2Number of Shares.  The Administrator will have sole discretion to determine the number of SARs granted to any Service Provider.
9.3Exercise Price and Other Terms.  The Administrator, subject to the provisions of the Plan, will have sole discretion to determine the terms and conditions of SARs granted under the Plan.  The foregoing notwithstanding, the Exercise Price at the date of grant shall not be less than the Fair Market Value of the SAR.
9.4SAR Agreement.  Each SAR grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the SAR, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.
12

9.5Expiration of SARs.  A SAR granted under the Plan will expire upon the date determined by the Administrator, in its sole discretion, and as set forth in the Award Agreement.  Notwithstanding the foregoing, the rules of Sections 6.4(b), (c) and (d) will also apply to SARs.
9.6Payment of SAR Amount.  Upon exercise of a SAR, a Participant will be entitled to receive payment from the Corporation an amount determined by multiplying:  (i) the difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times (ii) the number of Shares with respect to which the SAR is exercised.  At the discretion of the Administrator, the payment upon SAR exercise may be in cash, in Shares of equivalent value, other securities, other Awards, other property or a combination of any of the foregoing.
9.7Buyout Provisions.  The Administrator may at any time offer to buy out for a payment in cash or Shares a SAR previously granted based on such terms and conditions as the Administrator shall establish and communicate to the Participant at the time that such offer is made.
ARTICLE 10
PERFORMANCE UNITS AND PERFORMANCE SHARES
10.1Grant of Performance Units/Shares.  Subject to the terms and conditions of the Plan, Performance Units and Performance Shares may be granted to Service Providers at any time and from time to time, as will be determined by the Administrator, in its sole discretion.  The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares granted to each Participant.
10.2Value of Performance Units/Shares.  Each Performance Unit will have an initial value that is established by the Administrator on or before the date of grant.  Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant.
10.3Performance Objectives and Other Terms.  The Administrator will set performance objectives in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers.  The time period during which the performance objectives must be met will be called the "Performance Period."  Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the "Performance Period," and such other terms and conditions as the Administrator, in its sole discretion, will determine.  The Administrator may set performance objectives based upon the achievement of Corporation-wide, divisional, or individual goals, applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.
10.4Performance Measures.  Performance Measures may be based on any one or more of the following: earnings (e.g., earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization; or earnings per share); financial return ratios (e.g., return on investment; return on invested capital; return on equity; or return on assets); increase in revenue, operating or net cash flows; cash flow return on investment; total shareholder return; market share; net operating income, operating income or net income; debt load reduction; expense management; economic value added; Stock price; and strategic business objectives, consisting of one or more objectives based on meeting specific cost targets, business expansion goals and goals relating to acquisitions or divestitures. Performance Measures may be based on the performance of the Company as a whole or of any one or more business units of the Company and may be measured relative to a peer group or an index. Performance Measures may vary from Participant to Participant. Performance Periods may overlap and Participants may participate simultaneously with respect to Award for which the Committee has prescribed different Performance Periods.
13

10.5Earning of Performance Units/Shares.  After the applicable "Performance Period" has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the "Performance Period," to be determined as a function of the extent to which the corresponding performance objectives have been achieved.  After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives for such Performance Unit/Share.
10.6Form and Timing for Payment of Performance Units/Shares.  Payment of earned Performance Units/Shares will be made as soon after the expiration of the applicable Performance Period at the time determined by the Administrator.  The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof.
10.7Cancellation of Performance Units/Shares.  On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited to the Corporation, and again will be available for grant under the Plan.
ARTICLE 11
OTHER STOCK BASED AWARDS
Other Stock Based Awards may be granted either alone, in addition to, or in tandem with, other Awards granted under the Plan and/or cash awards made outside of the Plan. The Administrator shall have authority to determine the Service Providers to whom and the time or times at which Other Stock Based Awards shall be made, the amount of such Other Stock Based Awards, and all other conditions of the Other Stock Based Awards including any dividend and/or voting rights.
ARTICLE 12
DISSOLUTION OR LIQUIDATION; OR CHANGE IN CONTROL
12.1Dissolution or Liquidation.  In the event of the proposed dissolution or liquidation of the Corporation, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction.  The Administrator in its discretion may provide for a Participant to have the right to exercise his or her Award, to the extent applicable, until 10 days prior to such transaction as to all of the Awarded Stock covered thereby, including Shares as to which the Award would not otherwise be exercisable. In addition, the Administrator may provide that any Corporation repurchase option or forfeiture rights applicable to any Award shall lapse 100%, and that any Award vesting shall accelerate 100%, provided the proposed dissolution or liquidation takes place at the time and in the manner contemplated.  To the extent it has not been previously exercised or vested, an Award will terminate immediately prior to the consummation of such proposed action.
12.2Change in Control.  If a Change in Control occurs and a Participant’s Awards are not continued, converted, assumed, or replaced by (i) the Corporation or an Affiliate of the Corporation, or (ii) a successor entity in such manner that the value of the awards is not diminished upon effecting the change, such Awards shall become fully exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse immediately prior to such Change in Control. Upon, or in anticipation of, a Change in Control, the Administrator may cause any and all Awards outstanding hereunder to terminate at a specific time in the future, including but not limited to the date of such Change in Control, and shall give each Participant the right to exercise such Awards during a period of time as the Administrator, in its sole and absolute discretion, shall determine, but in no case shorter than ten (10) trading days.

14

ARTICLE 13
MISCELLANEOUS PROVISIONS
13.1No Uniform Rights to Awards.  The Corporation has no obligation to uniformly treat Participants or holders or beneficiaries of Awards. The terms and conditions of Awards and the Administrator's determinations and interpretations with respect thereto need not be the same with respect to each Participant and may be made selectively among Participants, whether or not such Participants are similarly situated.
13.2Share Certificates.  All certificates for Shares or other securities of the Corporation or Affiliate delivered under the Plan pursuant to any Award or the exercise thereof shall be subject to such stop transfer orders and other restrictions as the Administrator may deem advisable under the Plan, the applicable Award Agreement or the rules, regulations and other requirements of the SEC, the NYSE or any other stock exchange or quotation system upon which such Shares or other securities are then listed or reported and any applicable Federal or state laws, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.
13.3No Rights as a Service Provider.  Neither the Plan nor any Award shall confer upon a Participant any right with respect to continuing his or her relationship as a Service Provider, nor shall they interfere in any way with the right of the Participant or the right of the Corporation or its Affiliate to terminate such relationship at any time, with or without cause.
13.4No Rights as Shareholder.  No Participant or holder or beneficiary of any Award shall have any rights as a shareholder with respect to any Shares to be distributed under the Plan until he or she has become the holder of such Shares. In connection with each grant of Restricted Stock, except as provided in the applicable Award Agreement, the Participant shall not be entitled to the rights of a shareholder in respect of such Restricted Shares.  Except as otherwise provided in Section 4.3 or the applicable Award Agreement, no adjustments shall be made for dividends or distributions on (whether ordinary or extraordinary, and whether in cash, Shares, other securities or other property), or other events relating to, Shares subject to an Award for which the record date is prior to the date such Shares are delivered.
13.5No Trust or Fund Created.  Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Corporation or Affiliate, on one hand, and a Participant or any other person, on the other.  To the extent that any person acquires a right to receive payments from the Corporation or Affiliate pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Corporation or Affiliate.
13.6No Fractional Shares.  No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Administrator shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares or whether such fractional Shares or any rights thereto shall be cancelled, terminated or otherwise eliminated.
15

13.7Requirement of Consent and Notification of Election Under Code § 83(b) or Similar Provision.  No election under Code § 83(b) (to include in gross income in the year of transfer the amounts specified in Code § 83(b)) or under a similar provision of law may be made unless expressly permitted by the terms of the applicable Award Agreement or by action of the Administrator in writing prior to the making of such election. If an Award recipient, in connection with the acquisition of Shares under the Plan or otherwise, is expressly permitted under the terms of the applicable Award Agreement or by such Administrator action to make such an election and the Participant makes the election, the Participant shall notify the Administrator of such election within 10 days of filing notice of the election with the IRS or other governmental authority, in addition to any filing and notification required pursuant to regulations issued under Code § 83(b) or other applicable provision.
13.8Requirement of Notification Upon Disqualifying Disposition Under Code § 421(b).  If any Participant shall make any disposition of Shares delivered pursuant to the exercise of an Incentive Stock Option under the circumstances described in Code § 421(b) (relating to certain disqualifying dispositions) or any successor provision of the Code, such Participant shall notify the Corporation of such disposition within 10 days of such disposition.
13.9Leaves of Absence.  Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence and will resume on the date the Participant returns to work on a regular schedule as determined by the Corporation; provided, however, that no vesting credit will be awarded for the time vesting has been suspended during such leave of absence. A Service Provider will not cease to be an Employee in the case of (i) any leave of absence approved by the Corporation or (ii) transfers between locations of the Corporation or between the Corporation or its Affiliate. For purposes of Incentive Stock Options, no such leave may exceed 3 months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Corporation is not so guaranteed, then 6 months from the first day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Non-Qualified Stock Option.
13.10Notices.  Any written notice to the Corporation required by any provisions of the Plan shall be addressed to the Secretary of the Corporation and shall be effective when received.
13.11Non-Transferability of Awards.  Other than pursuant to a domestic relations order (within the meaning of Rule 16a-12 promulgated under the Exchange Act) and unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution, and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate.
13.12Date of Grant.  The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator.  Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.
13.13Amendment and Termination of Plan.
(a)Amendment and Termination.  The Board may at any time amend, alter, suspend or terminate the Plan.  Unless sooner terminated, this Plan shall terminate on [DATE], 2023, the date that is 10 years from the date the Plan was originally adopted by the Board or approved by the shareholders of the Corporation, whichever was earlier.
16

(b)Shareholder Approval.  The Corporation will obtain shareholder approval of the Plan and of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws.
(c)Effect of Amendment or Termination.  Subject to Section 14.15 of the Plan, no amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant, unless mutually agreed upon between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Corporation. Termination of the Plan will not affect the Administrator's ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.
13.14Conditions Upon Issuance of Shares.
(a)Legal Compliance.  Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Corporation with respect to such compliance.
(b)Investment Representations.  As a condition to the exercise or receipt of an Award, the Corporation may require the person exercising or receiving such Award to represent and warrant at the time of any such exercise or receipt that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Corporation, such a representation is required.
13.15Severability.  Notwithstanding any contrary provision of the Plan or an Award to the contrary, if any one or more of the provisions (or any part thereof) of this Plan or the Awards shall be held invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of the Plan or Award, as applicable, shall not in any way be affected or impaired thereby.
13.16Inability to Obtain Authority.  The inability of the Corporation to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Corporation's counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Corporation of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not have been obtained.
13.17Shareholder Approval.  The Plan shall be duly approved by the shareholders of the Corporation within 12 months after the date the Plan was adopted, or shall otherwise be rendered not effective.
13.18Governing Law.  The validity, construction and effect of the Plan and any rules and regulations relating to the Plan and any Award Agreement shall be determined in accordance with the laws of the State of Illinois, without giving effect to the conflict of laws provisions thereof.
13.19Section 409A.  It is the intention of the Corporation that no Award shall be “deferred compensation” subject to Code § 409A, unless and to the extent that the Administrator specifically determines otherwise, and this Plan and the terms and conditions of all Awards shall be interpreted accordingly.  The terms and conditions governing any Awards that the Administrator determines will be subject to Code § 409A, including, without limitation, any rules for elective or mandatory deferral of the delivery of cash or shares of Common Stock pursuant thereto and any rules regarding treatment of such Awards in the event of a Change in Control, shall be set forth in the applicable Award Agreement and rules established by the Administrator, and shall comply in all respects with Code § 409A.  The following rules will apply to Awards intended to be subject to Code § 409A (“409A Awards”):
17

(a)If a Participant is permitted to elect to defer an Award or any payment under an Award, such election will be permitted only at times in compliance with Code § 409A, including, without limitation, applicable transition rules thereunder.
(b)The Corporation shall have no authority to accelerate distributions relating to Code § 409A Awards in excess of the authority permitted under Code § 409A.
(c)Any distribution of a Code § 409A Award following a separation from service that would be subject to Code § 409A(a)(2)(A)(i) as a distribution following a separation from service of a “specified employee” as defined under Code § 409A(a)(2)(B)(i), shall occur no earlier than the expiration of the six-month period following such Separation.
(d)In the case of any distribution of a Code § 409A Award, if the timing of such distribution is not otherwise specified in this Plan or an Award Agreement or other governing document, the distribution shall be made not later than the end of the calendar year during which the settlement of the Code § 409A Award is specified to occur.
(e)In the case of an Award providing for distribution or settlement upon vesting or the lapse of a risk of forfeiture, if the time of such distribution or settlement is not otherwise specified in this Plan or an Award agreement or other governing document, the distribution or settlement shall be made not later than March 15 of the year following the year in which the Award vested or the risk of forfeiture lapsed.

This Plan is hereby adopted on this _____ day of __________________, 2014.

 
AKORN, INC.Back to Contents

 
By: ___________________________
Title:__________________________
18

Proxy Card

Proxy Card